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Inflammation is a well-established etiological factor in carcinogenesis. The immune 
system may also have the capacity to identify and clear malignant cells in a process 
known as tumor immunosurveillance. The objective of this dissertation is to examine 
these roles of host immunity in carcinogenesis in immunocompetent adults. Specifically, 
we quantified the risk of cancer incidence and mortality by circulating, pre-diagnostic 
levels of the white blood cell (WBC) subtypes, neutrophils, lymphocytes, monocytes, 
eosinophils, and basophils, and cytomegalovirus (CMV) IgG titer in two longitudinal 
cohorts, the Atherosclerosis Risk in Communities (ARIC), 1987-2008, and the third 
National Health and Nutrition Examination Survey (NHANES III), 1988-2011. 
Multivariate Cox analyses were used to estimate the hazard ratios (HR) and 95% 
confidence intervals (CI) of cancer incidence and mortality by levels of immune markers. 
High neutrophil count was associated with an increased risk of total (HR: 1.11, 95% CI: 
1.00, 1.25) and lung (HR: 1.59, 95% CI: 1.12, 2.26) cancer incidence, and total (HR: 
1.44, 95% CI: 1.22, 1.72), lung (HR: 1.66, 95% CI: 1.18, 2.33) and breast (HR: 2.09, 
95% CI: 1.10, 3.97) cancer mortality. Among men, high lymphocyte count was 
associated with a reduced risk of cancer incidence, after excluding prostate cancer (HR: 
0.75, 95% CI: 0.62, 0.91), and an increased risk of prostate cancer incidence (HR: 1.31, 
95% CI: 1.03, 1.66). Among women, lymphocyte count was positively associated with 
cancer mortality (HR: 1.40, 95% CI: 1.07, 1.82). The presence of basophils in circulation 
was associated with a reduced risk of cancer incidence (HR: 0.93, 95% CI: 0.85, 1.01) 
and mortality (HR: 0.87, 95% CI: 0.76, 1.00). Adjustment for the other WBC subtypes 
did not appreciably alter these estimates. No associations were found for monocyte or 
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eosinophil counts. Lastly, high CMV IgG antibody titer was associated with increased 
cancer mortality in black CMV seropositive persons (HR: 1.38, 95% CI: 1.02, 1.89), 
while no association was present in whites or Mexican Americans. Our findings of an 
association between circulating pre-diagnostic levels of neutrophils, lymphocytes, 
basophils, and CMV IgG and cancer incidence and mortality support a role for low-grade 
inflammation and subclinical immune suppression in carcinogenesis. 
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Overview and Specific Aims  
This overall objective of this dissertation is to explore the roles of low-grade 
inflammation and immune suppression in the context of tumor initiation, promotion and 
progression. Inflammation is a well-established factor in carcinogenesis, with known 
effects throughout the multi-stage pathway, from tumor initiation to metastasis (1-4). In 
prospective epidemiological studies, elevated levels of systemic markers of inflammation 
have been associated with an increased risk of cancer incidence and mortality (5-16). 
There is also strong evidence primarily from mice models supporting a role for the host 
immune response in blocking carcinogenesis through the identification and clearance of 
premalignant and malignant cells (17). The effectiveness of this anti-tumoral mechanism, 
known as tumor immunosurveillance, may to relate to the capacity of the immune system 
to mount a response.  
 
The burden of cancer risk attributable to subclinical immune dysfunction may be 
significant. As many as 20% of cancers have been linked to chronic infection (18). 
Additionally, subclinical inflammation and immunosuppression may party mediate the 
carcinogenic effects of many common exposures, including obesity, smoking, and age (4, 
19). In a review of the emerging field of cancer immuno-epidemiology, the need for 
prospective studies evaluating the association between immune biomarkers and cancer 
risk was highlighted (20). Such studies have the potential to clarify important etiologic 
pathways and to identify opportunities for prevention. In this dissertation, we utilized 
the immune makers, white blood cell (WBC) subtype count and cytomegalovirus 
(CMV) IgG antibody titer in a series of specific aims: 
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Specific Aim 1. To prospectively evaluate the association between the WBC 
subtypes, neutrophils, lymphocytes, monocytes, eosinophils and basophils, and 
cancer incidence (1987-2006) and mortality (1987-2008) in the Atherosclerosis Risk 
in Communities (ARIC) study. In men and women with total WBC counts within the 
normal reference range, we estimated the risk of total and site-specific cancer incidence 
and mortality by counts of the WBC subtypes using multivariable models, including 
mutual adjustment for each of the WBC subtypes. 
 
Specific Aim 2. To explore effect modification by sex, race, cigarette smoking status, 
and the genetic markers, percent European ancestry and the Duffy null 
polymorphism (neutrophils only), on the prospective association between the WBC 
subtypes, neutrophils, lymphocytes, monocytes, eosinophils and basophils, and 
cancer incidence (1987-2006) and mortality (1987-2008) in the ARIC study. We 
examined potential effect modifiers known to modulate the host immune response. In 
analyses of neutrophil count, effect modification by percent European ancestry and the 
Duffy null polymorphism were investigated in order to explore the implications of racial 
differences in absolute neutrophil count. 
 
Specific Aim 3. To prospectively examine the association between levels of CMV 
IgG antibody titer and cancer-specific mortality in the third National Health and 
Nutrition Examination Survey (NHANES III) study, 1988-2011. We estimated the 
independent association between levels of CMV IgG antibody titer and cancer mortality 
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among CMV seropositive individuals, ages 40 to 70 years. We also evaluated effect 
modification by sex, race and cigarette smoking status. 
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Background  
Inflammation and cancer 
A role for inflammation in the etiology and progression of cancer is well established (1-
3). Based on data from in vitro and in vivo studies, chronic inflammation may initiate 
carcinogenesis by inducing mutagenesis directly, via the production of radicals, or 
indirectly, by inactivating critical DNA repair proteins and other mechanisms, including 
epigenetic changes (4, 21-23). Inflammation may also promote tumor growth and 
metastasis through mechanisms primarily directed by the tumor itself. Inflammatory cells 
are an important component of the tumor microenvironment, which can be co-opted to 
promote tumor cell proliferation and angiogenesis, inhibit tumor cell death, and induce 
immune suppression to subvert the host immune response against tumors (1-4, 24, 25).   
 
Findings from epidemiological studies support an etiological role for inflammation in 
carcinogenesis. Numerous studies have reported a positive association between chronic 
benign inflammatory conditions, such as pancreatitis and inflammatory bowel disease 
(IBD), and subsequent cancer risk (26-28). Furthermore, among IBD patients, the 
severity of inflammation was found to be an independent risk factor for cancer incidence 
(26, 29, 30). Additionally, as many as 20% of cancers have been linked to chronic 
infections (18). It is widely hypothesized that the association between infectious agents, 
including persistent Heliobacter pylori and hepatitis B and C, and cancer is partly 
mediated by inflammation (3, 31, 32). Among individuals with no underlying immune 
conditions, inflammation is also a proposed mechanism underlying the association 
between common exposures, such as age, cigarette smoke, and obesity, and cancer (4, 
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19). Furthermore, long-term use of non-steroidal anti-inflammatory drugs (NSAIDs) has 
been shown to reduce the incidence and mortality of certain cancers, including colorectal, 
breast, prostate, lung, stomach, esophageal, and pancreatic cancers (33-37).  
 
Prospective epidemiological studies have reported a modest positive association between 
levels of circulating inflammatory markers and the risk of total cancer incidence and 
mortality (5, 7-9, 11-13, 15); A positive association has also been found for certain site-
specific cancers, including lung (7, 8, 10, 13-15), colorectal (6, 7, 10, 14, 16, 38), and 
breast (7, 10) cancers. In these studies, a significant association was present after 
adjustment for many potential confounders, including age, sex, race and cigarette 
smoking status. Additionally, a positive association persisted after excluding incident 
cancers and cancer deaths within the first several years of follow-up to account for the 
presence of subclinical disease (6, 9-11, 38).  
 
In the majority of the aforementioned studies, systemic inflammation was quantified 
using levels of circulating total WBC count and/or C-reactive protein (CRP), which are 
non-specific inflammatory markers (7-16, 38). A few other studies have examined the 
association between select cytokines (i.e., interleukin-6 and tumor necrosis factor-) (8, 
39) and other acute phase reactants (i.e., erythrocyte sedimentation rate, serum globulin, 
and fibrinogen) (5, 6), and cancer incidence and mortality. Thus, the epidemiologic 
literature is limited with regard to characterizing and quantifying the impact of low-grade 
inflammation on tumor initiation, promotion and progression (20). This limitation is 
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particularly profound as in vivo models evaluating the effects of inflammation in the 
early stages of carcinogenesis are largely missing (4).  
 
Tumor immunosurveillance 
The tumor immunosurveillance concept, first described by Burnet and Thomas in the late 
1950’s (40, 41), posits a role for the host immune system in the identification and 
clearance of premalignant and malignant cells. More recently, experimental studies in 
murine models have provided convincing support for this anti-tumoral response, leading 
to a resurgence of interest in this theory (13, 36, 37). In these studies, the capacity of 
certain immune cells, mediators and modulators to mount a response is inversely 
associated with the development and progression of cancer. These findings have been 
reported for components of both the innate and adaptive immune systems. Additionally, 
in in vitro and in vivo studies, tumor cells that escape elimination by the host immune 
system have been shown to have reduced immunogenicity (42). This mechanism of 
tumor survival and growth, termed tumor immunoselection, has been proposed to be the 
seventh hallmark of cancer (43).  
 
In epidemiological studies, an increased risk of cancer in severely immunosuppressed 
patients has been reported in several studies. Among transplant patients, for example, 
immunosuppression is the strongest, known risk factor for cancer (40-42). Kidney 
transplant patients have a two to five-fold increased risk of de novo cancer compared to 
the age-matched general population (43-46), and in studies comparing renal transplant 
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patients to controls on kidney waiting lists and dialysis patients, this increased risk of 
cancer persists (47, 48).  
 
In transplant patients, an increased incidence of cancers of primarily viral origin is 
consistently reported (41, 43-47, 49, 50), while the association with common epithelial 
cancers remains unclear (47, 50-53). Similarly, patients diagnosed with human 
immunodeficiency virus (HIV) or acquired immune deficiency syndrome (AIDS) are at 
increased risk of developing cancers of viral origin, but have been shown to have a 
slightly reduced risk of breast, ovarian, colon, and prostate cancer (54, 55). Importantly, 
however, the interpretation of these findings is challenging given the diverse effects of 
immunomodulating medications and underlying co-morbid conditions on both immune 
functions and cancer risk in the severely immunocompromised. Additionally, differential 
screening and medical surveillance in the immunosuppressed may account for the 
decreased risk of certain cancers (50). 
 
Few epidemiological studies have examined the relationship between host immune 
capacity and cancer in immunocompetent individuals (20). In numerous studies, a history 
of allergies has been associated with a reduced risk of cancer, particularly pancreatic 
cancer and gliomas (44, 45). The mechanism underlying this inverse association has been 
hypothesized to be the tumor immunosurveillance response, given that allergies indicate a 
state of heightened immunity, however, there is limited data directly linking immune 
components of the allergic response to cancer risk (45, 46). Additional support for the 
tumor immunosurveillance response comes from cross-sectional studies in which natural 
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killer (NK) cell-mediated cytotoxicity and lymphocyte proliferation, measures of immune 
capacity, were suppressed in cancer-free individuals with a familial history of cancer 
compared to controls with no family history of cancer (56-60). To date, only one 
prospective study has directly explored the association between immune capacity and 
cancer risk. In this study of 3,625 healthy Japanese men and women, high NK cytotoxic 
activity was associated with a 41% reduction in cancer incidence after 11 years of follow-
up (47). Notably, the paucity of epidemiological studies directly exploring the tumor 
immunosurveillance response may be partly due to the lack of cohort studies with 
available measures of immune capacity and prospectively collected information on 
cancer outcomes. 
 
Immune biomarkers and cancer 
In a review of the emerging field of cancer immuno-epidemiology, Nakachi et al. (20) 
highlight the need to explore additional, novel immune biomarkers in order to better 
characterize low-grade inflammation and immune capacity in the context of tumor 
development and progression. In response to this knowledge gap, we identified several 
markers that may help to elucidate the role of the host immune system in the 
carcinogenesis pathway. These markers include the WBC subtypes, neutrophils, 
lymphocytes, monocytes, eosinphils and basophils, and CMV IgG antibody titer. 
 
WBC subtype counts 
In prospective studies, total WBC count, a nonspecific marker of systemic inflammation, 
has been consistently, positively associated with cancer risk and cancer-specific mortality 
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(5, 6, 9-12), with the exception of a few studies (63-65). Risk estimates comparing the 
highest and lowest quartile of WBC count, within the normal reference range, were 1.1 to 
1.4 for non-lung cancer incidence and 1.65 to 1.75 for cancer-specific mortality, after 
multivariable-adjustment of potential confounders such as smoking (9-12).  
 
Total WBC count consists of five diverse cell types, which have differential roles in the 
host immune response (3, 66, 67). In healthy adults, neutrophils account for 50 to 70% of 
the total WBC count while lymphocytes (30%), monocytes  (5%), eosinophils (1-3%) and 
basophils (0 to 3%) constitute the remaining cell types. Neutrophils and monocytes are 
activated early in the acute and innate inflammatory responses, particularly in response to 
bacterial infection, whereas T and B lymphocytes are involved predominantly with 
adaptive immune responses, and eosinophils and basophils are closely linked to allergic 
responses (48). Data from laboratory studies suggest that the WBC subtypes may also 
have specific roles in carcinogenesis, with the capacity to exert both pro- and anti-
tumoral effects (24). However, to date, only three epidemiological studies have explored 
the association between pre-diagnostic WBC subtype counts and subsequent cancer 
development and progression.  
 
In one of these studies, conducted in a large U.S. based cohort of adult men and women 
(N= 10,675), the highest tertile of eosinophil count was associated with a 42% reduced 
risk of colorectal cancer incidence, compared to the lowest tertile, in multivariable-
adjusted models including age, race, sex, education level, cigarette smoking status and 
total WBC count. Notably, this association held after excluding cancer cases within the 
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first five years of follow-up to account for the presence of subclinical disease and after 
excluding persons with eosinophil counts >0.3 x109 cells/L, as levels above this limit 
may indicate an acute response. Furthermore, this association seemed to be specific to 
colorectal cancer as no association was found between eosinophil count and lung or 
breast cancer incidence (49).  
 
Additionally, in a community-based cohort study conducted in Denmark, Sajadieh et al 
(50) examined the association between counts of circulating WBC subtypes and cancer 
incidence among 669 middle aged and elderly men and women without prevalent cancer 
or cardiovascular disease (CVD) at baseline. In the main analyses, elevated monocyte 
count (>0.60 x109 cells/L) was associated with a two-fold increased risk of total cancer 
incidence after adjustment for sex, age, smoking, level of CRP, alcohol usage, and heart 
rate variability. In age- and sex-adjusted models only, no association was found between 
the other WBC subtypes and cancer incidence.  
 
While these results are intriguing, they must be interpreted in light of several limitations. 
First, meaningful cut-offs of WBC subtype count were not evaluated. Specifically, the 
range of monocyte count in the highest quintile was 0.60 to 3.9 x109 cells/L, while the 
normal reference range for monocyte count in adults is 0.2 to 0.95 x109 cells/L (48). 
Thus, it is unclear if the increased risk of cancer incidence associated with the highest 
quintile of monocyte count reflects variations within this normal range or is largely 
driven by persons with abnormal monocyte counts. Furthermore, information on the 
range and distribution of the other WBC subtypes was not provided. Second, this study 
12 
was limited by a relatively short follow-up period of 6.3 years and the possibility of 
reverse causality was not evaluated. Third, in analyses of neutrophils, lymphocytes, 
basophils and eosinophils, multivariable-adjusted models were not conducted and effect 
modification was not assessed. Fourth, due to the limited number of outcomes, cancer 
mortality and cancer incidence site-specific analyses were not possible.  
 
Additionally, in the Sajadieh et al study (50), racial differences could not be addressed 
given the racial composition of the cohort. Race may be a particularly relevant factor 
when studying neutrophils as racial differences in the levels of circulating neutrophil 
count have been widely reported, with significantly lower levels in healthy black adults 
compared to whites (51-53). This difference has been linked to a single nucleotide 
polymorphsim (SNP) in the Duffy antigen receptor for chemokines (DARC) (54). It is 
plausible that neutrophil function also differs by race, and that this may have implications 
for carcinogenesis. However, this hypothesis has not been previously investigated.  
 
Finally, in a study of nearly 10,000 elderly Korean men and women, the highest quartile 
of monocyte count was significantly associated with increased cancer mortality during a 
total of 6.5 years of follow-up, based on a non-adjusted comparison of survival curves 
(55). In this study, there was no association between the other WBC subtype counts and 
cancer mortality. 
 
CMV IgG antibody titer 
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Cytomegalovirus (CMV) is an endemic beta herpes virus with seroprevalence estimates 
in the U.S. ranging from 36.6% in 6-11 year olds to 90.8% of adults ages 80 years and 
older (56). Following infection, CMV cannot be cleared by the host immune system 
resulting in an extensive and life-long immune response to ensure viral latency. In 
immunocompetent individuals, a low level, baseline CMV IgG antibody titer is 
established post infection. Among immunocompetent persons, CMV IgG levels are 
hypothesized to vary depending on the frequency and intensity of subclinical CMV 
reactivation (57-59).  
 
Cytomegalovirus (CMV) is postulated to be an etiological factor in carcinogenesis, based 
on laboratory studies. Specifically, in in vivo and in vitro studies, CMV has been shown 
to alter the expression of factors regulating cell survival, replication, motility and 
adhesion (60-63). Cytomegalovirus (CMV) may also promote carcinogenesis through its 
effects on host immunity, via the impairment cellular immunity by inducing T-cell 
anergy (64, 65) and the deregulation the host inflammatory response (60). A pro-tumoral 
role for CMV is also supported by clinical studies showing CMV viral products in tumor 
samples of the colon, cervix, breast and prostate, but not in the surrounding tissue (66-69) 
However, these findings are not consistent across all studies of tissue samples (70) and, in 
a cross-sectional study of South African men, circulating CMV IgG level did not vary in 




Notably, it is also possible that CMV reactivation is an epiphenomenon of immune 
dysfunction, rather than a causal factor (60). Cytomegalovirus reactivation is dependent 
on host immune function (72, 73), including subclinical changes in immune capacity and 
inflammation. Indeed, increased CMV reactivation has been found to occur in 
immunosuppressed populations such as the elderly (74), astronauts in space (75), and in 
persons experiencing stress or loneliness (76). As such, CMV IgG antibody titers may be 
an informative marker of immune function, generally (57, 59, 77), and tumor 
immunosurveillance, specifically, in addition to its potential causal role in 
carcinogenesis.  
 
Few prospective studies have explored the relationship between CMV infection and the 
risk of cancer incidence and mortality. In two large studies, CMV seropositivity was not 
associated with an increased risk of prostate cancer incidence (78, 79). Additionally, the 
presence of CMV viral products in benign tissue samples was not associated with 
subsequent cancer risk (80). Cytomegalovirus (CMV) seropositivity was also not 
associated with breast cancer risk in a cohort of young women, however, among CMV 
seropositive women, elevated CMV IgG conferred an increased risk of invasive breast 
cancer (81) and a significant increase in CMV IgG antibodies was found to precede 
diagnosis (82).  
 
To our knowledge, only one earlier study has evaluated the relationship between CMV 
infection and cancer mortality. In a large cohort based in the United Kingdom, the highest 
tertile of CMV IgG antibodies was positively associated with all cause mortality, as 
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compared to a CMV seronegative group, and a suggestive, but not statistically 
significant, association was observed for cancer mortality and CVD mortality (58). 
However, in analyses restricted to CMV seropositive individuals, there was no 
association by titer level (58). Notably, a major limitation of this study is the inclusion of 
persons with a history of cancer at baseline. Thus, the temporality of the reported 
associations is questionable. Additionally, these study findings may not be generalizable 
to U.S. populations, where the prevalence of CMV infection is significantly higher (56, 
58) and the patterns of seroprevalence may also differ. 
 
Study populations 
To explore the role of WBC subtype counts and CMV IgG levels in tumor initiation, 
promotion and progression, we used data from two large, well-established cohort studies 
based in the United States.  
 
ARIC 
The ARIC study is an ongoing prospective cohort initiated in 1987 to investigate the 
etiology of atherosclerosis and its sequelae. In total, 15,792 men and women, ages 45 to 
64 years, were recruited to ARIC from four U.S. communities, Forsyth County, NC; 
Jackson, MS; Washington County, MD; and suburban Minneapolis, MN. Probability 
sampling was employed to ensure that the study population is representative of the source 
communities, with the exception of Jackson, MS, where only African Americans were 
included and Forsyth County, NC, where African Americans were oversampled. Cohort 
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participants underwent a clinical exam at baseline (1987-1989) and at three follow-up 
visits conducted triennially (1990-1992, 1993-1995 and 1996-1998).  
 
At enrollment and each of the follow-up study visits, ARIC technicians collected fasting 
blood samples and other clinical data relating to cardiovascular risk.  Participants also 
reported information on sociodemographic factors, medical history, reproductive history, 
physical activity, alcohol and tobacco use, and other lifestyle behaviors via standardized 
questionnaires. Demographic, health information and aspirin use was updated annually 
by telephone interview and participant information was linked to cancer registry 




NHANES III is a cross-sectional study of non-institutionalized, civilian, United States 
citizens aged two months and older. This study was conducted between 1988 and 1994 
and was designed to provide nationally representative estimates of health conditions. To 
achieve this, a complex, multi-stage, clustered, stratified sampling approach was 
undertaken, with oversampling of African Americans, Mexican Americans, children (< 5 
years) and the elderly (> 60 years) to obtain reliable statistics for these groups.  Sample 
weights were generated for each person to account for this non-random sampling 
approach and non-response. These weights, based on U.S. Census Bureau population 
estimates at the time, assign the number of people in the U.S. population represented by 
each participant.  
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Participation in NHANES III consisted of two phases: (1) an extensive interview in the 
participant’s residence and (2) a visit to the Mobile Examination Center (MEC) where 
blood was collected and a series of clinical examinations and five automated 
questionnaires were conducted. Detailed sociodemographic and health information was 
collected, including cancer and immune-related risk factors such as age, race/ethnicity, 
sex, income, education level, BMI, personal history of cancer, prior diagnoses of 
autoimmune or inflammatory disease, recent infections and allergies reactions, physical 
activity, tobacco and alcohol consumption, menopausal status and hormone use. 
Additionally, participant information was linked to the NDI through 2011. 
 
Outline of dissertation 
This dissertation is comprised of five research chapters (chapters 2-6). Our study of the 
prospective associations between WBC subtype counts and cancer incidence and 
mortality is divided into four chapters, with separate sections for neutrophils (chapter 2), 
lymphocytes (chapter 3), basophils (chapter 4), and monocytes (chapter 5). In chapter 6, 
we explore the association between CMV IgG levels and subsequent cancer mortality 
among CMV seropositive adults. This dissertation concludes with a summary of our 
findings, implications for cancer prevention research and for the clinical setting, and 
directions for future epidemiological studies.  
18 
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Chapter 2. A prospective study of neutrophil count and the risk of 
cancer incidence and mortality in the Atherosclerosis Risk in 
Communities (ARIC) study 
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Abstract 
Several prospective studies have reported a positive association between total white 
blood cell (WBC) count and cancer incidence and mortality. However, subtypes of total 
WBC count may have distinct roles in inflammation-mediated tumorigenesis. We 
examined the relationship between pre-diagnostic neutrophil count, the predominant 
WBC subtype, and subsequent cancer incidence and mortality in the Atherosclerosis Risk 
in Communities (ARIC) study. Participants were included if they had a total WBC count 
within the normal range and no prior cancer at baseline blood draw. Cox proportional 
hazard models were used to estimate the multivariable-adjusted hazard ratio (HR) and 
95% confidence interval (CI) by tertile of neutrophil count. During follow-up, 2,136 
incident cancers (1987-2006) and 952 cancer deaths (1987-2008) were detected. 
Compared to the lowest tertile, the highest neutrophil count tertile was associated with an 
increased risk of total cancer incidence (HR: 1.11, 95% CI: 1.00, 1.25) and, specifically, 
lung cancer incidence (HR: 1.59, 95% CI: 1.12, 2.26). In stratified analyses, a significant 
increased risk was present among current smokers only (HR: 1.30, 95% CI: 1.03, 1.64). 
The highest tertile of neutrophil count was also associated with an increased risk of 
cancer mortality, overall (HR: 1.44, 95% CI: 1.22, 1.72), and across strata of sex, race 
and smoking status. In cancer mortality site-specific analyses, high neutrophil count was 
associated with an increased risk of lung (HR: 1.66, 95% CI: 1.18, 2.33) and breast 
cancer mortality (HR: 2.09, 95% CI: 1.10, 3.97). Our findings support a role for low-
grade inflammation in tumor development and progression and suggest a specific effect 





Inflammation has been implicated in the development and progression of cancer in 
observational (1-7) and experimental studies (8-11). Total white blood cell (WBC) count 
is a common clinical marker of non-specific, systemic inflammation. Prospective 
epidemiological studies have reported a modest association between higher levels of 
circulating total WBC count, within the clinically normal reference range, and increased 
risk of both cancer incidence and cancer mortality (2, 6, 7, 12, 13). A similar, significant 
association was observed even after excluding incident cancers and cancer deaths within 
the first several years of follow-up to account for possible reverse causality (6, 7, 12, 13). 
Collectively, these studies support a role for low-grade inflammation in cancer 
development and progression. 
 
White blood cells (WBC) consist of diverse cell types, which have defined roles in the 
host immune response (14). These cell types have also been shown to have specific 
effects on carcinogenesis (8). In particular, neutrophils, the predominant WBC subtype, 
are activated early in the acute and innate inflammatory responses. These cells are also 
implicated, more broadly, in the regulation of chronic inflammation and the adaptive 
immune response (14, 15). Additionally, in vitro and in vivo studies support a direct pro-
tumoral role for neutrophils in the tumor microenvironment via the production of reactive 
oxygen species, cytokines and proteases (15-18). This is consistent with findings in the 
clinical setting, in which higher levels of circulating neutrophil count at the time of 




To date, few prospective studies have examined the relationship between WBC subtypes 
and either cancer incidence or mortality, including only one study evaluating neutrophil 
count. In this previous study, no association was found between neutrophil count and 
subsequent cancer incidence in sex- and age-adjusted models. However, factors that may 
potentially confound or modify this association, such as cigarette smoking and body mass 
index (BMI), were not assessed (22). To our knowledge, the association between 
neutrophil count and cancer mortality has not been previously studied.  
 
Furthermore, circulating neutrophil count varies significantly by race, with a lower 
distribution of counts found in healthy black adults than in whites (23-25). This 
difference has been linked to a single nucleotide polymorphism (SNP) in the Duffy 
antigen receptor for chemokines (DARC) (26). It remains unknown whether or not this 
genetic variant affects the innate immune response, particularly in the context of cancer 
development and progression.  
 
The present study evaluates the association between neutrophil count, within the 
clinically normal range, and subsequent cancer incidence and cancer mortality, overall 
and by race, sex, smoking status, and polymorphisms of the DARC gene. Given the 
emerging literature on the role of low-grade inflammation in the carcinogenesis pathway, 
and the specific contribution of neutrophils (8, 10, 11), we hypothesize that higher levels 
of circulating neutrophils may be associated with an increased risk of cancer incidence 
and cancer mortality.   
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Materials and Methods 
Study population 
This study was conducted in the ARIC study, an ongoing, prospective cohort initiated 
between 1987 and 1989 to investigate the etiology of atherosclerosis and its sequelae. 
Men and women (N=15,792), ages 45 to 64 years, were enrolled from four U.S. 
communities, Forsyth County, NC; Jackson, MS; Washington County, MD; and suburban 
Minneapolis, MN. Participants were identified using probability sampling in Minneapolis 
and Washington County, while in Jackson, blacks were exclusively recruited and in 
Forsyth County blacks were oversampled (27). Participants from Washington County 
were not included in these analyses as baseline WBC subtype count was missing for more 
than 85% of participants (28). At enrollment, participants provided a blood sample and 
reported information on sociodemographic factors, medical history, reproductive history, 
physical activity, alcohol and tobacco use and other lifestyle behaviors via standardized 
questionnaires.  
 
The analytic cohort included both men and women that met the following eligibility 
criteria: (1) not residing in Washington County, MD (N=11,792); (2) no personal history 
of cancer, excluding cases of non-melanoma skin cancer (N=11,175); (3) white or black 
race (N=11,140); (4) total WBC count within two standard deviations of the mean in 
whites and blacks, separately (range: 3.0 to 10.9 x 109 cells/L) (N=10,351); (5) not 
missing baseline neutrophil count (N=10,348); and (6) not missing information on cancer 




Total and differential WBC counts were measured at baseline and three years later at 
Visit 2. In the main analyses, baseline WBC subtype counts were evaluated. Following 
venipuncture, samples were stored at 4°C and within 24 hours total WBC count was 
measured using automated particle counters in local, independent clinical laboratories. 
The WBC subtypes were measured as a proportion of total WBCs and counts were 
subsequently calculated by multiplying this proportion by total WBC count. Based on 
repeat testing of individuals conducted one to two weeks apart, reliability coefficients for 
total WBC count were estimated to be greater than 0.96 for each laboratory (29, 30).  
 
Outcome ascertainment 
The incidence of a first primary cancer, including date of diagnosis and site of cancer, 
was ascertained from study initiation through December 31, 2006 (1, 30). Cancer 
incidence was primarily identified by linkage to well-established state and/or county 
cancer registries that have a high completeness (≥90%) of cancer data (30). Hospital 
surveillance was used to identify cancer cases in Jackson prior to establishment of the 
Mississippi state cancer registry in 1996 (31), as well as all additional cancer cases for the 
other study sites (30, 32). At present, data on stage at diagnosis, cancer subtype and 
treatment are not consistently available for all cancers and, therefore, were not 
incorporated in analyses. 
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Vital status was available through December 31, 2008. Deaths were identified through 
contact with relatives, physician or designated contact, or through a search of obituaries, 
funeral and hospital records, death certificates and the National Death Index (NDI). The 
date and cause of death were confirmed by death certificate for all reported deaths. Cause 
of death was coded using the Ninth International Statistical Classification of Diseases and 
Related Health Problems (ICD-9) for deaths through 1998 and ICD-10 for all subsequent 
deaths. Cause-specific mortality from death certificate was available for 98% of 
decedents (33).  
 
Assessment of covariates 
Participants reported their highest education attainment, regular alcohol use, and intake of 
aspirin in the two weeks prior to baseline study visit. They also provided information on 
current cigarette smoking status and, if applicable, the average number of years of 
smoking and cigarettes smoked per day. These values were used to calculate pack-years 
([cigarettes per day*years smoking]/20 cigarettes per pack) among ever smokers. 
Exposure to environmental tobacco smoke (ETS) was defined as being in close proximity 
to smokers for more than 1 hour per week (34, 35). Body mass index (BMI), calculated 
as weight divided by height squared [weight (kg)/height(m)2], and waist circumference 
were collected by trained technicians at baseline study visit. A history of cardiovascular 
disease (CVD) was defined as having a prior diagnosis of angina pectoris, coronary heart 
disease, intermittent claudication or stroke. Participants were categorized as having 
hypertension if they reported use of any hypertensive medications or if they had systolic 
blood pressure ≥140 mmHg or diastolic blood pressure ≥90 mmHg. Diabetes was defined 
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as having a fasting glucose level ≥126 mg/dl, a non-fasting glucose level ≥200 mg/dl, a 
self-reported physician diagnosis of diabetes, or use of blood sugar lowering medications 
in the two weeks prior to enrollment. Women were categorized as being premenopausal if 
they had a menstrual cycle within two years of baseline or postmenopausal (36). Women 
missing information on menopausal status were categorized as being postmenopausal if 
they were 55 years of age or older. Postmenopausal hormone use was categorized as 
current, former or never (36).  
 
Genotyping of the rs2814778 polymorphism in the DARC gene was performed using the 
ABI TaqMan technology, and the proportion of European ancestry was measured using a 
genome-wide admixture mapping scan with 1,350 ancestry-informative SNPs. 
Genotyping methods have been described previously (26, 37). 
 
Statistical analyses  
Baseline neutrophil count was categorized as tertiles based on race-specific cut points, 
given the significant differences in the mean and standard deviation in whites and blacks 
(25, 38). Race-specific tertiles of neutrophil count (whites tertile 1: 1.100-3.135, tertile 2: 
3.136-4.189, tertile 3: 4.200-9.180; blacks tertile 1: 0.333-2.035, tertile 2: 2.040, 3.024, 
tertile 3: 3.024, 7.600 x109 cells/L) were then combined across the total analytic study 
population. Baseline descriptive characteristics were compared by neutrophil count tertile 
using the chi-square test for categorical variables or ANOVA for continuous variables.  
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Cox proportional hazards models were used to estimate the hazard ratio (HR) and 95% 
confidence interval (CI) for cancer incidence and cancer mortality by tertile of neutrophil 
count. Tests for linear trend across categories of neutrophil count were calculated by 
introducing an ordinal variable into models, which represented the rank order of the 
categories. In analyses of cancer incidence, follow-up time was accrued from age at 
baseline blood draw, with the origin defined as age 40 years and staggered late entries for 
persons over age 40 at baseline, to the first of the following events: (1) age at first 
primary cancer diagnosis, (2) age at death, or (3) age at end of follow-up (December 31, 
2006). In analyses of cancer mortality, individuals were followed from age at baseline 
blood draw to (1) age at death or (2) age at end of follow-up (December 31, 2008). In 
models in which time accrued from year at baseline blood draw to (1) year at first 
primary cancer diagnosis or cancer death, (2) year at other death, or (3) year at end of 
follow-up, similar HRs were estimated and are not presented here. Multivariable models 
included the baseline covariates sex, race (white, black), study site (Jackson, MS, Forsyth 
County, Minneapolis, MN), BMI (<18.5, 18.5-24.9, 25.0-29.9, 30.0-34.9, >35.0 kg/m2), 
waist circumference (continuous), education attainment (<high school diploma, high 
school diploma, >high school or college graduate, graduate school), cigarette smoking 
status (never, former, current), pack-years (continuous), ETS (<1 hour/week, >1 
hour/week), alcohol intake (g/wk), aspirin use in two weeks prior to blood draw (yes/no), 
and medical history (yes/no) of CVD, hypertension, and diabetes. Missing pack-year and 
waist circumference information was replaced with the median value. Further adjustment 
by counts of the other WBC subtypes (lymphocyte count tertile (<1.65, 1.66-2.14, >2.15 
x109 cells/L), monocyte count tertile (<0.272, 0.273-0.399, >0.400 x109 cells/L), 
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eosinophil count tertile (<0.07, 0.07-0.174, >0.175 x109 cells/L) and basophil category 
(<0.03, >0.03 x109 cells/L)) was also performed. Effect modification between neutrophil 
count and covariates known to modulate immune function, including race, sex, age, 
cigarette smoking status, aspirin use and BMI, was assessed by introducing a cross-
product term in models and using the Wald test to test for statistical significance. 
Additionally, among black participants, effect modification by the presence of the Duffy 
null polymorphism and percent European ancestry was evaluated. The proportional 
hazards assumption was assessed by introducing an interaction term between neutrophil 
count and follow-up time into models. In all cases, the interaction term was not 
statistically significant, confirming this assumption. Rates of cancer incidence and cancer 
mortality were standardized to the age, race and sex distribution of the analytic cohort. 
  
Cancer site-specific analyses were conducted in models of cancer incidence and cancer 
mortality for the four most common cancers (i.e., female breast cancer, colorectal cancer, 
lung cancer, and prostate cancer, Appendix A, Table A.1). Additionally, the following 
sensitivity analyses were performed: (1) excluding incident cancer cases within one and 
five years from baseline blood draw in order to address the possibility of bias due to 
reverse causation; (2) excluding persons who used aspirin in the two weeks prior to 
baseline; (3) excluding participants with neutrophil counts greater than two standard 
deviations from the mean, in whites and blacks separately, to more rigorously restrict 
analyses to persons without acute inflammation or underlying inflammatory disease; and 
(4) using neutrophil count measured at Visit 2 as the exposure of interest and, 
accordingly, accumulating time at risk from age at Visit 2 (1990-1992). Lastly, in cancer 
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mortality analyses, sub-distribution hazard ratios were estimated using the Fine and Gray 
approach to account for the issue of competing risks (39). All analyses were conducted 
using STATA version 11.2 (Stata Corporation, College Station, TX, 2012).  
 
Results 
The distributions of neutrophil count by select baseline characteristics are shown in Table 
2.1. The median neutrophil count was 3.60 x 109 cells/L (interquartile range (IQR): 2.91, 
zhighest neutrophil count tertile were significantly more likely to be male, less educated, 
have a higher BMI and waist circumference, consume more alcohol, and have a medical 
history of CVD, hypertension and diabetes, compared to those in the lowest tertile. 
Additionally, exposure to tobacco smoke, based on current cigarette smoking status, 
pack-years and ETS, was greater in the highest tertile of neutrophil count compared to the 
lowest. In whites, there were similar differences in the distribution of baseline 
characteristics by neutrophil count tertile, while, in blacks, there was no significant 
differences in sex, education attainment, BMI, pack-years, exposure to ETS or 
hypertension (Appendix A, Table A.2).  
 
Cancer incidence 
Between 1987 and 2006, 2,136 incident cancers developed over a median follow-up of 
18.1 years. Table 2.2 presents the multivariable-adjusted associations between neutrophil 
count tertile and cancer incidence overall and stratified by select factors. Overall, the 
highest neutrophil count tertile was associated with a 1.11-fold (95% CI: 1.00, 1.25, p-
trend=0.06) increased risk of cancer incidence, compared to the lowest tertile. There was 
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no significant interaction between neutrophil count and race, sex, cigarette smoking 
status, BMI or aspirin use (all p-interaction terms >0.1). However, in stratified analyses, 
neutrophil count was significantly associated with cancer incidence among current 
smokers (HR: 1.30, 95% CI: 1.03, 1.64, p-trend=0.05), but not among former or never 
smokers. The significant association between high neutrophil count and cancer incidence 
in the total study population persisted after excluding incident cancer events within one 
and five years of follow up and among persons who did not use aspirin in the two weeks 
prior to blood draw. Similar significant results were also found in analyses excluding 
persons with neutorphil counts greater than two standard deviations from the mean. In 
analyses using neutrophil count measured at Visit 2, the association between the highest 
tertile of neutrophil count and cancer incidence was no longer statistically significant 
(HR: 1.08, 95% CI: 0.94, 1.25). 
 
In cancer-site specific analyses, neutrophil count tertile was associated with an increased 
risk of developing lung cancer (HR: 1.59, 95% CI: 1.12, 2.26, p-trend=0.01) and a non-
significant increased risk of colorectal cancer incidence (HR: 1.35, 95% CI: 0.95, 1.92, p-
trend=0.10). There was no association with breast cancer incidence in females or prostate 
cancer incidence in males (Figure 2.1).  
 
Cancer mortality 
Between 1987 and 2008, 952 cancer deaths occurred during a median follow-up of 21.7 
years. In the total study population, the highest neutrophil count tertile was associated 
with a 44% (HR: 1.44, 95% CI: 1.22, 1.72, p-trend<0.0001) increased risk of cancer 
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mortality, compared to the lowest tertile of neutrophil count (Table 2.3). This association 
remained significant after excluding incident cancer cases within one and five years from 
baseline and in analyses restricted to participants with neutrophil counts within two 
standard deviations of the mean. There was no evidence of a statistical interaction by 
race, sex, cigarette smoking status, BMI or aspirin use (all p-interaction terms >0.1), and 
a significant positive association between neutrophil count tertile and cancer mortality 
held across strata of cigarette smoking status (current smokers HR: 1.37, 95% CI: 1.02, 
1.84, p-trend=0.02; former smokers HR: 1.42, 95% CI: 1.07, 1.89, p-trend=0.02; never 
smokers HR: 1.47, 95% CI: 1.06, 2.05, p-trend=0.02) (Table 3). In analyses using 
neutrophil count measured at Visit 2, a significant positive association persisted between 
the highest tertile of neutrophil count and total cancer mortality (HR: 1.39, 95% CI: 1.11, 
1.76). 
 
In cancer-site specific analyses, we observed an increased risk of lung cancer death (HR: 
1.66, 95% CI: 1.18, 2.33, p-trend=0.005) and female breast cancer death (HR: 2.09, 95% 
CI: 1.10, 3.97, p-trend=0.02) when comparing the highest neutrophil count tertile to the 
lowest (Figure 2.2). Upon excluding deaths due to lung cancer, a significant positive 
association remained between the highest tertile of neutrophil count and non-lung cancer 
mortality in never smokers (Appendix A, Table A.3). Furthermore, in analyses restricted 
to postmenopausal women, a positive, but non-significant association was observed for 
breast cancer deaths (HR: 2.25, 95% CI: 0.96, 5.27). There was no association between 
neutrophil count and colorectal or prostate cancer mortality (Figure 2.2).  
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Additionally, the highest tertile of neutrophil count was associated with an increased risk 
of CVD death (HR: 1.45, 95% CI: 1.23, 1.71, p-trend<0.0001) and non-cancer mortality 
(HR: 1.62, 95% CI: 1.40, 1.87, p-trend<0.0001), compared to the lowest tertile. In 
competing risk analyses, accounting for deaths from causes other than cancer, the 
association between the highest neutrophil count tertile and cancer mortality persisted 
(sub-distribution HR: 1.38, 95% CI: 1.16, 1.64).  
 
Other WBC subtypes 
Correlations across baseline WBC subtype counts are presented in Appendix A, Table 
A.4. In models of cancer incidence and mortality, mutual adjustment for the other WBC 
subtypes did not significantly alter risk estimates (Table 2.4). Additionally, for 
comparison with our main models, we also estimated the risk of cancer incidence and 
cancer mortality by quartile of total WBC count (Appendix A, Tables A.5). In 
multivariable-adjusted models, there was no association between total WBC count and 
cancer incidence, while the highest quartile of total WBC count was associated with a 
47%  (HR: 1.47, 95% CI: 1.20, 1.81) increased risk of cancer mortality. 
 
Stratification by genetic markers 
In a subset of black participants with available genetic data (N=3,131), the median 
proportion of European ancestry was 0.17 (IQR: 0.11, 0.22) and 70% were carriers of the 
Duffy null polymorphism. The highest tertile of neutrophil count was more strongly 
associated with both cancer incidence (HR: 1.27, 95% CI: 0.96, 1.68) and cancer 
mortality (HR: 1.40, 95% CI: 0.95, 2.07) in carriers of the Duffy null polymorphism than 
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in non-carriers (HRcancer incidence: 0.94, 95% CI: 0.51, 1.76 and HRcancer mortality: 1.01, 95% 
CI: 0.42, 2.42), although this difference was not statistically significant (p-
interaction=0.58 and 0.72, respectively).  
 
Additionally, percent European ancestry significantly modified the association between 
neutrophil count tertile and cancer incidence (p-interaction=0.009), such that higher 
levels of neutrophil count was more strongly associated with cancer incidence in blacks 
with lower percent European ancestry. However, there was no significant interaction in 
models of cancer mortality. 
 
Discussion 
In this large, prospective cohort study, high pre-diagnostic neutrophil count was 
associated with an increased risk of total cancer incidence, independent of the effects of 
the other WBC subtypes. However, in further analyses, this association was limited to 
current smokers and was specific to cases of lung cancer. High neutrophil count was also 
associated with an increased risk of total cancer mortality. This significant association 
persisted after mutual adjustment for the other WBC subtypes and after excluding cancer 
cases within the first five years of follow-up to account for the presence of subclinical 
disease. Additionally, a significant positive association held across strata of sex, race, and 
cigarette smoking status, In cancer mortality site-specific analyses, significant 
associations were observed for lung and breast cancers.  
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Although neutrophils are primarily involved in the acute inflammatory response, these 
cells also have a role in regulating chronic inflammation. Thus, neutrophils, may be an 
informative marker of inflammation. There is also evidence from in vitro and in vivo 
studies to suggest that neutrophils may directly exert pro-tumoral effects in the tumor 
microenvironment (16, 40, 41), generally, and in breast and lung cancers, specifically 
(20, 42, 43). Our study expands upon these findings by reporting, for the first time, that 
higher neutrophil count, measured years prior to the onset of cancer, may also have pro-
tumoral effects, particularly with respect to tumor progression.  
 
Only one previous study has examined the association between circulating neutrophil 
count and subsequent cancer incidence. In that study, conducted among 669 Danish 
adults, no association was found in age- and sex-adjusted models (22). In contrast, in the 
present study, we found a positive association between neutrophil count and cancer 
incidence in multivariable-adjusted models. However, given that this association was 
limited to current cigarette smokers, our finding may be explained by residual 
confounding by tobacco use, despite having adjusted for pack-years and ETS. There is 
little data to support the alternate explanation, that tobacco may modify the function of 
neutrophil count (44, 45).   
 
To our knowledge, this is the first prospective study to examine the association between 
pre-diagnostic neutrophil count and cancer mortality. Our finding of a significant positive 
association, regardless of cigarette smoking status, is consistent with previous studies, in 
which total WBC count was positively associated with total (6, 7, 12), lung and breast 
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cancer mortality (7). The stronger association with cancer mortality than with cancer 
incidence in this study suggests that the neutrophil-mediated inflammatory response may 
lead to the development of more aggressive disease. Alternatively, higher baseline 
neutrophil count or its sequelae may impact treatment resistance and, in turn, prognosis. 
In the present study, we were unable to evaluate these possibilities, as information on 
stage at diagnosis and treatment were not consistently available.  
 
Although there was no evidence of effect modification by self-reported race in the 
present study, we did observe a significantly stronger association between neutrophil 
count and cancer incidence in individuals with lower percent European ancestry, 
suggesting that a genetic variant(s) related to race may affect neutrophil function, 
particularly in the context of cancer initiation. One possible candidate is the Duffy null 
polymorphism, which is present nearly exclusively in black populations and has been 
linked to lower circulating neutrophil count (26). While we did find a stronger association 
between neutrophil count and cancer incidence and mortality in carriers of the Duffy null 
polymorphism, this interaction did not reach statistical significance. This is not entirely 
unexpected as any negative health effects associated with this genetic variant are 
expected to be subtle given the high frequency of this polymorphism in black populations 
(26).  
 
Certain limitations of this study warrant further consideration. First, we utilized a one-
time measurement of neutrophil count. However in another study with over 40 years of 
follow-up, accounting for time-varying measures of total WBC count, measured every 
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two years, as compared to using a single baseline measurement, did not appreciably alter 
risk estimates (46). Additionally, in a subset of the analytic cohort, the correlation 
between neutrophil counts measured at baseline and Visit 2, three years later, was 0.65, 
indicating that this marker is fairly stable in the short-term, and in analyses using 
neutrophil count measured at Visit 2, similar associations were found for both cancer 
incidence and mortality. Another limitation of this study is that the effects of race cannot 
be completely differentiated from geography as nearly all blacks were recruited from 
Jackson, MS while whites were identified at the other three study sites.  
 
This study also has several strengths. The ARIC study is a prospective, population-based 
cohort with over 20 years of follow-up for cancer outcomes and good representation of 
both whites and blacks. Few other cohorts with prospectively collected information on 
cancer endpoints have also measured baseline WBC subtype counts. Additionally, 
detailed information was available on a wide-array of socio-demographic characteristics, 
lifestyle risk factors and medical history, as well as genetic markers.  
 
Our findings provide the first prospective evidence linking the neutrophil-mediated 
inflammatory response in healthy men and women to subsequent cancer incidence and 
mortality. This adds to the mounting evidence linking low-grade inflammation to tumor 
development and progression and expands upon laboratory data suggesting a specific role 
for neutrophils in carcinogenesis. Future studies are necessary to explore the role of the 
downstream products of neutrophil activation and other WBC subtypes in cancer 
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Table 2.1 Baseline characteristics by tertile of neutrophil count in ARIC participants, 
1987-1989 
  Neutrophil Counta 
  Tertile 1  Tertile 2 Tertile 3 
Total, N 3,463 3,432 3,442 
Study Siteb, %     
    Jackson, MS 33.7 30.9 30.0 
    Forsyth County, NC 31.1 34.9 35.5 
    Minneapolis, MN 35.3 34.2 34.5 
Male, % 41.1 47.1 47.2 
Blacks, % 35.9 36.0 36.0 
Age (years), Mean (SD)  53.8 (5.6) 54.0 (5.8) 53.9 (5.9) 
Education, %     
    <High school 20.6 22.2 23.1 
    High school or college 
graduate 37.5 39.2 40.2 
    Graduate school 41.9 38.6 36.7 
    Missing, N 4 8 5 
BMI (kg/m2), %     
    <18.5 0.6 0.6 1.2 
    18.5-24.99 36.1 30.5 28.8 
    25.0 29.99 39.5 40.1 39.5 
    30.0-34.99 17.2 19.3 19.2 
    >35.00 6.7 9.5 11.1 
    Missing, N 2 2 5 
Waist Circumference (cm), 
Mean (SD) 
94.5 (13.2) 97.2 (13.7) 98.2 (14.5) 
    Missing, N 0 0 3 
Cigarette Smoking Status, %     
    Never 51.5 41.4 29.8 
    Former 34.9 34.7 27.9 
    Current 13.6 23.9 42.3 
    Missing, N 3 3 2 
Pack-Yearsc, Mean (SD) 23.5 (21.8) 24.3 (21.7) 25.5 (21.9) 
    Missing, N 60 66 64 
ETSd (hours/week), %     
    <1 35.5 30.3 23.4 
    >1 64.5 69.7 76.6 
    Missing, N 25 19 18 
Alcohol Intakee, Mean (SD) 
(g/wk) 96.5 (101.0) 109.4 (131.5) 124.8 (151.7) 
    Missing, N 17 34 17 
CVDf, % 7.5 9.6 12.2 
Hypertensiong, % 32.2 36.4 37.0 
    Missing, N 0 2 1 
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Table 2.1 (continued) Baseline characteristics by tertilea of neutrophil count in ARIC 
participants 
 Neutrophil Count  
 Tertile 1  Tertile 2 Tertile 3 
Diabetesh, % 7.8 11.5 16.1 
    Missing, N 3 4 7 
Aspirin usedi, % 44.0 44.8 46.3 
    Missing, N 29 32 21 
Abbreviations: BMI, body mass index; SD, standard deviation; ETS, environmental tobacco smoke; 
CVD, cardiovascular disease. a Neutrophil count tertiles defined based on race-specific cut-offs and 
combined across the analytic cohort. bParticipants from Washington County, MD were excluded 
from analyses due to substantial missing WBC subtype count data at this site. cPack-years among 
ever smokers only. Pack-years was calculated as the average number of cigarettes smoked per day 
multiplied by the number of years of smoking and divided by 20. dETS defined as the average 
number of hours per week of close contact with people when they are smoking. eAlcohol intake 
among participants who reported usually having at least one drink per week. fCVD defined as 
having a history of angina pectoris, coronary heart disease, intermittent claudication, or stroke. 
gHypertension defined as use of any hypertensive medications, systolic blood pressure >140 
mmHg, or diastolic blood pressure >90 mmHg. hDiabetes defined as having a fasting glucose level 
>126 mg/dl, non-fasting glucose level >200 mg/dl, a physician diagnosis of diabetes, or using 








Table 2.2 Multivariable-adjusted hazard ratios for cancer incidence by tertile of neutrophil count, 






HR (95% CI) c 
Overall     
1 660 56777.3 193.8 1.00 (Reference) 
2 700 54285.1 208.1 1.04 (0.93, 1.16) 
3 766 51924.3 222.8 1.11 (1.00, 1.25) 
P-Trend     0.06 
Whites     
1 435 36907.5 198.3 1.00 (Reference) 
2 462 35535.8 209.9 1.00 (0.87, 1.14) 
3 537 34126.6 243.8 1.11 (0.97, 1.28) 
P-Trend    0.12 
Blacks     
1 225 19869.8 185.8 1.00 (Reference) 
2 247 18749.3 204.5 1.15 (0.96, 1.38) 
3 229 17797.7 185.6 1.10 (0.91, 1.34) 
P-Trend    0.31 
Men     
1 327 22633.5 236.7 1.00 (Reference) 
2 388 24948.7 241.5 1.03 (0.89, 1.20) 
3 438 2360.3 263.4 1.15 (0.99, 1.34) 
P-Trend    0.07 
Womend     
1 333 34143.9 163.3 1.00 (Reference) 
2 321 29336.5 177.7 1.07 (0.91, 1.24) 
3 328 28294.0 186.0 1.08 (0.92, 1.27) 
P-Trend    0.36 
Current Smokers    
1 97 7469.3 213.4 1.00 (Reference) 
2 205 12051.5 254.9 1.27 (0.99, 1.63) 
3 373 21347.6 259.1 1.30 (1.03, 1.64) 
P-Trend    0.05 
Former Smokers    
1 252 19604.4 219.4 1.00 (Reference) 
2 244 19013.7 204.4 0.92 (0.77, 1.10) 
3 216 14693.1 218.2 1.04 (0.86, 1.25) 
P-Trend    0.76 
Never Smokers    
1 311 29665.3 176.2 1.00 (Reference) 
2 259 23196.9 184.6 1.06 (0.89, 1.25) 
3 177 15883.6 172.5 1.07 (0.89, 1.30) 
P-Trend       0.44 
Abbreviations: HR, hazard ratio; CI, confidence interval. aNeutrophil count tertiles defined based on race-
specific cut-offs and combined across the analytic cohort. bIncidence rate per 1,000 individuals from 1987 
to 2006 standardized to the age, race and sex distribution of the analytic cohort. cModels adjusted for study  
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Table 2.2 (continued) Multivariable-adjusted hazard ratios for cancer incidence by tertile of neutrophil 
count, stratified by race, sex and cigarette smoking status, in the ARIC study, 1987-2006 
 
site (Jackson, Forsyth County, Minneapolis), race (white, black), sex, body mass index (<18.5, 18.5-24.9, 
25.0-29.9, 30.0-34.9, >35.0 kg/m2), waist circumference (continuous), education level (<high school 
diploma, high school diploma, >high school or college graduate, graduate school) smoking status (never, 
former, current), pack-years (continuous), environmental tobacco smoke (<1, >1 hour/week), alcohol intake 
(continuous), aspirin use in the two weeks prior to blood draw (yes/no), medical history (yes/no) of 
cardiovascular disease, hypertension, and diabetes. dAdditionally adjusted for menopausal status and HRT 
use (pre/peri-menopausal, postmenopausal and current HRT user, postmenopausal and former HRT user, 
postmenopausal and never HRT user). 
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Figure 2.1 Multivariable-adjusted hazard ratios for site-specific cancer incidence by tertile of neutrophil 
count in the ARIC study, 1987-2006. Light gray=tertile 1; Medium gray=tertile 2; Dark gray=tertile 3. 
Neutrophil count tertiles defined based on race-specific cut-offs and combined across the analytic cohort. 
Models adjusted for study site (Jackson, Forsyth County, Minneapolis), race (white, black), sex, body mass 
index (<18.5, 18.5-24.9, 25.0-29.9, 30.0-34.9, >35.0 kg/m2), waist circumference (continuous), education 
level (<high school diploma, high school diploma, >high school or college graduate, graduate school) 
smoking status (never, former, current), pack-years (continuous), environmental tobacco smoke (<1, >1 
hour/week), alcohol intake (continuous), aspirin use in the two weeks prior to blood draw (yes/no), medical 
history (yes/no) of cardiovascular disease, hypertension, and diabetes. Models of female breast cancer were 
additionally adjusted for menopausal status and HRT use (pre/peri-menopausal, postmenopausal and 




















Table 2.3 Multivariable-adjusted hazard ratios for cancer mortality by tertile of neutrophil count, 







HR (95% CI) c 
Overall     
1 236 70232.2 69.7 1.00 (Reference) 
2 297 67064.1 87.3 1.13 (0.95, 1.35) 
3 418 63627.6 121.5 1.44 (1.22, 1.72) 
P-Trend    <0.0001 
Whites     
1 139 46230.9 64.4 1.00 (Reference) 
2 178 44179.8 80.8 1.07 (0.86, 1.35) 
3 284 42013.4 129.2 1.47 (1.18, 1.84) 
P-Trend    <0.0001 
Blacks     
1 97 24001.3 79.2 1.00 (Reference) 
2 119 22884.3 98.9 1.22 (0.93, 1.60) 
3 134 21614.2 107.7 1.37 (1.04, 1.79) 
P-Trend    0.03 
Men     
1 127 28080.2 95.1 1.00 (Reference) 
2 175 30647.7 109.8 1.10 (0.87, 1.39) 
3 237 29132.9 141.7 1.28 (1.02, 1.61) 
P-Trend    0.03 
Womend     
1 109 42152.1 53.1 1.00 (Reference) 
2 122 36416.5 67.6 1.15 (0.88, 1.49) 
3 181 34494.6 103.1 1.63 (1.26, 2.09) 
P-Trend    <0.0001 
Current Smokers    
1 60 8806.4 120.4 1.00 (Reference) 
2 118 14760.7 145.8 1.15 (0.83, 1.57) 
3 236 25868.4 160.9 1.37 (1.02, 1.84) 
P-Trend    0.02 
Former Smokers    
1 95 24383.1 87.9 1.00 (Reference) 
2 97 23468.1 80.9 0.98 (0.73, 1.30) 
3 110 18021.5 112.0 1.42 (1.07, 1.89) 
P-Trend    0.02 
Never Smokers    
1 81 36998.5 45.4 1.00 (Reference) 
2 81 28796.3 58.5 1.22 (0.89, 1.66) 
3 72 19737.7 67.0 1.47 (1.06, 2.05) 
P-Trend       0.02 
Abbreviations: HR, hazard ratio; CI, confidence interval. aNeutrophil count tertiles defined based on race-
specific cut-offs and combined across the analytic cohort. bIncidence rate per 1,000 individuals from 1987 
to 2006 standardized to the age, race and sex distribution of the analytic cohort. cModels adjusted for study  
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Table 2.3 (continued) Multivariable-adjusted hazard ratios for cancer incidence by tertile of neutrophil 
count, stratified by race, sex and cigarette smoking status, in the ARIC study, 1987-2006 
 
site (Jackson, Forsyth County, Minneapolis), race (white, black), sex, body mass index (<18.5, 18.5-24.9, 
25.0-29.9, 30.0-34.9, >35.0 kg/m2), waist circumference (continuous), education level (<high school 
diploma, high school diploma, >high school or college graduate, graduate school) smoking status (never, 
former, current), pack-years (continuous), environmental tobacco smoke (<1, >1 hour/week), alcohol intake 
(continuous), aspirin use in the two weeks prior to blood draw (yes/no), medical history (yes/no) of 
cardiovascular disease, hypertension, and diabetes. dAdditionally adjusted for menopausal status and HRT 
use (pre/peri-menopausal, postmenopausal and current HRT user, postmenopausal and former HRT user, 






Figure 2.2 Multivariable-adjusted hazard ratios for site-specific cancer mortality by tertile of neutrophil 
count in the ARIC study, 1987-2008. Light gray=tertile 1; Medium gray=tertile 2; Dark gray=tertile 3. 
Neutrophil count tertiles defined based on race-specific cut-offs and combined across the analytic cohort. 
Models adjusted for study site (Jackson, Forsyth County, Minneapolis), race (white, black), sex, body mass 
index (<18.5, 18.5-24.9, 25.0-29.9, 30.0-34.9, >35.0 kg/m2), waist circumference (continuous), education 
level (<high school diploma, high school diploma, >high school or college graduate, graduate school) 
smoking status (never, former, current), pack-years (continuous), environmental tobacco smoke (<1, >1 
hour/week), alcohol intake (continuous), aspirin use in the two weeks prior to blood draw (yes/no), medical 
history (yes/no) of cardiovascular disease, hypertension, and diabetes. Models of female breast cancer were 
additionally adjusted for menopausal status and HRT use (pre/peri-menopausal, postmenopausal and 

























Table 2.4 Multivariable-adjusted hazard ratios for cancer incidence and 
mortality by tertile of neutrophil count accounting for levels of lymphocytes, 
monocytes, eosinophils and basophils in the ARIC study, 1987-2008 
Neutrophil Count 
by Tertilea 
N Person-Years HR (95% CI) b 
Cancer Incidence    
1 649 56010.3 1.00 (Reference) 
2 702 53735.9 1.09 (0.96, 1.23) 
3 759 51483.0 1.16 (1.02, 1.33) 
P-Trend    0.02 
Cancer Mortality    
1 234 69263.8 1.00 (Reference) 
2 292 66405.1 1.17 (0.96, 1.42) 
3 412 63086.7 1.38 (1.14, 1.69) 
P-Trend   0.001 
Abbreviations: HR, hazard ratio; CI, confidence interval. aNeutrophil count tertiles defined based on race-
specific cut-offs and combined across the analytic cohort. bModels adjusted for study site (Jackson, Forsyth 
County, Minneapolis), race (white, black), sex, body mass index (<18.5, 18.5-24.9, 25.0-29.9, 30.0-34.9, 
>35.0 kg/m2), waist circumference (continuous), education level (<high school diploma, high school 
diploma, >high school or college graduate, graduate school) smoking status (never, former, current), pack-
years (continuous), environmental tobacco smoke (<1, >1 hour/week), alcohol intake (continuous), aspirin 
use in the two weeks prior to blood draw (yes/no), medical history (yes/no) of cardiovascular disease, 
hypertension, diabetes, lymphocyte count tertile (<1.65, 1.66-2.14, >2.15 x109 cells/L), monocyte count 
tertile (<0.272, 0.273-0.399, >0.400 x109  cells/L), eosinophil count tertile (<0.07, 0.07-0.174, >0.175 x109 
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Table A.1 Leading types of cancer incidence and 






Lung 279 294 
Colorectal 213 41 
Female Breast 375 61 
Prostate 482 41 
a1987-2006. b1987-2008.
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Table A.2 Baseline characteristics by tertile of neutrophil count in white and black ARIC participants, 1987-1989 
  Neutrophil Count (109 cells/L) 
  Whites (N=6,620) Blacks (N=3,717) 
  
Tertile 1              
(1.100-3.135) 
Tertile 2                  
(3.136-4.189) 
Tertile 3              
(4.200-9.180) 
Tertile 1                 
(0.333-2.035) 
Tertile 2              
(2.040-3.024) 
Tertile 3              
(3.024-7.600) 
Total, N 2,221 2,196 2,203 1,242 1,236 1,239 
Study Sitea, %        
    Jackson, MS 0 0 0 93.9 85.8 83.5 
    Forsyth County, NC 45.3 46.7 46.6 5.6 14 15.7 
    Minneapolis, MN 54.7 53.3 53.4 0.6 0.2 0.8 
Male, % 42.2 51.7 52.4 39.1 39.0 37.9 
Age (years), Mean (SD)  54.0 (5.6) 54.3 (5.8) 54.1 (5.9) 53.4 (5.8) 53.4 (5.8) 53.7 (6.0) 
Education, %        
    <High school 8.4 11.0 13.3 42.3 42.2 40.6 
    High school or college 
graduate 43.0 45.3 46.5 27.8 28.4 29.1 
    Graduate school 48.7 43.7 40.2 29.8 29.5 30.3 
    Missing, N 2 3 3 2 5 2 
BMI (kg/m2), %        
    <18.5 0.5 0.6 1.2 0.6 0.6 1.2 
    18.5-24.99 44.6 36.3 33.5 20.9 20.1 20.6 
    25.0 29.99 38.9 42.2 41.8 40.6 36.4 35.6 
    30.0-34.99 12.8 15.7 16.3 24.9 25.8 24.4 
    >35.00 3.2 5.2 7.2 13.0 17.1 18.2 
    Missing, N 2 1 2 0 1 3 
Waist Circumference (cm), 
Mean (SD) 92.8 (12.1) 95.7 (12.8) 96.9 (13.6) 97.6 (14.4) 99.8 (14.9) 100.4 (15.7) 
Missing, N 0 0 1 0 0 2 
Cigarette Use, %        
    Never 50.6 39.6 23.6 53.2 44.5 41.0 


























Abbreviations: BMI, body mass index; SD, standard deviation; ETS, environmental tobacco smoke; CVD, cardiovascular disease. a Neutrophil count tertiles 
defined based on race-specific cut-offs and combined across the analytic cohort. bParticipants from Washington County, MD were excluded from analyses due to 
substantial missing WBC subtype count data at this site. cPack-years among ever smokers only. Pack-years was calculated as the average number of cigarettes 
smoked per day multiplied by the number of years of smoking and divided by 20. dETS defined as the average number of hours per week of close contact with 
people when they are smoking. eAlcohol intake among participants who reported usually having at least one drink per week. fCVD defined as having a history of 
angina pectoris, coronary heart disease, intermittent claudication, or stroke. gHypertension defined as use of any hypertensive medications, systolic blood 
pressure >140 mmHg, or diastolic blood pressure >90 mmHg. hDiabetes defined as having a fasting glucose level >126 mg/dl, non-fasting glucose level >200 




Table A.2 (continued) Baseline characteristics by tertile of neutrophil count in white and black ARIC participants, 1987-1989 
 Neutrophil Count (109 cells/L) 
 Whites (N=6,620) Blacks (N=3,717) 
 
Tertile 1              
(1.100-3.135) 
Tertile 2                  
(3.136-4.189) 
Tertile 3              
(4.200-9.180) 
Tertile 1                 
(0.333-2.035) 
Tertile 2              
(2.040-3.024) 
Tertile 3              
(3.024-7.600) 
    Current 9.8 20.6 44.3 20.6 26.9 38.8 
    Missing, N 2 1 1 1 2 1 
Pack-Yearsb, Mean (SD) 23.3 (21.7) 24.2 (21.9) 25.5 (22.0) 23.3 (21.9) 23.4 (21.6) 23.5 (21.7) 
    >1 58.5 66.3 75.8 75.3 75.9 77.9 
    Missing, N 18 9 10 7 10 8 
Alcohol Intaked, Mean (SD) 
(g/wk) 92.2 (94.8) 104.9 (119.0) 120.5 (136.7) 111.8 (119.5) 124.0 (165.1) 137.8 (189.4) 
    Missing, N 3 6 3 14 28 14 
CVDe, % 7.6 9.7 12.5 7.3 9.5 11.8 
Hypertensionf, % 20.6 25.9 28.3 52.9 55.2 58.1 
    Missing, N 0 2 0 0 0 1 
Diabetesg, % 4.7 7.7 10.8 13.5 18.4 25.7 
    Missing, N 0 2 1 3 2 6 
Aspirin usedh, % 53.7 52.5 54.7 26.6 30.9 31.4 





















Abbreviations: HR, hazard ratio; CI, confidence interval. aNeutrophil count tertiles defined based on race-specific cut-offs and combined across the analytic 
cohort. bIncidence rate per 1,000 individuals from 1987 to 2006 standardized to the age, race and sex distribution of the analytic cohort. Mortality rate per 1,000 
individuals from 1987 to 2008 standardized to the age, race and sex distribution of the analytic cohort. cModels adjusted for study site (Jackson, Forsyth County, 
Minneapolis), race (white, black), sex, body mass index (<18.5, 18.5-24.9, 25.0-29.9, 30.0-34.9, >35.0 kg/m2), waist circumference (continuous), education level 
(<high school diploma, high school diploma, >high school or college graduate, graduate school) smoking status (never, former, current), pack-years (continuous), 
environmental tobacco smoke (<1, >1 hour/week), alcohol intake (continuous), aspirin use in the two weeks prior to blood draw (yes/no), medical history 
(yes/no) of cardiovascular disease, hypertension, and diabetes.  
Table A.3 Multivariable-adjusted hazard ratios for non-lung cancer incidence and mortality by tertile of neutrophil count and stratified by cigarette 
smoking status in the ARIC study, 1987-2008  
  














HR (95% CI)c 
Cancer Incidence         
1 159.2 1.00 (Reference) 200.3 1.00 (Reference) 167.9 1.00 (Reference) 
2 180.2 1.10 (0.83, 1.45) 182.7 0.91 (0.76, 1.10) 180.4 1.08 (0.91, 1.28) 
3 181.8 1.21 (0.93, 1.57) 187.5 0.96 (0.79, 1.17) 169.7 1.07 (0.88, 1.30) 
P-Trend  0.13   0.66  0.43 
Cancer Mortality           
1 79.1 1.00 (Reference) 69.4 1.00 (Reference) 40.4 1.00 (Reference) 
2 71.8 0.81 (0.53, 1.22) 57.1 0.90 (0.64, 1.25) 54.6 1.33 (0.96, 1.85) 





Table A.4 Correlations of baseline counts of total WBC and subtype counts in ARIC, 1987-1989 
 Total WBC Neutrophil Lymphocyte Monocyte Eosinophil Basophil 
Total WBC 1.0000           
Neutrophil 0.8649 1.0000         
Lymphocyte 0.4764 0.0609 1.0000       
Monocyte 0.4562 0.3299 0.1764 1.0000     
Eosinophil 0.1839 0.474 0.1268 0.0091 1.0000   
Basophil 0.1473 0.0808 0.0837 -0.0408 0.3446 1.0000 
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Table A.5 Multivariable-adjusted hazard ratios for 
cancer incidence and mortality by quartile of total 
WBC count in the ARIC study, 1987-2008 
WBC Count   
(x109 cells/L) 
HRa (95% CI) 
Cancer Incidence  
Quartile 1 (3.3 – 4.8) 1.00 (Reference) 
Quartile 2 (4.9 – 5.8) 0.95 (0.84, 1.07) 
Quartile 3 (5.9 – 7.0) 1.02 (0.90, 1.16) 
Quartile 4 (7.1 – 10.7) 1.07 (0.94, 1.22) 
P-Trend 0.20 
Cancer Mortality  
Quartile 1 (3.3 – 4.8) 1.00 (Reference) 
Quartile 2 (4.9 – 5.8) 1.14 (0.93, 1.40) 
Quartile 3 (5.9 – 7.0) 1.40 (1.14, 1.71) 
Quartile 4 (7.1 – 10.7) 1.47 (1.20, 1.81) 
P-Trend <0.001 
Abbreviations: WBC, white blood cell; HR, hazard ratio; CI, confidence interval. aModels adjusted for 
study site (Jackson, Forsyth County, Minneapolis), race (white, black), sex, body mass index (<18.5, 18.5-
24.9, 25.0-29.9, 30.0-34.9, >35.0 kg/m2), waist circumference (continuous), education level (<high school 
diploma, high school diploma, >high school or college graduate, graduate school) smoking status (never, 
former, current), pack-years (continuous), environmental tobacco smoke (<1, >1 hour/week), alcohol intake 
(continuous), aspirin use in the two weeks prior to blood draw (yes/no), medical history (yes/no) of 
cardiovascular disease, hypertension, and diabetes. 







Chapter 3. Lymphocyte count, cancer incidence and mortality in the 
Atherosclerosis Risk in Communities (ARIC) study: Differential 
associations in men and women 
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Abstract 
The tumor immunosurveillance hypothesis posits a role for host immune factors in the 
identification and clearance of premalignant and malignant cells. Lymphocytes, which 
constitute the adaptive immune response, may have an important role in this anti-tumoral 
mechanism. We hypothesized that circulating levels of pre-diagnostic lymphocyte count 
would be inversely associated with subsequent cancer incidence and mortality. To 
evaluate this, we used data from the Atherosclerosis Risk in Communities (ARIC) study. 
Participants included men and women with total white blood cell (WBC) counts within 
the normal reference range and no history of cancer at baseline (N=10,316). Total WBC 
and subtype counts were measured at baseline (1987-1989) and cancer incidence and 
mortality were available through 2006 and 2008, respectively. Cox proportional hazards 
models were used to estimate the multivariable-adjusted hazard ratios (HR) and 95% 
confidence intervals (CI) by tertile of lymphocyte count in men and women, separately. 
During follow-up, a total of 2,153 incident primary cancers and 956 cancer deaths 
occurred. In men, lymphocyte count was not associated with total cancer incidence. 
However, in cancer incidence site-specific analyses, high lymphocyte count was 
associated with an increased risk of prostate cancer (HR: 1.31, 95% CI: 1.03, 1.66) and 
there was a non-linear reduced risk of colorectal cancer. After excluding cases of prostate 
cancer, the highest tertile of lymphocyte count was associated with 25% reduced risk of 
cancer incidence (HR: 0.75, 95% CI: 0.62, 0.91). An inverse association with non-
prostate cancer incidence persisted after mutual adjustment for other WBC subtype 
counts, among men with lymphocyte counts within the normal reference range, and after 
excluding cancer cases within the first five years of follow-up. In women, the highest 
   
63 
tertile of lymphocyte count was associated with an increased risk of cancer mortality, 
overall (HR: 1.40, 95% CI: 1.07, 1.82), and among current smokers. In men, high 
lymphocyte count was associated with a reduced risk of cancer incidence, excluding 
cases of prostate cancer, while in women, high lymphocyte count was associated with an 
increased risk of cancer mortality. Future studies are necessary to explore the differential 
effects of lymphocytes on carcinogenesis by sex.
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Introduction 
The tumor immunosurveillance concept, proposed in the late 1950’s, posits a role for the 
host immune system in identifying and clearing premalignant and malignant cells (1). 
Recently, this hypothesis has received a resurgence of interest in the literature (2-4), in 
part, due to the accumulating evidence from in vivo studies linking impairment of 
lymphocyte function with the increased development of cancer (2, 3, 5-9). These findings 
lend more definitive support for the tumor immunosurveillance process and suggest a 
possible role for lymphocytes in this anti-tumoral mechanism.  
 
Lymphocytes, a subtype of total white blood cells (WBC), include B and T cells, which 
constitute the cellular basis of the adaptive immune response. Additionally, the third 
broad type of lymphocytes, natural killer (NK) cells, are a component of the innate 
immune system (10).  In in vitro studies, T cells and NK cells have been shown to exert 
anti-tumoral effects through the recognition of tumor antigens, direct cytotoxic effects, 
and the production of certain cytokines (2, 9, 11, 12). However, certain subsets of T cells 
may also have the capacity to exert pro-tumoral effects (13).  
 
Few observational studies have examined the relationship between lymphocytes and 
tumor development and progression. In the clinical setting, higher concentrations of NK 
cells and T lymphocytes in the tumor infiltrate have been associated with prolonged 
survival of colorectal, ovarian and gastric cancers (14-18), while other lymphocyte 
subsets have been associated with poorer prognosis (13, 19-21). Additionally, circulating 
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neutrophil to lymphocyte ratio (NLR) at diagnosis has been inversely associated with 
cancer survival in many studies (22-24). 
 
In a prospective epidemiological study of healthy Japanese adults, moderate and high NK 
cell cytotoxic activity, a measure of lymphocyte function, were associated with reduced 
risks of subsequent total cancer incidence over an 11 year period (25). To date, only one 
previous study has evaluated the association between circulating pre-diagnostic 
lymphocyte count and subsequent cancer incidence. In this study, no association was 
found based on age- and sex-adjusted models only (26). To expand upon these findings, 
we prospectively evaluated the relationship between circulating lymphocyte count and 
cancer incidence and mortality in the Atherosclerosis Risk in Communities (ARIC) study, 
a large, prospective, community-based cohort. We hypothesized that higher levels of pre-
diagnostic lymphocyte count would be associated with a subsequent reduced risk of 
cancer incidence and mortality, providing further support for the tumor 
immunosurveillance concept.  
 
Materials and Methods 
Study population 
This study was conducted in the ARIC study, an ongoing, prospective cohort initiated 
between 1987 and 1989 to investigate the etiology of atherosclerosis and its sequelae. 
Men and women (N=15,792), ages 45 to 64 years, were enrolled from four U.S. 
communities, Forsyth County, NC; Jackson, MS; Washington County, MD; and suburban 
Minneapolis, MN. Participants were identified using probability sampling in Minneapolis 
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and Washington County, while in Jackson, blacks were exclusively recruited and in 
Forsyth County blacks were oversampled (27). Participants from Washington County 
were not included in these analyses as baseline WBC subtype counts were missing for 
more than 85% of participants (28). At enrollment, participants provided a blood sample 
and reported information on sociodemographic factors, medical history, reproductive 
history, physical activity, alcohol and tobacco use and other lifestyle behaviors via 
standardized questionnaires.  
 
The analytic cohort included both men and women that met the following eligibility 
criteria: (1) not residing in Washington County, MD (N=11,792); (2) no personal history 
of cancer, excluding cases of non-melanoma skin cancer (N=11,175); (3) white or black 
race (N=11,140); (4) total WBC count within two standard deviations of the mean in 
whites and blacks, separately (N=10,351); (5) not missing baseline lymphocyte count 
(N=10,339); and (6) not missing information on cancer incidence (N=10,177) or 
mortality (N=10,316).  
 
Exposure ascertainment 
Total and differential WBC counts were measured at baseline and three years later at 
Visit 2 (1990-1992). In the main analyses, only baseline WBC subtype counts were used. 
Following venipuncture, samples were stored at 4°C and within 24 hours total WBC 
count was measured using automated particle counters in local, independent clinical 
laboratories. Subtypes were measured as a proportion of total WBCs and counts were 
then calculated by multiplying the subtype proportion by the total WBC count. Based on 
   
67 
repeat testing of individuals conducted one to two weeks apart, reliability coefficients for 
total WBC count were estimated to be greater than 0.96 for each laboratory (29, 30).  
 
Outcome ascertainment 
The incidence of a first primary cancer, including date of diagnosis and site of cancer, 
was ascertained from study initiation through December 31, 2006 (30, 31). Cancer 
incidence was primarily identified by linkage to well-established state and/or county 
cancer registries that have a high completeness (≥90%) of cancer data (30). Hospital 
surveillance was used to identify cancer cases in Jackson prior to establishment of the 
Mississippi state cancer registry in 1996 (32), and all additional cancer cases for the other 
study sites (30, 33). At present, data on stage at diagnosis, cancer subtype and treatment 
are not consistently available for all cancers. 
 
Vital status was available through December 31, 2008. Deaths were identified through 
contact with relatives, physician or designated contact, or through a search of obituaries, 
funeral and hospital records, death certificates and the National Death Index (NDI). The 
date and cause of death were confirmed by death certificate for all reported deaths. Cause 
of death was coded using the Ninth International Statistical Classification of Diseases and 
Related Health Problems (ICD-9) for deaths through 1998 and ICD-10 for all subsequent 
deaths. Cause-specific mortality from death certificate was available for 98% of 
decedents (34).  
 
Assessment of covariates 
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Participants reported their highest education attainment, regular alcohol use, and intake of 
aspirin in the two weeks prior to baseline study visit. They also provided information on 
current cigarette smoking status and, if applicable, the average number of years of 
smoking and cigarettes smoked per day. These values were used to calculate pack-years 
([cigarettes per day*years smoking]/20 cigarettes per pack) among ever smokers. 
Exposure to environmental tobacco smoke (ETS) was defined as being in close proximity 
to smokers for more than 1 hour per week (35, 36). Body mass index (BMI), calculated 
as weight (kg)/[height(m)]2, and waist circumference were collected by trained 
technicians at baseline study visit. A history of cardiovascular disease (CVD) was 
defined as having a prior diagnosis of angina pectoris, coronary heart disease, intermittent 
claudication or stroke. Participants were categorized as having hypertension if they 
reported use of any hypertensive medications or if they had systolic blood pressure ≥140 
mmHg or diastolic blood pressure ≥90 mmHg. Diabetes was defined as having a fasting 
glucose level ≥126 mg/dl, a non-fasting glucose level ≥200 mg/dl, a self-reported 
physician diagnosis of diabetes, or use of blood sugar lowering medications in the two 
weeks prior to enrollment. Women were categorized as being premenopausal if they had 
a menstrual cycle within two years of baseline or postmenopausal (37). Women missing 
information on menopausal status were categorized as being postmenopausal if they were 
55 years of age or older. Postmenopausal hormone use was categorized as current, former 
or never (37).  
 
Statistical analyses  
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Baseline descriptive characteristics were compared by tertile of lymphocyte count using 
the chi-square test for categorical variables or ANOVA for continuous variables. Risk 
analyses are presented separately for men and women as we observed significant 
differences in the associations between lymphocyte count and cancer incidence and 
mortality by sex. Cox proportional hazards models were used to estimate the hazard ratio 
(HR) and 95% confidence interval (CI) for cancer incidence and mortality by tertile of 
lymphocyte count. Tests for linear trend across categories of lymphocyte count were 
calculated by introducing the median value of each tertile as a continuous variable into 
models. To explore the potential of non-linearity, we also modeled lymphocyte count 
continuously using restricted cubic splines with knots at the 10th, 50th and 90th percentiles. 
In spline models, excluding values in the top and bottom 1% to account for the effects of 
outliers did not appreciably alter risk estimates. Additional analyses were performed 
examining the association between tertile of NLR and cancer incidence and mortality. 
Tertiles of NLR were defined separately for whites and blacks, given that blacks have 
significantly lower levels of circulating neutrophils (38, 39), and combined across the 
total analytic cohort. In analyses of cancer incidence, follow-up time was accrued from 
age at baseline blood draw, with the origin defined as age 40 years and staggered late 
entries for persons over age 40 at baseline, to the first of the following events: (1) age at 
first primary cancer diagnosis, (2) age at death, or (3) age at end of follow-up (December 
31, 2006). In analyses of cancer mortality, individuals were followed from age at baseline 
blood draw to (1) age at death or (2) age at end of follow-up (December 31, 2008). In 
models in which time accrued from year at baseline blood draw to (1) year at first 
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primary cancer diagnosis or cancer death, (2) year at other death, or (3) year at end of 
follow-up, similar HRs were estimated and are not presented here. 
 
Cox multivariable models included the baseline covariates, race (white, black), study site 
(Jackson, MS, Forsyth County, Minneapolis, MN), BMI (<18.5, 18.5-24.9, 25.0-29.9, 
30.0-34.9, >35.0 kg/m2), waist circumference (continuous), education attainment (<high 
school diploma, high school diploma, >high school or college graduate, graduate school), 
cigarette smoking status (never, former, current), pack-years (continuous), ETS (<1 
hour/week, >1 hour/week), alcohol intake (g/wk), aspirin use in two weeks prior to blood 
draw (yes/no), and medical history of CVD (yes/no), hypertension (yes/no), and diabetes 
(yes/no). In women, the additional covariates, menopausal status and HRT use 
(premenopausal, postmenopausal and current HRT user, postmenopausal and former 
HRT user, postmenopausal and never HRT user) were included in models. Additionally, 
mutual adjustment by counts of the other WBC subtypes (neutrophils, monocytes, 
basophils and eosinopohils) was performed in both men and women. Missing pack-year 
and waist circumference information was replaced with the median value. Effect 
modification between lymphocyte count (and NLR) and select covariates known to 
modulate the host immune response, including sex, race, cigarette smoking status, BMI, 
menopausal status and aspirin use, was assessed by introducing a cross-product term in 
models and using the Wald test to test for statistical significance. The proportional 
hazards assumption was assessed by introducing an interaction term between lymphocyte 
count tertile (and NLR tertile) and follow-up time into models. In all cases, the 
interaction term was not statistically significant, confirming this assumption. Rates of 
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cancer incidence and cancer mortality were standardized to the age and race distribution 
of the analytic cohort. 
  
Cancer site-specific analyses were conducted in models of cancer incidence and cancer 
mortality for the four most common cancers (i.e., female breast cancer, colorectal cancer, 
lung cancer, and prostate cancer). Additionally, the following sensitivity analyses were 
performed: (1) excluding incident cancer cases and deaths within one and five years from 
baseline blood draw in order to address any bias due to reverse causation; (2) excluding 
individuals with lymphocyte counts outside the normal reference range, 1.5 to 3.0 x 109 
cells/L, to more rigorously restrict analyses to individuals with no underlying acute or 
chronic immune conditions; (3) removing ever smokers and users of aspirin in the two 
weeks prior to baseline; and (4) using lymphocyte count measured at Visit 2 as the 
exposure of interest in a subset of participants with available data (N=6,582); In these 
analyses time at risk was initiated at age at Visit 2. Finally, in cancer mortality analyses, 
sub-distribution hazard ratios were estimated using the Fine and Gray approach to 
account for the issue of competing risks (40). All analyses were conducted using STATA 
version 11.2 (Stata Corporation, College Station, TX, 2012).  
 
Results 
Table 3.1 presents the distribution of baseline characteristics by tertile of lymphocyte 
count. The median lymphocyte count in the analytic cohort was 1.89 x 109 cells/L 
(interquartile range: 1.54, 2.30 x 109 cells/L). Individuals with higher circulating 
lymphocyte count were more likely to be female, black, less educated and have a higher 
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BMI and mean waist circumference. They were also more likely to have a medical 
history of CVD, hypertension and diabetes and reported more frequent use of tobacco and 
alcohol and greater exposure to ETS. We observed a similar distribution of the baseline 




Between 1987 and 2006, over a median follow-up time of 18.1 years, 1,163 and 990 
incident primary cancer cases were ascertained in men and women, respectively. There 
was a significant interaction between lymphocyte count tertile and sex in models of 
cancer incidence (all p-interaction terms<0.009). Figure 3.1 presents the multivariable-
adjusted HR for total and site-specific cancer incidence by tertile of lymphocyte count in 
men. Overall, there was no significant association between lymphocyte count tertile and 
cancer incidence. However, in cancer incidence site-specific analyses, men in the middle 
tertile of lymphocyte count had a 48% (HR: 0.52, 95% CI: 0.32, 0.86) reduced risk of 
colorectal cancer although there was no association for the highest tertile of lymphocyte 
count compared to the lowest tertile (HR: 0.77, 95% CI: 0.48, 1.23) (Figure 3.1). In 
models of prostate cancer incidence, there was a positive, linear association with 
lymphocyte count tertile (HRtertile 3 v tertile 1: 1.31, 95% CI: 1.03, 1.66, p-trend=0.02). There 
was no significant association between lymphocyte count tertile and lung cancer 
incidence. 
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Given the differential association between lymphocyte count tertile and cancer incidence 
by organ site, we evaluated the risk of cancer incidence in men excluding cases of 
prostate cancer (Table 3.2). There was a significant reduced risk of non-prostate cancer 
incidence among men in both the middle (HR: 0.68, 95% CI: 0.56, 0.82) and highest 
tertile (HR: 0.75, 95% CI: 0.62, 0.91) of lymphocyte count, relative to the lowest tertile. 
This association held across strata of race and current cigarette use (Table 3.2, all p-
interaction terms >0.2), and after excluding incident cancers diagnosed within one and 
five years of follow-up. Additionally, there was no effect modification by age, BMI, or 
recent aspirin use. Mutual adjustment with the other WBC subtypes did not appreciably 
alter risk estimates (Appendix B, Table B.2). In analyses restricted to the normal 
reference range of lymphocyte count, 1.5 to 3.0 x 109 cells/L, a significantly reduced risk 
of non-prostate cancer incidence persisted in men in the middle tertile of lymphocyte 
count (HR: 0.75, 95% CI: 0.59, 0.94) and there was a non-significant reduced risk in men 
in the highest tertile (HR: 0.83, 95% CI: 0.66, 1.05). Similarly, after excluding aspirin 
users, a significant reduced risk of non-prostate cancer incidence persisted in the middle 
tertile of lymphocyte count only. When using lymphocyte count measured at Visit 2, a 
non-significant reduced risk of non-prostate cancer incidence was found for the middle 
(HR: 0.84, 95% CI: 0.67, 1.06) and highest (HR: 0.86, 95% CI: 0.68, 1.09) tertiles of 
lymphocyte count, compared to the lowest. In spline regression models, there was a 
reduced risk of non-prostate cancer incidence with increasing values of lymphocyte count 
up to 2.3 x109 cells/L, at which point the risk plateaus (Figure 3.2, p-linearity=0.004). 
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Among women, there was no association between lymphocyte count tertile and cancer 
incidence, overall, or in analyses stratified by race, menopausal status and current 
cigarette use (all p-interaction terms >0.09) (Table 3.3). Additionally, no significant 
associations were found for the incidence of major female cancer types, including breast, 
lung and colorectal cancer (Figure 3.3).  
 
Cancer mortality 
During a median follow-up time of 21.4 years, between 1987 and 2008, 539 and 400 
cancer deaths occurred in men and women, respectively. We observed a significant 
interaction between lymphocyte count tertile and sex in models of cancer mortality (all p-
interaction terms<0.05). Figure 3.4 presents multivariable-adjusted risk estimates of total 
and site-specific cancer mortality in men. There was no significant association between 
lymphocyte count and lung, colorectal or prostate cancer mortality. However, in models 
of total cancer mortality, there was a slight inverse association between the middle tertile 
of lymphocyte count and cancer mortality, although this estimate did not achieve 
statistical significance. Excluding cases of prostate cancer mortality did not alter risk 
estimates (Table 3.4). Additionally, there was no effect modification by race, cigarette 
smoking status, BMI or asprin use (all p-interaction terms >0.4). 
  
In women, the highest tertile of lymphocyte count was associated with a 40% (HR: 1.40, 
95% CI: 1.07, 1.82, p-trend=0.02) increased risk of cancer mortality (Table 3.5). A 
significant association persisted after excluding cancer deaths within one and five years 
of baseline and after excluding participants with lymphocyte counts outside the normal 
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reference range (HR: 1.35, 95% CI: 0.99, 1.83). After further adjustment for the other 
WBC subtypes, a positive association between lymphocyte count and cancer mortality 
persisted, however this association was no longer linear (Appendix B, Table B.2). Similar 
findings were estimated in pre/peri-menopausal and postmenopausal women (Table 3.5). 
In analyses stratified by cigarette use, a positive association between the highest tertile of 
lymphocyte count and cancer mortality was observed in current smokers, but not in 
former and never smokers, although there was no significant interaction term between 
lymphocyte count tertile and smoking status (Table 3.5; all p-interaction terms >0.3). 
Additionally, there was no association between lymphocyte count and cancer mortality in 
women who did not use aspirin in the two weeks prior to blood draw. There was no 
evidence of a statistical interaction between the highest tertile of lymphocyte count and 
race, menopausal status, age, BMI or recent aspirin intake (all p-interaction terms >0.2). 
In the analysis using lymphocyte count measured at Visit 2, lymphocyte count was not 
significantly associated with cancer mortality (HR: 1.24, 95% CI: 0.88, 1.76). 
  
In women, lymphocyte count tertile was not associated with colorectal or breast cancer 
mortality but there was a suggestive increased risk of lung cancer mortality in women 
with high lymphocyte count compared to low (HR: 1.62, 95% CI: 0.93, 2.84, p-
trend=0.09) (Figure 3.5). A suggestive positive association was also found between the 
highest tertile of lymphocyte count and non-lung cancer mortality (HR: 1.32, 95% CI: 
0.97, 1.80, p-trend=0.08).  
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Finally, lymphocyte count tertile was not associated with CVD or non-cancer mortality in 
men or women. In competing risks analyses, a significant association persisted between 
the highest tertile of lymphocyte count and cancer mortality among women (sub-
distribution HR: 1.40, 95% CI: 1.08, 1.83). 
 
NLR 
There was no evidence of effect modification between NLR and sex in models of cancer 
incidence or mortality (all p-interactions >0.6). Furthermore, there were no associations 
between tertile of NLR and cancer incidence or mortality, overall, or in strata of sex, 
race, or cigarette smoking status (Appendix B, Table B.3).  
 
Discussion 
To our knowledge, this is the first study to report a differential association between 
lymphocyte count and cancer incidence and mortality by sex. In this large prospective 
study, men with high lymphocyte counts had a reduced risk of developing cancer, with 
the exception of prostate cancer. The significant inverse association with non-prostate 
cancer incidence remained in analyses limited to incident cancers diagnosed at least five 
years post baseline blood draw to account for the presence of subclinical disease, among 
never smokers and non-users of aspirin, and after mutual adjustment for the other WBC 
subtypes. In cancer incidence site-specific analyses, the reduced risk of cancer incidence 
was strongest for colorectal cancer, while high lymphocyte count was significantly 
associated with an increased risk of prostate cancer incidence. In contrast, among women, 
high lymphocyte count was associated with an increased risk of total cancer mortality, 
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but not cancer incidence. This positive association with cancer mortality, however, did 
not persist among never smokers or non-users of aspirin. 
  
Our finding of an inverse association between circulating lymphocyte count and non-
prostate cancer incidence in men lend credence to the tumor immunosurveillance 
concept. Moreover, our results support the hypothesis that lymphocytes are involved in 
this anti-tumoral mechanism. To date, the majority of the evidence for the tumor 
immunosurveillance concept comes from studies conducted in mice models (2, 41). 
Congruent with our findings, these studies report an increased risk of spontaneous and 
chemically induced tumors in mice with impaired lymphocyte function (5-8). 
Additionally, based on in vitro and in vivo studies, specific lymphocyte subsets, 
including NK cells and cytotoxic T cells, have the capacity to both recognize tumor 
antigens and kills tumor cells, directly or indirectly, through the production of cytokines 
(9).  
 
The present study expands upon these laboratory findings by demonstrating that inter-
individual variations of circulating, pre-diagnostic lymphocyte count within the normal 
reference range have implications for cancer risk. Notably, although circulating 
lymphocyte count is not a direct measure of functional immunity, our findings are 
consistent with prior studies, which have measured lymphocyte function in healthy adult 
populations. Specifically, in several cross-sectional studies, NK cell-mediated 
cytotoxicity and lymphocyte proliferation were lower in cancer-free individuals with a 
familial history of cancer compared to controls with no family history of cancer (42-46), 
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and in a longitudinal study of 3,625 Japanese men and women, high NK cytotoxic 
activity was associated with a 41% reduction in total cancer risk over an 11 year period of 
follow-up (25).  
 
To our knowledge, only one previous study has evaluated the association between 
circulating lymphocyte count and subsequent cancer incidence. In contrast to our 
findings, in this study of 669 Danish men and women, no association was found in sex- 
and age-adjusted models (26). However, effect modification by sex was not evaluated in 
this study, and other factors such as race, BMI and cigarette smoking status were not 
accounted for in models. 
 
In men, the effect of circulating lymphocyte count on cancer risk differed by cancer site. 
While elevated lymphocyte count was associated with a reduced risk of colorectal cancer 
incidence, we observed a positive association between lymphocyte count and prostate 
cancer risk. Interestingly, epidemiological studies evaluating the association between 
allergies, a Th2 mediated condition, and cancer risk, have also noted differences in the 
risk of prostate cancer compared to other cancer types. Having a history of allergies has 
been associated with a reduced risk of certain cancers, particularly pancreatic cancer and 
gliomas (47, 48), and an increased risk of prostate cancer in many (49-55) but not all 
prospective studies (56, 57). However, the mechanism underlying this differential effect 
on the prostate remains unknown. 
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It is also possible that the positive association between lymphocyte count and prostate 
cancer incidence reflect a screening bias, such that men with higher lymphocyte counts 
are more likely to receive PSA screening. In the present study, we were not able to 
evaluate this, as information on PSA screening was not collected. However, this 
explanation is not entirely convincing given that our analyses were restricted to 
lymphocyte counts within the normal reference range and differential screening patterns 
within this range would not be expected. Additionally, the differential association with 
prostate cancer incidence seems to be specific to lymphocytes; Similar findings have not 
been observed in individuals with elevated levels of other circulating immune markers 
(58-60), further suggesting that the observed increased risk of prostate cancer is not an 
artifact due to differential PSA screening.  
 
Unlike in men, in women, high levels of pre-diagnostic lymphocyte count were 
associated with a 40% increased risk of cancer mortality. However, in stratified analyses, 
this significant association did not persist among never smokers or in women who did not 
take aspirin in the two weeks prior to baseline. Thus, we cannot exclude the possibility of 
residual confounding by cigarette use, despite having adjusted for pack-years, and aspirin 
use. In particular, cigarette use is a strong positive confounder in our analyses, associated 
with both increased lymphocyte counts and increased cancer incidence and mortality. 
Additionally, in this study, detailed information on aspirin use, including duration of use, 
was not collected. Alternatively, the lack of an association in these strata may be due the 
limited sample size in these subgroups. Thus, larger studies are necessary to clarify the 
association between lymphocytes and cancer mortality in women. 
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The observed sex-related differences in lymphocyte activity may reflect differences in the 
absolute and relative counts of lymphocyte subsets in men and women. It is hypothesized 
that the effect of androgens on thymocyte cells alters the make-up of peripheral T cells 
(61). Consistent with this hypothesis, many studies have reported higher levels of CD3+ 
and CD4+ cells, higher ratios of CD3+/CD4+ and CD4+/CD8+, and lower levels of NK 
cells in healthy adult women, compared to men (62-66). Given that CD8+ cytotoxic T 
lymphocytes and NK cells are critical components in the tumor immunosurveillance 
response (9), this shift in the distribution of T lymphocyte subsets may explain the 
potential anti-tumoral effect of lymphocytes in men and pro-tumoral effect in women. In 
the present study, while the majority of circulating lymphocytes are T cells, information 
on T cell subsets was not available. Future studies are warranted to evaluate this 
hypothesis.  
 
Our study findings must be interpreted in light of certain additional limitations. By 
utilizing a one-time measurement of lymphocyte count, we did not account for time-
varying changes in the level of this marker or intra-individual variation. However, in 
ARIC, peripheral lymphocyte count was measured at two time points, baseline and three 
years later, at Visit 2. The correlation between continuous values of lymphocyte count 
over time was 0.70 and 0.67 in men and women, respectively, and the agreement across 
tertiles was 61.3% and 58.4% in men and women. These comparisons indicate that 
lymphocyte count is fairly stable in this population of healthy adults. Indeed, in 
sensitivity analyses using lymphocyte counts measured at Visit 2, a reduced risk of non-
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prostate cancer incidence persisted in men with high lymphocyte count, although the 
positive association between lymphocyte count and cancer mortality in women was no 
longer present. In the present study, we were also not able to explore the effect of 
lymphocytes on tumor stage, grade or treatment, as this information was not available. 
This study also has several strengths. The ARIC study is a prospective, population-based 
cohort with over 20 years of follow-up for cancer incidence and mortality. Additionally, 
detailed information was available on a wide-array of socio-demographic characteristics, 
lifestyle risk factors and medical history.  
 
In summary, among men with total WBC counts within the normal reference range, high 
lymphocyte count was associated with a reduced risk of cancer incidence, excluding 
prostate cancer, and an increased risk of prostate cancer incidence. In contrast, in women, 
high lymphocyte count was associated with an increased risk of total cancer mortality, 
however this association may reflect residual confounding due to factors including 
cigarette smoking and aspirin use. Based on these novel findings, circulating lymphocyte 
count may be a novel marker of the tumor immunosurveillance response in men. 
Furthermore, we hypothesize that the differences in lymphocyte-mediated carcinogenesis 
by sex and organ site may reflect differences, due to hormonal effects, in the absolute and 
relative levels of circulating and localized lymphocyte subsets. Future studies are 
necessary to validate our study findings and to investigate this hypothesis.  
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Table 3.1 Baseline characteristics by tertile of lymphocyte count in ARIC participants, 
1987-1989 
  Lymphocyte Count (109 cells/L) 
  
Tertile 1      
(0.09, 1.65) 
Tertile 2         
(1.66, 2.14) 
Tertile 3       
(2.15, 6.08) 
Total, N 3,447 3,453 3,439 
Study Sitea, %     
    Jackson, MS 23.0 28.1 43.6 
    Forsyth County, NC 36.2 38.3 26.9 
    Minneapolis, MN 40.9 33.6 29.5 
Male, % 48.7 46.3 40.5 
Blacks, % 26.6 32.6 48.7 
Age (years), Mean (SD)  54.0 (5.9) 53.9 (5.8) 53.8 (5.7) 
Education, %     
    <High school 17.4 20.5 27.9 
    High school or college 
graduate 40.0 38.8 38.1 
    Graduate school 42.5 40.7 33.9 
    Missing, N 8 3 6 
BMI (kg/m2), %     
    <18.5 0.7 1.0 0.6 
    18.5-24.99 38.8 32.7 23.8 
    25.0 29.99 40.4 39.0 39.9 
    30.0-34.99 14.6 18.4 22.7 
    >35.00 5.5 8.9 13.0 
    Missing, N 5 2 2 
Waist Circumference (cm), 
Mean (SD) 
94.2 (13.1) 96.6 (13.9) 99.1 (14.3) 
    Missing, N 1 1 1 
Cigarette Smoking Status, %     
    Never 46.8 41.5 34.5 
    Former 37.2 33.7 26.5 
    Current 16.1 24.8 39.0 
    Missing, N 4 0 4 
Pack-Yearsb, Mean (SD) 23.8 (21.7) 24.6 (21.9) 25.0 (21.9) 
    Missing, N 53 64 73 
ETSc (hours/week), %     
    <1 35.1 30.7 23.4 
    >1 64.9 69.3 76.6 
    Missing, N 23 23 16 
Alcohol Intaked, Mean (SD) 
(g/wk) 
110.4 (126.5) 113.7 (140.6) 106.5 (123.0) 
    Missing, N 13 15 40 
CVDe, % 8.7 9.0 11.7 
Hypertensionf, % 32.6 34.2 40.9 
    Missing, N 1 1 1 
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Table 3.1 (continued) Baseline characteristics by tertile of lymphocyte count in ARIC 
participants, 1987-1989 
 Lymphocyte Count (109 cells/L) 
 
Tertile 1      
(0.09, 1.65) 
Tertile 2         
(1.66, 2.14) 
Tertile 3       
(2.15, 6.08) 
Diabetesg, % 8.7 10.8 16.0 
    Missing, N 5 3 6 
Aspirin usedh, % 46.7 47.0 41.4 
    Missing, N 21 29 32 
Abbreviations: BMI, body mass index; SD, standard deviation; ETS, environmental 
tobacco smoke; CVD, cardiovascular disease. aParticipants from Washington County, MD 
were excluded from analyses due to substantial missing WBC subtype count data at this 
site. bPack-years among ever smokers only. Pack-years was calculated as the average 
number of cigarettes smoked per day multiplied by the number of years of smoking and 
divided by 20. cETS defined as the average number of hours per week of close contact 
with people when they are smoking. dAlcohol intake among participants who reported 
usually having at least one drink per week. eCVD defined as having a history of angina 
pectoris, coronary heart disease, intermittent claudication, or stroke. fHypertension defined 
as use of any hypertensive medications, systolic blood pressure >140 mmHg, or diastolic 
blood pressure >90 mmHg. gDiabetes defined as having a fasting glucose level >126 
mg/dl, non-fasting glucose level >200 mg/dl, a physician diagnosis of diabetes, or using 
sugar-lowering medications in two weeks prior to enrollment. hAspirin use in two weeks 
prior to study enrollment.
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Figure 3.1 Multivariable-adjusted hazard ratios of total and site-specific cancer incidence by tertile of 
lymphocyte count in men in the ARIC study, 1987-2006. Models adjusted for study site, race, body mass 
index (<18.5, 18.5-24.9, 25.0-29.9, 30.0-34.9, >35.0 kg/m2), waist circumference (continuous), education 
level (<high school diploma, high school diploma, >high school or college graduate, graduate school) 
smoking status (never, former, current), pack-years (continuous), environmental tobacco smoke (<1, >1 
hour/week), alcohol intake (continuous), aspirin use in two weeks prior to blood draw (yes/no), medical 
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Table 3.2 Multivariable-adjusted hazard ratios for cancer incidence by tertile of lymphocyte 







HR (95% CI)b 
Overall         
1 431 26120.4 258.1 1.00 (Reference) 
2 375 24662.0 243.6 0.89 (0.77, 1.02) 
3 347 20469.7 255.7 0.95 (0.82, 1.11) 
Excluding Prostate Cancer   
1 275 26120.4 166.2 1.00 (Reference) 
2 198 24662.0 126.3 0.68 (0.56, 0.82) 
3 204 20469.7 152.2 0.75 (0.62, 0.91) 
Whitesc       
1 208 19464.3 172.8 1.00 (Reference) 
2 141 18015.3 126.0 0.65 (0.52, 0.81) 
3 142 13144.4 167.1 0.78 (0.62, 0.98) 
Blacksc       
1 67 6656.1 151.4 1.00 (Reference) 
2 57 6646.7 127.0 0.77 (0.54, 1.11) 
3 62 7325.3 119.2 0.70 (0.48, 1.01) 
Current Smokersc       
1 68 3928.6 252.6 1.00 (Reference) 
2 75 6408.3 174.8 0.61 (0.44, 0.86) 
3 126 8462.2 206.5 0.79 (0.58, 1.07) 
Former Smokersc      
1 134 13055.8 160.2 1.00 (Reference) 
2 83 11234.2 118.4 0.74 (0.56, 0.98) 
3 57 7745.1 113.2 0.73 (0.53, 1.01) 
Never Smokersc       
1 73 9135.9 135.0 1.00 (Reference) 
2 40 7019.4 86.7 0.67 (0.45, 1.00) 
3 21 4244.3 88.3 0.63 (0.38, 1.05) 
Abbreviations: HR, hazard ratio; CI, confidence interval. aIncidence rate per 1,000 men from 1987 to 2006 
standardized to the age and race distribution of the analytic cohort. bModels adjusted for study site 
(Jackson, Forsyth County, Minneapolis), race (white, black), body mass index (<18.5, 18.5-24.9, 25.0-29.9, 
30.0-34.9, >35.0 kg/m2), waist circumference (continuous), education level (<high school diploma, high 
school diploma, >high school or college graduate, graduate school) smoking status (never, former, current), 
pack-years (continuous), environmental tobacco smoke (<1, >1 hour/week), alcohol intake (continuous), 
aspirin use in the two weeks prior to blood draw (yes/no), medical history (yes/no) of cardiovascular 









Figure 3.2 Multivariable-adjusted hazard ratios for non-prostate cancer incidence in men using restricted 
cubic splines with knots at the 10th (1.26 x109 cells/L), 50th (1.84 x109 cells/L), and 90th (2.68 x109 
cells/L) percentiles. Gray shading represents 95% confidence intervals. Multivariable models adjusted for 
study site, race, body mass index (<18.5, 18.5-24.9, 25.0-29.9, 30.0-34.9, >35.0 kg/m2), smoking status 
(never, former, current), pack-years (continuous), and environmental tobacco smoke (<1, >1 hour/week). 
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Figure 3.3 Multivariable-adjusted hazard ratios of total and site-specific cancer incidence by tertile of 
lymphocyte count in women in the ARIC study, 1987-2006. Models adjusted for study site, race, body 
mass index (<18.5, 18.5-24.9, 25.0-29.9, 30.0-34.9, >35.0 kg/m2), waist circumference (continuous), 
education level (<high school diploma, high school diploma, >high school or college graduate, graduate 
school) smoking status (never, former, current), pack-years (continuous), environmental tobacco smoke 
(<1, >1 hour/week), alcohol intake (continuous), aspirin use in two weeks prior to blood draw (yes/no), 
medical history (yes/no) of cardiovascular disease, hypertension, diabetes, menopausal status and HRT use 
(pre/peri-menopausal, postmenopausal and current HRT user, postmenopausal and former HRT user, 
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Table 3.3 Multivariable-adjusted hazard ratios for cancer incidence by tertile of lymphocyte 








HR (95% CI) b 
Overall         
1 279 28413.0 162.8 1.00 (Reference) 
2 332 29346.8 184.6 1.10 (0.94, 1.29) 
3 351 31416.6 192.0 1.03 (0.87, 1.22) 
P-Trend     0.72 
Whites       
1 219 21484.6 177.1 1.00 (Reference) 
2 234 19250.5 203.3 1.12 (0.93, 1.35) 
3 186 14416.4 216.8 1.02 (0.83, 1.25) 
P-Trend    0.79 
Blacks       
1 60 6928.5 141.4 1.00 (Reference) 
2 98 10096.3 156.6 1.04 (0.75, 1.44) 
3 165 17000.2 154.9 1.03 (0.76, 1.40) 
P-Trend    0.86 
Premenopausal       
1 104 10788.3 161.9 1.00 (Reference) 
2 90 8778.2 171.5 0.94 (0.68, 1.29) 
3 81 7970.4 181.0 1.03 (0.75, 1.42) 
P-Trend    0.86 
Postmenopausal       
1 175 17551.4 159.3 1.00 (Reference) 
2 242 20568.6 190.7 1.23 (1.00, 1.51) 
3 270 23446.2 197.6 1.13 (0.91, 1.41) 
P-Trend    0.32 
Current Smokers       
1 61 4331.2 185.9 1.00 (Reference) 
2 100 6187.1 235.2 1.14 (0.83, 1.58) 
3 146 11102.0 211.9 0.94 (0.69, 1.28) 
P-Trend    0.46 
Former Smokers       
1 60 7162.8 140.3 1.00 (Reference) 
2 74 7163.2 177.6 1.13 (0.80, 1.60) 
3 73 6403.5 182.0 1.17 (0.82, 1.69) 
P-Trend    0.39 
Never Smokers       
1 157 16914.0 155.0 1.00 (Reference) 
2 158 15996.5 167.8 1.04 (0.83, 1.30) 
3 132 13872.8 173.8 1.05 (0.82, 1.35) 
P-Trend       0.68 
Abbreviations: HR, hazard ratio; CI, confidence interval. aIncidence rate per 1,000 women from 1987 to 
2006 standardized to the age and race distribution of the analytic cohort. bModels adjusted for study site  
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Table 3.3 (continued) Multivariable-adjusted hazard ratios for cancer incidence by tertile of lymphocyte 
count, stratified by race, menopausal status, and cigarette smoking status, in women in the ARIC study, 
1987-2006 
 
(Jackson, Forsyth County, Minneapolis), race (white, black), body mass index (<18.5, 18.5-24.9, 25.0-29.9, 
30.0-34.9, >35.0 kg/m2), waist circumference (continuous), education level (<high school diploma, high 
school diploma, >high school or college graduate, graduate school) smoking status (never, former, current), 
pack-years (continuous), environmental tobacco smoke (<1, >1 hour/week), alcohol intake (continuous), 
aspirin use in the two weeks prior to blood draw (yes/no), medical history (yes/no) of cardiovascular 
disease, hypertension, diabetes, menopausal status and HRT use (pre/peri-menopausal, postmenopausal and 
current HRT user, postmenopausal and former HRT user, postmenopausal and never HRT user). 
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Figure 3.4 Multivariable-adjusted hazard ratios of total and site-specific cancer mortality by tertile of 
lymphocyte count in men in the ARIC study, 1987-2008. Models adjusted for study site, race, body mass 
index (<18.5, 18.5-24.9, 25.0-29.9, 30.0-34.9, >35.0 kg/m2), waist circumference (continuous), education 
level (<high school diploma, high school diploma, >high school or college graduate, graduate school) 
smoking status (never, former, current), pack-years (continuous), environmental tobacco smoke (<1, >1 
hour/week), alcohol intake (continuous), aspirin use in two weeks prior to blood draw (yes/no), medical 
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Table 3.4 Multivariable-adjusted hazard ratios for cancer mortality by tertile of 











HR (95% CI)b 
Overall    
1 192 32337.7 115.0 1.00 (Reference) 
2 166 30323.1 108.1 0.83 (0.67, 1.02) 
3 181 25245.7 132.1 0.89 (0.72, 1.10) 
P-Trend    0.28 
Excluding Prostate Cancer   
1 176 32261.7 105.1 1.00 (Reference) 
2 154 30261.8 100.5 0.83 (0.66, 1.03) 
3 168 25175.8 122.9 0.88 (0.70, 1.11) 
P-Trend    0.28 
Whites       
1 134 24210.4 111.1 1.00 (Reference) 
2 111 22162.9 99.2 0.79 (0.61, 1.03) 
3 109 16409.2 130.2 0.86 (0.65, 1.13) 
P-Trend    0.25 
Blacks       
1 58 8127.3 123.8 1.00 (Reference) 
2 55 8160.1 128.2 0.87 (0.60, 1.27) 
3 72 8836.5 136.2 0.93 (0.64, 1.34) 
P-Trend    0.71 
Current Smokers       
1 50 4693.5 191.5 1.00 (Reference) 
2 78 7573.2 183.1 0.95 (0.66, 1.36) 
3 112 10262.3 183.6 0.96 (0.68, 1.35) 
P-Trend    0.84 
Former Smokers       
1 94 16173.3 110.5 1.00 (Reference) 
2 64 13999.8 93.0 0.81 (0.59, 1.13) 
3 54 9562.5 102.9 0.95 (0.67, 1.35) 
P-Trend    0.65 
Never Smokers       
1 48 11470.9 88.3 1.00 (Reference) 
2 24 8750.0 55.5 0.59 (0.36, 0.99) 
3 15 5399.7 58.6 0.59 (0.32, 1.09) 
P-Trend       0.04 
Abbreviations: HR, hazard ratio; CI, confidence interval. aIncidence rate per 1,000 men from 1987 to 2006 
standardized to the age and race distribution of the analytic cohort. bModels adjusted for study site 
(Jackson, Forsyth County, Minneapolis), race (white, black), body mass index (<18.5, 18.5-24.9, 25.0-29.9, 
30.0-34.9, >35.0 kg/m2), waist circumference (continuous), education level (<high school diploma, high 
school diploma, >high school or college graduate, graduate school) smoking status (never, former, current), 
pack-years (continuous), environmental tobacco smoke (<1, >1 hour/week), alcohol intake (continuous), 
aspirin use in the two weeks prior to blood draw (yes/no), medical history (yes/no) of cardiovascular 
disease, hypertension, and diabetes.  
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Figure 3.5 Multivariable-adjusted hazard ratios of total and site-specific cancer mortality by tertile of 
lymphocyte count in women in the ARIC study, 1987-2006. Models adjusted for study site, race, body 
mass index (<18.5, 18.5-24.9, 25.0-29.9, 30.0-34.9, >35.0 kg/m2), waist circumference (continuous), 
education level (<high school diploma, high school diploma, >high school or college graduate, graduate 
school) smoking status (never, former, current), pack-years (continuous), environmental tobacco smoke 
(<1, >1 hour/week), alcohol intake (continuous), aspirin use in two weeks prior to blood draw (yes/no), 
medical history (yes/no) of cardiovascular disease, hypertension, diabetes, menopausal status and HRT use 
(pre/peri-menopausal, postmenopausal and current HRT user, postmenopausal and former HRT user, 
postmenopausal and never HRT user). Asterisk indicates p-value <0.05.  
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Table 3.5 Multivariable-adjusted hazard ratios for cancer mortality by tertile of lymphocyte 









HR (95% CI)c 
Overall         
1 91 35369.1 52.9 1.00 (Reference) 
2 128 36319.5 73.2 1.23 (0.94, 1.62) 
3 181 38255.5 95.8 1.40 (1.07, 1.82) 
P-Trend     0.02 
Whites         
1 72 26782.0 58.1 1.00 (Reference) 
2 73 24035.7 63.5 1.02 (0.73, 1.41) 
3 95 17823.5 106.8 1.36 (0.98, 1.87) 
P-Trend    0.06 
Blacks         
1 19 8587.1 45.2 1.00 (Reference) 
2 55 12283.8 87.8 1.82 (1.07, 3.09) 
3 86 20401.9 79.5 1.65 (1.00, 2.75) 
P-Trend    0.14 
Premenopausal       
1 25 13540.7 34.9 1.00 (Reference) 
2 31 10889.8 58.3 1.33 (0.77, 2.30) 
3 40 9744.0 88.4 1.68 (1.00, 2.84) 
P-Trend    0.05 
Postmenopausal       
1 66 21743.0 60.1 1.00 (Reference) 
2 97 25429.6 77.8 1.21 (0.86, 1.70) 
3 141 28481.5 100.8 1.39 (1.00, 1.95) 
P-Trend    0.05 
Current Smokers       
1 27 5295.2 80.2 1.00 (Reference) 
2 43 7743.8 95.8 1.15 (0.70, 1.88) 
3 103 13326.6 143.1 1.58 (1.02, 2.44) 
P-Trend    0.02 
Former Smokers       
1 24 8904.5 52.0 1.00 (Reference) 
2 34 8755.1 81.2 1.23 (0.72, 2.10) 
3 30 7813.8 71.3 1.13 (0.64, 1.99) 
P-Trend    0.70 
Never Smokers       
1 39 21151.5 41.9 1.00 (Reference) 
2 51 19820.6 55.1 1.30 (0.85, 1.98) 
3 48 17040.8 58.9 1.31 (0.84, 2.05) 
P-Trend    0.13 
Abbreviations: HR, hazard ratio; CI, confidence interval. aMortality rate per 1,000 women from 1987 to 
2008 standardized to the age and race distribution of the analytic cohort. bModels adjusted for study site 
(Jackson, Forsyth County, Minneapolis), race (white, black), body mass index (<18.5, 18.5-24.9, 25.0-29.9, 
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30.0-34.9, >35.0 kg/m2), waist circumference (continuous), education level (<high school diploma, high 
Table 3.5 (continued) Multivariable-adjusted hazard ratios for cancer mortality by tertile of lymphocyte 
count, stratified by race, menopausal status, and cigarette smoking status, in women in the ARIC study, 
1987-2006 
 
school diploma, >high school or college graduate, graduate school) smoking status (never, former, current), 
pack-years (continuous), environmental tobacco smoke (<1, >1 hour/week), alcohol intake (continuous), 
aspirin use in the two weeks prior to blood draw (yes/no), medical history (yes/no) of cardiovascular 
disease, hypertension, diabetes, menopausal status and HRT use (pre/peri-menopausal, postmenopausal and 





























































Table B.1 Baseline characteristics by tertile of lymphocyte count in male and female ARIC participants, 1987-1989 
  Lymphocyte Count (x109 cells/L) 
  Men (N=4,668) Women (N=5,671) 
  
Tertile 1      
(0.09, 1.65) 
Tertile 2          
(1.66, 2.14) 
Tertile 3       
(2.15, 6.08) 
Tertile 1      
(0.09, 1.65) 
Tertile 2         
(1.66, 2.14) 
Tertile 3       
(2.15, 6.08) 
Total, N 1,677 1,598 1,393 1,770 1,855 2,046 
Study Sitea, %       
    Jackson, MS 23.5 24.4 33.0 22.5 31.2 50.8 
    Forsyth County, NC 35.1 39.7 30.4 37.2 37.1 24.5 
    Minneapolis, MN 41.4 35.9 36.5 40.3 31.7 24.7 
Black, % 27.0 28.8 37.7 26.2 36.0 56.1 
Age (years), Mean (SD)  54.5 (5.8) 54.1 (5.9) 54.2 (5.7) 53.5 (5.8) 53.7 (5.8) 53.6 (5.7) 
Education, %       
    <High school 18.8 20.6 25.2 16.1 20.4 29.8 
    High school or college 
graduate 33.3 34.0 36.3 46.5 42.9 39.4 
    Graduate school 47.9 45.4 38.5 37.5 36.7 30.9 
    Missing, N 5 2 2 3 1 4 
BMI (kg/m2), %       
    <18.5 0.3 0.6 0.4 1.1 1.4 0.7 
    18.5-24.99 30.8 27.1 22.4 46.5 37.6 24.8 
    25.0 29.99 50.1 48.6 48.6 31.2 30.6 34.0 
    30.0-34.99 15.9 18.3 22.4 13.3 18.5 22.9 
    >35.00 2.9 5.3 6.3 7.9 11.9 17.5 
    Missing, N 2 0 1 3 2 1 
Waist Circumference (cm), 
Mean (SD) 
97.5 (10.4) 99.0 (11.5) 100.2 (11.6) 91.1 (14.6) 94.4 (15.3) 98.3 (15.9) 
    Missing, N 1 0 0 0 1 1 
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Table B.1 (continued) Baseline characteristics by tertiles of lymphocyte count in male and female ARIC participants, 1987-1989 
 Lymphocyte Count (x109 cells/L) 
 Men (N=4,668) Women (N=5,671) 
 
Tertile 1      
(0.09, 1.65) 
Tertile 2          
(1.66, 2.14) 
Tertile 3       
(2.15, 6.08) 
Tertile 1      
(0.09, 1.65) 
Tertile 2         
(1.66, 2.14) 
Tertile 3       
(2.15, 6.08) 
 
Cigarette Use, %       
    Never 34.0 27.2 19.6 58.9 53.8 44.6 
    Former 49.9 45.3 36.2 25.1 23.8 19.9 
    Current 16.2 27.5 44.2 16.0 22.4 35.5 
    Missing, N 1 0 1 3 0 3 
Pack-Yearsb, Mean (SD) 27.5 (22.8) 28.4 (22.9) 28.6 (22.7) 19.5 (18.7) 21.7 (20.0) 23.0 (20.3) 
    Missing, N 31 26 22 25 38 52 
ETSc (hours/week), %       
    <1 31.4 26.3 20.6 38.5 34.5 25.3 
    >1 68.6 73.7 79.4 61.5 65.5 74.7 
    Missing, N 15 9 8 8 14 8 
Alcohol Intaked, Mean (SD) 
(g/wk) 135.8 (145.4) 140.0 (166.6) 132.6 (142.1) 69.5 (70.9) 72.0 (65.4) 69.6 (75.2) 
    Missing, N 5 8 17 12 6 20 
CVDe, % 9.6 9.6 13.8 7.8 8.5 10.2 
Hypertensionf, % 35.9 35.0 36.1 29.5 33.4 44.1 
    Missing, N 0 0 1 1 1 0 
Diabetesg, % 10.0 10.4 15.6 7.5 11.1 16.3 
    Missing, N 3 0 4 2 3 2 
Menopausal Statush       
     Pre/Peri-menopausal -- -- -- 36.7 30.7 29.7 
    Postmenopausal -- -- -- 63.3 69.3 70.3 
HRT Use, %       
    Never -- -- -- 10.0 12.1 13.0 
    Former -- -- -- 37.0 42.2 46.7 
    Current -- -- -- 37.0 28.8 24.7 
 












Abbreviations: BMI, body mass index; SD, standard deviation; ETS, environmental tobacco smoke; CVD, cardiovascular disease; HRT, hormone 
replacement therapy. aParticipants from Washington County, MD were excluded from analyses due to substantial missing WBC subtype count data at 
this site. bPack-years among ever smokers only. Pack-years was calculated as the average number of cigarettes smoked per day multiplied by the number 
of years of smoking and divided by 20. cETS defined as the average number of hours per week of close contact with people when they are smoking. 
dAlcohol intake among participants who reported usually having at least one drink per week. eCVD defined as having a history of angina pectoris, 
coronary heart disease, intermittent claudication, or stroke. fHypertension defined as use of any hypertensive medications, systolic blood pressure >140 
mmHg, or diastolic blood pressure >90 mmHg. gDiabetes defined as having a fasting glucose level >126 mg/dl, non-fasting glucose level >200 mg/dl, a 
physician diagnosis of diabetes, or using sugar-lowering medications in two week prior to enrollment. hPre/Peri-menopausal defined as any women who 
reported having her menstrual period in the two years prior to baseline. iAspirin use in two weeks prior to study enrollment.   
Table B.1 (continued) Baseline characteristics by tertiles of lymphocyte count in male and female ARIC participants, 1987-1989 
 Lymphocyte Count (x109 cells/L) 
 Men (N=4,668) Women (N=5,671) 
 
Tertile 1      
(0.09, 1.65) 
Tertile 2          
(1.66, 2.14) 
Tertile 3       
(2.15, 6.08) 
Tertile 1      
(0.09, 1.65) 
Tertile 2         
(1.66, 2.14) 
Tertile 3       
(2.15, 6.08) 
    Missing, N -- -- -- 33 47 88 
Aspirin Usedj, % 42.9 44.2 39.8 50.3 49.3 42.5 
    Missing, N 13 15 10 8 14 22 
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Table B.2 Multivariable-adjusted hazard ratios for cancer incidence 
and mortality by tertile of lymphocyte count accounting for levels of 
neutrophils, monocytes, eosinophils and basophils in men and 
women in the ARIC study, 1987-2008 
 Men Women 
Lymphocyte Count 
by Tertile 
HR (95% CI)a HR (95% CI)b 
Cancer Incidencec   
1 1.00 (Reference) 1.00 (Reference) 
2 0.69 (0.56, 0.86) 1.22 (1.02, 1.46) 
3 0.72 (0.57, 0.91) 1.04 (0.85, 1.26) 
Cancer Mortality   
1 1.00 (Reference) 1.00 (Reference) 
2 0.84 (0.66, 1.07) 1.48 (1.09, 2.00) 
3 0.88 (0.68, 1.14) 1.28 (0.94, 1.75) 
Abbreviations: HR, hazard ratio; CI, confidence interval. aModels adjusted for study site (Jackson, Forsyth 
County, Minneapolis), race (white, black), body mass index (<18.5, 18.5-24.9, 25.0-29.9, 30.0-34.9, >35.0 
kg/m2), waist circumference (continuous), education level (<high school diploma, high school diploma, 
>high school or college graduate, graduate school) smoking status (never, former, current), pack-years 
(continuous), environmental tobacco smoke (<1, >1 hour/week), alcohol intake (continuous), aspirin use in 
the two weeks prior to blood draw (yes/no), medical history (yes/no) of cardiovascular disease, 
hypertension, and diabetes. bAdditional adjustment for menopausal status and HRT use (pre/peri-
menopausal, postmenopausal and current HRT user, postmenopausal and former HRT user, 
postmenopausal and never HRT user). cAmong men, excluding cases of prostate cancer. 
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Table B.3 Multivariable-adjusted hazard ratios for cancer 
incidence and mortality by tertile of NLR, stratified by sex, race, 
menopausal status and cigarette smoking status, in the ARIC 
study, 1987-2008 
 Cancer Incidence Cancer Mortality 
Neutrophil to 
Lymphocyte 
Ratio by Tertilea 
HR (95% CI)b HR (95% CI)b 
Overall     
1 1.00 (Reference) 1.00 (Reference) 
2 1.07 (0.95, 1.20) 1.17 (0.98, 1.39) 
3 1.01 (0.90, 1.14) 1.27 (1.06, 1.52) 
P-Trend 0.92 0.009 
Males   
1 1.00 (Reference) 1.00 (Reference) 
2 1.04 (0.88, 1.22) 1.19 (0.94, 1.52) 
3 1.04 (0.88, 1.22) 1.30 (1.02, 1.65) 
P-Trend 0.69 0.03 
Femalesc   
1 1.00 (Reference) 1.00 (Reference) 
2 1.06 (0.90, 1.24) 1.12 (0.87, 1.45) 
3 0.90 (0.76, 1.08) 1.13 (0.86, 1.49) 
P-Trend 0.26 0.38 
Whites   
1 1.00 (Reference) 1.00 (Reference) 
2 1.08 (0.93, 1.26) 1.25 (0.97, 1.61) 
3 1.03 (0.89, 1.20) 1.36 (1.06, 1.75) 
P-Trend 0.91 0.02 
Blacks   
1 1.00 (Reference) 1.00 (Reference) 
2 1.07 (0.89, 1.28) 1.10 (0.85, 1.43) 
3 0.92 (0.74, 1.14) 1.10 (0.82, 1.49) 
P-Trend 0.67 0.42 
Current Smokers   
1 1.00 (Reference) 1.00 (Reference) 
2 0.98 (0.79, 1.21) 1.04 (0.79, 1.36) 
3 1.04 (0.84, 1.28) 1.16 (0.89, 1.52) 
P-Trend 0.67 0.26 
Former Smokers   
1 1.00 (Reference) 1.00 (Reference) 
2 1.01 (0.83, 1.24) 1.01 (0.74, 1.39) 
3 0.95 (0.77, 1.17) 1.18 (0.86, 1.62) 
P-Trend 0.58 0.26 
Never Smokers   
1 1.00 (Reference) 1.00 (Reference) 
2 1.21 (1.00, 1.45) 1.58 (1.13, 2.21) 
3 1.02 (0.83, 1.25) 1.47 (1.03, 2.11) 
P-Trend 0.90 0.04 
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Table B.3 (continued) Multivariable-adjusted hazard ratios for cancer incidence and mortality by tertile 
NLR, stratified by sex, race, menopausal status and cigarette smoking status, in the ARIC study, 1987-2008 
 
Abbreviations: NLR, neutrophil to lymphocyte ratio; HR, hazard ratio; CI, confidence interval. aNLR 
tertiles defined based on race-specific cut-offs and then combined across the analytic cohort. bModels 
adjusted for study site (Jackson, Forsyth County, Minneapolis), race (white, black), body mass index 
(<18.5, 18.5-24.9, 25.0-29.9, 30.0-34.9, >35.0 kg/m2), waist circumference (continuous), education level 
(<high school diploma, high school diploma, >high school or college graduate, graduate school) smoking 
status (never, former, current), pack-years (continuous), environmental tobacco smoke (<1, >1 hour/week), 
alcohol intake (continuous), aspirin use in the two weeks prior to blood draw (yes/no), medical history 
(yes/no) of cardiovascular disease, hypertension, and diabetes. cAdditional adjustment for menopausal 
status and HRT use (pre/peri-menopausal, postmenopausal and current HRT user, postmenopausal and 
former HRT user, postmenopausal and never HRT user).  
 
 







Chapter 4. Pre-diagnostic basophil levels and the risk of cancer 
incidence and mortality in the Atherosclerosis Risk in Communities 
(ARIC) study 
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Abstract 
Allergies have been associated with a reduced risk of cancer in several studies. The white 
blood cell (WBC) subtypes, eosinophils and basophils are components of the allergic 
response. Data from laboratory and observational studies support an anti-tumoral role for 
eosinophils, however, the role of basopohils in carcinogenesis has not been well studied. 
In this study, we examined the prospective association between levels of circulating 
basophils and cancer incidence and mortality in the Atherosclerosis Risk in Communities 
(ARIC) study. Participants included men and women with total WBC counts within the 
normal reference range and no history of cancer at baseline (N=10,251). Total WBC and 
subtype counts were measured at baseline (1987-1989) and cancer incidence and 
mortality data were ascertained through 2006 and 2008, respectively. Cox proportional 
hazards models were used to estimate the multivariable-adjusted hazard ratios (HR) and 
95% confidence intervals (CI) by the presence (>1%) or absence (<1%) of basophils in 
the peripheral blood. During follow-up, a total of 2,138 incident primary cancers and 952 
cancer deaths were ascertained. The presence of circulating basophils was associated with 
a reduced risk of cancer incidence that approached statistical significance (HR: 0.93, 95% 
CI: 0.85, 1.01) and a significantly reduced risk of cancer mortality (HR: 0.87, 95% CI: 
0.76, 1.00). Similar risk estimates were found after mutual adjustment for the other WBC 
subtypes, including eosinophils, and after excluding persons with basophil counts outside 
the normal range (>0.19 x109 cells/L). In individuals with normal total WBC count, the 
presence of basophils in the peripheral blood was associated with a reduced risk of 
subsequent cancer incidence and mortality, independent of the effects of eosinophils. 
Future studies are warranted to explore to what extent this association is explained by 
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Introduction 
In epidemiological studies, a history of allergies has been associated with an overall 
reduced risk of cancer incidence and mortality, with the most consistent findings for 
pancreatic cancers and gliomas (1, 2). It is widely hypothesized that the heightened 
immune response characteristic of allergies may also enhance tumor immunosurveillance, 
the process in which the immune system identifies and clears premalignant and malignant 
cells (1, 3, 4). The white blood cell (WBC) subtypes, eosinophils and basophils, are 
important mediators of the allergic response (5, 6). In in vitro and in vivo studies, 
eosinophils have also been shown to have anti-tumoral properties (7-9). This is consistent 
with the findings from a prospective study conducted by co-authors of this paper, in 
which pre-diagnostic eosinophil count was inversely associated with colorectal cancer 
incidence (10). Additionally, elevated levels of eosinophils have been associated with 
improved prognosis of several cancer types, including breast, colorectal and head and 
neck (11-14).  
  
Basophils, which constitute 0 to 3% of total WBC count, have a unique role in acute and 
chronic allergic responses, as one of the primary producer of interleukin-4 (IL-4), which, 
in turn, promotes T helper 2 (Th2) cell differentiation (6, 15-18). However, to date, the 
role of basophils in carcinogenesis has not been well examined. In one study, cancer 
patients had lower levels of circulating basophil count compared to non-cancer patients 
(19). Additionally, in mice models, basophils were found to damage tumor cell receptors, 
which may hinder tumor growth and progression (20). 
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In the present study, we examined, for the first time, the association between circulating 
pre-diagnostic basophil count and cancer incidence and mortality in the Atherosclerosis 
Risk in Communities (ARIC) cohort, a large, community-based study. We hypothesized 
that basophil count would be inversely associated with cancer risk, independent of the 
effects of eosinophil count, indicating a possible role for this cell type in the tumor 
immunosurveillance response. 
 
Materials and Methods 
Study population 
This study was conducted in the ARIC study, an ongoing, prospective cohort initiated 
between 1987 and 1989 to investigate the etiology of atherosclerosis and its sequelae. 
Men and women (N=15,792), ages 45 to 64 years, were enrolled from four U.S. 
communities, Forsyth County, NC; Jackson, MS; Washington County, MD; and suburban 
Minneapolis, MN. Participants were identified using probability sampling in Minneapolis 
and Washington County, while in Jackson, blacks were exclusively recruited and in 
Forsyth County blacks were oversampled (21). Participants from Washington County 
were not included in these analyses as baseline WBC subtype count was missing for more 
than 85% of participants (10). At enrollment, participants provided a blood sample and 
reported information on sociodemographic factors, medical history, reproductive history, 
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The analytic cohort included both men and women that met the following eligibility 
criteria: (1) not residing in Washington County, MD (N=11,792); (2) no personal history 
of cancer, excluding cases of non-melanoma skin cancer (N=11,175); (3) white or black 
race (N=11,140); (4) total WBC count within two standard deviations of the mean in 
whites and blacks, separately, given the differences in total WBC count by race (22) 
(N=10,351); (5) not missing baseline basophil count (N=10274); and (6) not missing 
information on cancer incidence (N=10,114) or cancer mortality (N=10,251). 
 
Exposure ascertainment 
Total and differential WBC counts were measured at baseline and three years later at 
Visit 2. In the main analyses, baseline WBC subtype counts were used. Following 
venipuncture, samples were stored at 4°C and within 24 hours total WBC count was 
measured using automated particle counters in local, independent clinical laboratories. 
Subtypes were measured as a proportion of total WBCs, with a detectable limit of 1%, 
and absolute WBC subtype counts were calculated by multiplying the subtype proportion 
by the total WBC count. Based on repeat testing of individuals conducted one to two 
weeks apart, reliability coefficients for total WBC count were estimated to be greater than 
0.96 for each laboratory (23, 24). The distribution of basophil counts in the analytic 
cohort is presented in Appendix C, Figure C.1. 
 
Outcome ascertainment 
Cancer incidence, including date of diagnosis and site of cancer, was ascertained from 
study initiation through December 31, 2006 (24, 25). Cancer incidence was primarily 
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identified by linkage to well-established state and/or county cancer registries that have a 
high completeness (≥90%) of cancer data (24). Hospital surveillance was used to identify 
cancer cases in Jackson prior to establishment of the Mississippi state cancer registry in 
1996 (26), and all additional cancer cases for the other study sites (24, 27). At present, 
data on stage at diagnosis, cancer subtype, and treatment are not consistently available for 
all cancers. 
 
Vital status was available through December 31, 2008. Deaths were identified through 
contact with relatives, physician or designated contact, or through a search of obituaries, 
funeral and hospital records, death certificates and the National Death Index (NDI). The 
date and cause of death were confirmed by death certificate for all reported deaths. Cause 
of death was coded using the Ninth International Statistical Classification of Diseases and 
Related Health Problems (ICD-9) for deaths through 1998 and ICD-10 for all subsequent 
deaths. Cause-specific mortality is available for 98% of decedents (28).  
 
Assessment of covariates 
Participants reported their highest education attainment, regular alcohol use, and intake of 
aspirin in the two weeks prior to baseline study visit. They also provided information on 
current cigarette smoking status and, if applicable, the average number of years of 
smoking and cigarettes smoked per day. These values were used to calculate pack-years 
([cigarettes per day*years smoking]/20 cigarettes per pack) among ever smokers. 
Exposure to environmental tobacco smoke (ETS) was defined as being in close proximity 
to smokers for more than 1 hour per week (29, 30). Body mass index (BMI), calculated 
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as weight (kg) divided by height (m) squared, and waist circumference were collected by 
trained technicians at baseline study visit. A history of cardiovascular disease (CVD) was 
defined as having a prior diagnosis of angina pectoris, coronary heart disease, intermittent 
claudication or stroke. Participants were categorized as having hypertension if they 
reported use of any hypertensive medications or if they had systolic blood pressure ≥140 
mmHg or diastolic blood pressure ≥90 mmHg. Diabetes was defined as having a fasting 
glucose level ≥126 mg/dl, a non-fasting glucose level ≥200 mg/dl, a self-reported 
physician diagnosis of diabetes, or use of blood sugar lowering medications in the two 
weeks prior to enrollment. History of asthma (ever or never) was based on self-report. 
Women were categorized as being premenopausal if they had a menstrual cycle within 
two years of baseline or postmenopausal (31). Women missing information on 
menopausal status were categorized as being postmenopausal if they were 55 years of age 
or older. Postmenopausal hormone use was categorized as current, former or never (31).  
 
Statistical analyses  
In 50% of the analytic cohort, basophils constituted less than 1% of the total WBC count 
and, thus, were not quantifiable. Therefore, we created binary categories of basophil 
count based on the absence (<1%) or presence (>1%) of basophils in the peripheral 
blood. Baseline descriptive characteristics were compared by category of basophil level 
using the chi-square test for categorical variables or ANOVA for continuous variables. 
Cox proportional hazards models were used to estimate the hazard ratio (HR) and 95% 
confidence interval (CI) for cancer incidence and mortality by binary categories of 
basophil level. In analyses of cancer incidence, follow-up time was accrued from age at 
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baseline blood draw, with the origin defined as age 40 years and staggered late entries for 
persons over age 40 at baseline, to the first of the following events: (1) age at first 
primary cancer diagnosis, (2) age at death, or (3) age at end of follow-up (December 31, 
2006). In analyses of cancer mortality, individuals were followed from age at baseline 
blood draw to (1) age at death or (2) age at end of follow-up (December 31, 2008). In 
models in which time accrued from year at baseline blood draw to (1) year at first 
primary cancer diagnosis or cancer death, (2) year at other death, or (3) year at end of 
follow-up, similar HRs were estimated and are not presented here. 
 
Multivariable models included the baseline covariates, race (white, black), study site 
(Jackson, MS, Forsyth County, Minneapolis, MN), body mass index (<18.5, 18.5-24.9, 
25.0-29.9, 30.0-34.9, >35.0 kg/m2), waist circumference (continuous), education 
attainment (<high school diploma, high school diploma, >high school or college 
graduate, graduate school), cigarette smoking status (never, former, current), pack-years 
(continuous), ETS (<1 hour/week, >1 hour/week), alcohol intake (g/wk), aspirin use in 
two weeks prior to blood draw (yes/no), and medical history of CVD (yes/no), 
hypertension (yes/no), and diabetes (yes/no). In women, the additional covariates, 
menopausal status and HRT use (premenopausal, postmenopausal and current HRT user, 
postmenopausal and former HRT user, postmenopausal and never HRT user) were 
included in models. Models mutually adjusting for counts of the other WBC subtypes, 
neutrophils, lymphocytes, monocytes, and eosinophils, were also conducted. Missing 
pack-year and waist circumference information was replaced with the median value. 
Effect modification between basophil count and select covariates known to modulate the 
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host immune response, including race, sex, cigarette smoking status, BMI, and NSAIDs 
use, was assessed by introducing a cross-product term in models and using the Wald test 
to test for statistical significance. Additionally, we evaluated the interaction between 
basophil count category and eosinophil count tertile to explore a potential synergistic 
effect between these inflammatory factors. For all models, the proportional hazards 
assumption was assessed by introducing an interaction term between monocyte count and 
follow-up time. In all cases, the interaction term was not statistically significant, 
confirming this assumption. Rates of cancer incidence and cancer mortality were 
standardized to the age, race, and sex distribution of the analytic cohort. 
  
Cancer site-specific analyses were conducted in models of cancer incidence and cancer 
mortality for the four most common cancers (i.e., female breast cancer, colorectal cancer, 
lung cancer, and prostate cancer). Additionally, the following sensitivity analyses were 
performed: (1) excluding incident cancer cases and deaths within one and five years from 
baseline blood draw in order to address any bias due to reverse causation, (2) excluding 
participants who reported a diagnosis of asthma, used aspirin in the two weeks prior to 
baseline, and ever smokers to address the possibility of residual confounding by these 
variables; (3) excluding persons with absolute basophil counts outside the normal 
reference range (>0.19 x109 cells/L); and (4) using basophil count measured at Visit 2 as 
the exposure of interest in a subset of the participants with available data (N=6,577); In 
these analyses, time at risk was initiated at age at Visit 2. Finally, in cancer mortality 
analyses, sub-distribution hazard ratios were estimated using the Fine and Gray approach 
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to account for the issue of competing risks (32). All analyses were conducted using 
STATA version 11.2 (Stata Corporation, College Station, TX, 2012). 
 
Note: The association between eosinophil count and site-specific cancer incidence in this 
cohort has been previously reported (10). We present the risk of total cancer incidence 
and mortality by eosionphil count tertile in Appendix C, Tables C.1 and C.2, respectively. 
 
Results 
Table 4.1 presents the distribution of baseline characteristics by binary category of 
basophil level. Among the 50% of the analytic cohort with basophils constituting 1% or 
greater of the total WBC count (median: 1%, interquartile range (IQR): 1%, 1%), the 
median basophil count was 0.06 x 109 cells/L (IQR: 0.049 to 0.079 x 109 cells/L). 
Participants with >1% of basophils in the peripheral blood were more likely to be female, 
black, less educated, have a higher BMI, greater exposure to ETS, and have a medical 
history of hypertension and diabetes. Among persons with a history of asthma, there was 
no significant difference in basophil level. 
 
Cancer incidence 
Between 1987 and 2006, a total of 163,150.9 person years and 2,138 incident primary 
cancers were accrued. As presented in Table 4.2, the presence of basophils in the 
peripheral blood (>1%) was associated with a 7% (HR: 0.93, 95% CI: 0.85, 1.01) reduced 
risk of total cancer incidence, although this association did not reach statistical 
significance. A suggestive inverse association remained after mutual adjustment for the 
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other WBC subtype counts (HR: 0.94, 95% CI: 0.85, 1.04; Table 4.2), after excluding 
incident cancer cases that developed within the first five years of baseline, and among 
non-asthmatics and persons who did not use aspirin in the two weeks prior to blood draw, 
but no association was found in never smokers (Table 4.2). Forty-six participants had 
absolute basophil counts exceeding the normal reference range (0 to 0.19x109 cells/L); 
excluding these individuals did not appreciably alter risk estimates. Additionally, further 
adjustment for a history of asthma did not significantly alter risk estimates suggesting 
that basophils do not entirely mediate the effects of asthma.  
 
There was no evidence of a statistical interaction between the presence of basophils and 
race, sex, cigarette smoking status, BMI, or aspirin use (all p-interaction>0.3), and the 
joint effects of high basophil and eosinophil counts were not synergistic (p-interaction 
term=0.9). Using basophil level measured at Visit 2, a non-significant inverse association 
was found between basophils and cancer incidence (HR: 0.92, 95% CI: 0.81, 1.05). In 
cancer incidence site-specific analyses, the presence of basophils was associated with a 
suggestive reduced risk of lung cancer (HR: 0.94, 95% CI: 0.85, 1.03), but there was no 
association with colorectal, female breast or prostate cancer incidence (Table 4.3).  
 
Cancer mortality 
Between 1987 and 2008, there were 201,099.8 person-years and 952 cancer deaths. 
Individuals with detectable basophils in the peripheral blood had a 13% (HR: 0.87, 95% 
CI: 0.76, 1.00) reduced risk of dying of cancer compared to those with no basophils 
(Table 4.4). Similar risk estimates were found after mutual adjustment for the other WBC 
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subtypes, including eosinophil count, (HR: 0.87, 95% CI: 0.75, 1.01; Table 4.4). 
Additionally, there was no evidence of a statistical interaction by race, sex, cigarette 
smoking status, BMI, aspirin use, or eosinophil count tertile (all p-interaction terms>0.2).  
A significant inverse association between basophil level and cancer mortality remained 
among non-smokers (HR: 0.76, 95% CI: 0.58, 1.00; Table 4.4), non-asthmatics (HR: 
0.86, 95% CI: 0.75, 0.99), persons who did not use aspirin in the two weeks prior to 
blood draw (HR: 0.80, 95% CI: 0.67, 0.95), and persons with absolute basophil counts 
within the normal reference range (HR: 0.87, 95% CI: 0.76, 1.00). A suggestive, but non-
statistically significant inverse association was found after excluding cancer cases within 
five years of baseline (HR: 0.91, 95% CI: 0.80, 1.05). In multivariable-adjusted models, 
inclusion of asthma yielded a slightly attenuated but still significant risk estimate, 
suggesting that asthma does not entirely mediate this association. In the analysis using 
basophil level measured at Visit 2, a non-significant inverse association was found (HR: 
0.86, 95% CI: 0.70, 1.05). 
 
In cancer mortality site-specific analyses, the presence of basophils in the peripheral 
blood was associated with a significantly reduced risk of lung cancer mortality (HR: 0.78, 
95% CI: 0.61, 0.99), but not colorectal, breast or prostate cancer mortality (Table 4.5). 
Upon further stratification by cigarette smoking use, the significant association with lung 
cancer mortality was present among current smokers only (HR: 0.74, 95% CI: 0.55, 1.00; 
Appendix C, Table C.3), while the presence of basophils was associated was a reduced 
risk of non-lung cancer mortality in never smokers (HR: 0.74, 95% CI: 0.56, 0.99; 
Appendix C, Table C.3). Lastly, the presence of basophils was not associated with non-
 
    
120 
cancer mortality or CVD mortality. In analyses accounting for such competing causes of 
death, the inverse association with cancer mortality remained.  
 
Discussion 
In this prospective cohort study, the presence of basophils in the peripheral blood was 
associated with a suggestive reduced risk of total cancer incidence and a significantly 
reduced risk of cancer mortality. These associations were independent of the effects of 
eosinophils and the other WBC subtypes. Additionally, a significant inverse association 
with cancer mortality persisted among never smokers, non-asthmatic, and persons with 
basophil counts within the normal reference range. To our knowledge, this is the first 
prospective study to examine the association between circulating basophils and cancer 
incidence and mortality. Our findings lend indirect support to the tumor 
immuosurveillance concept and suggest that variations of basophil levels within the 
normal range may reflect the effectiveness of this anti-tumoral mechanism. 
  
Consistent with our findings, Galoppin et al. (19), previously reported lower levels of 
circulating basophil count in cancer patients compared to healthy persons without cancer. 
Interestingly, Galoppin et al. (19) also observed a decreased concentration of histamine in 
the blood of cancer patients, possibly due to this reduced basophil count. This finding 
suggests that basophils may have an etiological role in carcinogenesis, in part, through 
the production of histamine, which has the capacity to promote natural killer (NK) cell 
survival and stimulate NK and T cell activity, cellular components involved in 
eliminating premalignant and malignant cells (33). Additionally, basophils are a major 
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producer of the cytokine, IL-4 (16, 17), which may have anti-tumoral properties through 
the promotion of cytotoxic T lymphocyte activity (34) and the inhibition of tumor cell 
proliferation (35, 36). Findings from a study conducted in mice, offer an alternate 
explanation for our findings; in this study, basophils were found to damage tumor cell 
receptors, which may hinder tumor growth and progression (20). 
 
Eosinophils, another component of total WBC count with a critical role in the allergic 
response, have been previously found to be inversely associated with colorectal cancer 
incidence in this cohort (10). A priori, we hypothesized that basophils, which have a non-
redundant function in the allergic response (6, 18), may also have an independent or 
synergistic role in carcinogenesis. In support of this hypothesis, inclusion of eosinophil 
count and the other WBC subtypes, in multivariable models did not alter the significant 
association between basophil level and cancer mortality. Of note, we did not find any 
evidence of a synergistic effect between basophils and eosinophils in models of cancer 
incidence and mortality. 
 
In the present study, we could not examine if basophils mediate the relationship between 
allergies and cancer, as data on allergies were not collected. However, by restricting the 
study population to persons with total WBC counts within the normal reference range, we 
minimized the number of persons with severe allergic reactions. Indeed, only 0.4% 
(N=46) of the analytic cohort had basophil counts above the normal reference range, 
which is commonly indicative of allergic sensitivity (37). Nevertheless, we expect 
considerably more participants to have milder forms of allergies given that the prevalence 
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of allergies in the United States has been estimated to be as high as 20% (38). Notably, 
inclusion of the variable self-reported diagnosis of asthma into models did not have a 
significant effect on risk estimates, suggesting that our findings are not largely mediated 
by asthma, a form of allergy. Future studies are necessary to explore the effect of 
allergies on the association between basophils and cancer and to examine whether allergy 
induced basophilia is associated with a further reduction of cancer incidence and 
mortality.   
 
In this study, we also found basophils to be more strongly associated with cancer 
mortality than cancer incidence. This observation may indicate a specific role for 
basophils in the development of more aggressive disease. Alternatively, basophil count 
may modulate treatment responsiveness. In the present study, we were unable to evaluate 
these possibilities as information on tumor stage and grade at diagnosis and treatment 
was not widely collected in ARIC.  
 
An additional limitation of the present study is the use of a one-time measure of basophil 
count. However, in comparisons of baseline basophil count with a one-time repeat 
measure, collected three years later, we found 63% agreement by binary category, using 
the kappa statistic. This suggests that the presence of basophils in the peripheral blood is 
fairly stable over the short-term. Indeed, in sensitivity analyses utilizing basophil level 
measured at Visit 2 in a subset of the analytic cohort, similar but non-significant findings 
were estimated for cancer incidence and mortality. Furthermore, we would expect any 
effects of intra-individual variation to only attenuate our findings. This study also has 
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several strengths. Few other prospective cohort studies have collected information on 
both baseline WBC differential counts and subsequent cancer incidence and mortality. 
Additionally, detailed information was available on a wide-array of socio-demographic 
characteristics, lifestyle risk factors and medical history.  
 
In conclusion, in individuals with total WBC counts within the normal reference range, 
the presence of basophils in the peripheral blood was associated with a reduced risk of 
cancer incidence and mortality. Our findings suggest that basophils may be an 
independent risk factor for cancer initiation, promotion and progression. Moreover, these 
findings provide support for the tumor immunosurveillance concept, generally, and may 
also indicate a specific role for basophils in this process. Future studies are warranted to 
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Table 4.1 Baseline characteristics by the absence/presence of basophils in the 
peripheral blood in ARIC participants, 1987-1989 






Total, N 5,193 5,081 
Study Sitea, %   
    Jackson, MS 26.1 36.4 
    Forsyth County, NC 26.4 41.8 
    Minneapolis, MN 47.6 21.8 
Male, % 46.3 44.0 
Blacks, % 30.6 40.7 
Age (years), Mean (SD)  53.8 (5.7) 54.0 (5.8) 
Education, %   
    <High school 18.8 24.8 
    High school or college 
graduate 40.7 37.4 
    Graduate school 40.5 37.8 
    Missing, N 9 8 
BMI (kg/m2), %   
    <18.5 0.5 1.1 
    18.5-24.99 31.3 32.5 
    25.0 29.99 40.6 38.9 
    30.0-34.99 18.6 18.5 
    >35.00 9.1 9.0 
    Missing, N 4 5 
Waist Circumference (cm), 
Mean (SD) 
96.5 (13.8) 96.7 (14.0) 
    Missing, N 2 1 
Cigarette Smoking Status, %   
    Never 40.6 41.1 
    Former 33.8 31.2 
    Current 25.6 27.6 
    Missing, N 5 3 
Pack-Yearsb, Mean (SD) 25.0 (21.8) 25.0 (21.9) 
    Missing, N 80 108 
ETSc (hours/week), %   
    <1 30.9 28.6 
    >1 69.1 71.5 
    Missing, N 28 34 
Alcohol Intaked, Mean (SD) 
(g/wk) 108.9 (127.2) 112.0 (134.3) 
    Missing, N 27 32 
CVDe, % 9.8 9.8 
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Table 4.1 (continued) Baseline characteristics by the absence/presence of 
basophil count in the peripheral blood in ARIC participants 






Hypertensionf, % 34.2 37.2 
    Missing, N 1 2 
Diabetesg, % 11.2 12.3 
    Missing, N 8 6 
Asthma, % 4.6 5.2 
    Missing, N 4 2 
Aspirin usedh, % 45.9 44.4 
    Missing, N 35 47 
Abbreviations: BMI, body mass index; SD, standard deviation; ETS, environmental tobacco 
smoke; CVD, cardiovascular disease; HRT, hormone replacement therapy. aParticipants from 
Washington County, MD were excluded from analyses due to substantial missing WBC subtype 
count data at this site. bPack-years among ever smokers only. Pack-years was calculated as the 
average number of cigarettes smoked per day multiplied by the number of years of smoking and 
divided by 20. cETS defined as the average number of hours per week of close contact with 
people when they are smoking. dAlcohol intake among participants who reported usually having 
at least one drink per week. eCVD defined as having a history of angina pectoris, coronary heart 
disease, intermittent claudication, or stroke. fHypertension defined as use of any hypertensive 
medications, systolic blood pressure >140 mmHg, or diastolic blood pressure >90 mmHg. 
gDiabetes defined as having a fasting glucose level >126 mg/dl, non-fasting glucose level >200 
mg/dl, a physician diagnosis of diabetes, or using sugar-lowering medications in two weeks prior 
to enrollment. hAspirin use in two weeks prior to study enrollment. 
 










































Table 4.2 Multivariable-adjusted hazard ratios for cancer incidence by the absence/presence of basophils, stratified by 
race, sex and cigarette smoking status, in the ARIC study, 1987-2006  
 N Person-Years 
Age-Standardized 
Ratea 
HR (95% CI)b HR (95% CI)c 
Overall           
Absence (<1%) 1113 81841.6 218.5 1.00 (Reference) 1.00 (Reference) 
Presence (>1%) 1009 80345.0 202.9 0.93 (0.85, 1.01) 0.94 (0.85, 1.04) 
Whites      
Absence (<1%) 815 57666.0 218.5 1.00 (Reference) 1.00 (Reference) 
Presence (>1%) 618 48861.7 202.9 0.89 (0.79, 0.99) 0.90 (0.79, 1.02) 
Blacks      
Absence (<1%) 298 24175.6 194.6 1.00 (Reference) 1.00 (Reference) 
Presence (>1%) 391 31483.4 194.5 0.98 (0.84, 1.14) 0.99 (0.84, 1.17) 
Males      
Absence (<1%) 608 36813.2 259.4 1.00 (Reference) 1.00 (Reference) 
Presence (>1%) 536 34121.1 243.7 0.90 (0.79, 1.02) 0.95 (0.83, 1.09) 
Femalesd      
Absence (<1%) 505 45028.3 184.6 1.00 (Reference) 1.00 (Reference) 
Presence (>1%) 473 46224.0 169.1 0.94 (0.82, 1.07) 0.91 (0.79, 1.06) 
Current Smokers     
Absence (<1%) 351 19608.4 184.6 1.00 (Reference) 1.00 (Reference) 
Presence (>1%) 320 21085.8 169.1 0.86 (0.74, 1.01) 0.85 (0.72, 1.02) 
Former Smokers      
Absence (<1%) 381 27960.0 266.7 1.00 (Reference) 1.00 (Reference) 
Presence (>1%) 328 25088.8 236.0 0.92 (0.79, 1.09) 0.90 (0.76, 1.08) 
Never Smokers      
Absence (<1%) 380 34231.9 183.0 1.00 (Reference) 1.00 (Reference) 
Presence (>1%) 361 34150.4 175.9 0.98 (0.84, 1.14) 1.02 (0.86, 1.21) 
 







Table 4.2 (continued) Multivariable-adjusted hazard ratios for cancer incidence by the absence/presence of basophils, stratified by race, sex and cigarette 
smoking status, in the ARIC study, 1987-2006  
 
Abbreviations: HR, hazard ratio; CI, confidence interval. aIncidence rate per 1,000 individuals from 1987 to 2008 standardized to the age, race and sex 
distribution of the analytic cohort. bModels adjusted for study site (Jackson, Forsyth County, Minneapolis), race (white, black), body mass index (<18.5, 18.5-
24.9, 25.0-29.9, 30.0-34.9, >35.0 kg/m2), waist circumference (continuous), education level (<high school diploma, high school diploma, >high school or college 
graduate, graduate school) smoking status (never, former, current), pack-years (continuous), environmental tobacco smoke (<1, >1 hour/week), alcohol intake 
(continuous), aspirin use in the two weeks prior to blood draw (yes/no), medical history (yes/no) of cardiovascular disease, hypertension, and diabetes. 
cAdditionally adjusted for baseline counts of neutrophils, lymphocytes, monocytes and eosinophils. dAdditionally adjusted for menopausal status and HRT use 
(pre/peri-menopausal, postmenopausal and current HRT user, postmenopausal and former HRT user, postmenopausal and never HRT user. 
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Table 4.3 Multivariable-adjusted hazard ratios of site-specific cancer 
incidence by the absence/prescence of basophls in the ARIC study, 1987-
2006 
 N Person-Years HR (95% CI)a 
Lung    
Absence (<1%) 146 81841.6 1.00 (Reference) 
Presence (>1%) 133 80345.0 0.93 (0.85, 1.03) 
Colorectal    
Absence (<1%) 109 81841.6 1.00 (Reference) 
Presence (>1%) 99 80345.0 0.89 (0.67, 1.19) 
Breastb    
Absence (<1%) 182 45028.3 1.00 (Reference) 
Presence (>1%) 190 46224.0 1.05 (0.85, 1.30) 
Prostatec    
Absence (<1%) 244 36737.9 1.00 (Reference) 
Presence (>1%) 227 34037.9 0.95 (0.79, 1.15) 
Abbreviations: HR, hazard ratio; CI, confidence interval. aModels adjusted for study site (Jackson, Forsyth 
County, Minneapolis), race (white, black), body mass index (<18.5, 18.5-24.9, 25.0-29.9, 30.0-34.9, >35.0 
kg/m2), waist circumference (continuous), education level (<high school diploma, high school diploma, 
>high school or college graduate, graduate school) smoking status (never, former, current), pack-years 
(continuous), environmental tobacco smoke (<1, >1 hour/week), alcohol intake (continuous), aspirin use in 
the two weeks prior to blood draw (yes/no), medical history (yes/no) of cardiovascular disease, 
hypertension, and diabetes. bAmong women only; Additionally adjusted for menopausal status and HRT 
use (pre/peri-menopausal, postmenopausal and current HRT user, postmenopausal and former HRT user, 
postmenopausal and never HRT user). cAmong men only. 
 






































Table 4.4 Multivariable-adjusted hazard ratios for cancer mortality by absence/presence of basophils, stratified by race, 
sex and cigarette smoking status, in the ARIC study, 1987-2008   
 N Person-Years 
Age-Standardized 
Ratea 
HR (95% CI)b HR (95% CI)c 
Overall          
Absence (<1%) 506 101458.7 100.0 1.00 (Reference) 1.00 (Reference) 
Presence (>1%) 441 98438.1 86.4 0.87 (0.76, 1.00) 0.87 (0.75, 1.01) 
Whites       
Absence (<1%) 343 72053.0 95.6 1.00 (Reference) 1.00 (Reference) 
Presence (>1%) 258 60310.7 85.1 0.88 (0.75, 1.05) 0.89 (0.74, 1.09) 
Blacks       
Absence (<1%) 163 29405.6 108.0 1.00 (Reference) 1.00 (Reference) 
Presence (>1%) 183 38127.4 88.9 0.84 (0.68, 1.04) 0.84 (0.66, 1.05) 
Males       
Absence (<1%) 287 45367.2 113.5 1.00 (Reference) 1.00 (Reference) 
Presence (>1%) 249 41807.5 106.0 0.88 (0.73, 1.05) 0.93 (0.75, 1.13) 
Femalesd       
Absence (<1%) 219 55821.5 78.6 1.00 (Reference) 1.00 (Reference) 
Presence (>1%) 192 56630.6 65.3 0.85 (0.69, 1.04) 0.79 (0.63, 0.99) 
Current Smokers      
Absence (<1%) 216 24048.9 159.0 1.00 (Reference) 1.00 (Reference) 
Presence (>1%) 194 25192.6 151.2 0.85 (0.70, 1.04) 0.89 (0.71, 1.11) 
Former Smokers      
Absence (<1%) 156 34711.0 86.9 1.00 (Reference) 1.00 (Reference) 
Presence (>1%) 146 30844.7 86.0 1.01 (0.79, 1.28) 0.99 (0.76, 1.30) 
Never Smokers       
Absence (<1%) 133 42638.5 64.7 1.00 (Reference) 1.00 (Reference) 
Presence (>1%) 101 42377.7 41.5 0.76 (0.58, 1.00) 0.67 (0.50, 0.91) 
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Table 4.4 (continued) Multivariable-adjusted hazard ratios for cancer mortality by absence/presence of basophils, stratified by race, sex and cigarette smoking 
status, in the ARIC study, 1987-2008   
 
Abbreviations: HR, hazard ratio; CI, confidence interval. aMortality rate per 1,000 individuals from 1987 to 2008 standardized to the age, race and sex 
distribution of the analytic cohort. bModels adjusted for study site (Jackson, Forsyth County, Minneapolis), race (white, black), body mass index (<18.5, 18.5-
24.9, 25.0-29.9, 30.0-34.9, >35.0 kg/m2), waist circumference (continuous), education level (<high school diploma, high school diploma, >high school or college 
graduate, graduate school) smoking status (never, former, current), pack-years (continuous), environmental tobacco smoke (<1, >1 hour/week), alcohol intake 
(continuous), aspirin use in the two weeks prior to blood draw (yes/no), medical history (yes/no) of cardiovascular disease, hypertension, and diabetes. 
cAdditionally adjusted for baseline counts of neutrophils, lymphocytes, monocytes and eosinophils. dAdditionally adjusted for menopausal status and HRT use 
(pre/peri-menopausal, postmenopausal and current HRT user, postmenopausal and former HRT user, postmenopausal and never HRT user).
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Table 4.5 Multivariable-adjusted hazard ratios of site-specific cancer 
mortality by the presence/absence of basophils in the ARIC study, 1987-
2008 
 N Person-Years HR (95% CI)a 
Lung    
Absence (<1%) 162 101458.7 1.00 (Reference) 
Presence (>1%) 131 98438.1 0.78 (0.61, 0.99) 
Colorectal    
Absence (<1%) 16 101458.7 1.00 (Reference) 
Presence (>1%) 25 98438.1 1.61 (0.84, 3.09) 
Breastb    
Absence (<1%) 27 55821.5 1.00 (Reference) 
Presence (>1%) 34 56630.6 1.14 (0.68, 1.92) 
Prostatec    
Absence (<1%) 20 45559.4 1.00 (Reference) 
Presence (>1%) 20 41723.8 1.16 (0.60, 2.24) 
Abbreviations: HR, hazard ratio; CI, confidence interval. aModels adjusted for study site (Jackson, Forsyth 
County, Minneapolis), race (white, black), body mass index (<18.5, 18.5-24.9, 25.0-29.9, 30.0-34.9, >35.0 
kg/m2), waist circumference (continuous), education level (<high school diploma, high school diploma, 
>high school or college graduate, graduate school) smoking status (never, former, current), pack-years 
(continuous), environmental tobacco smoke (<1, >1 hour/week), alcohol intake (continuous), aspirin use in 
the two weeks prior to blood draw (yes/no), medical history (yes/no) of cardiovascular disease, 
hypertension, and diabetes. bAmong women only; Additionally adjusted for menopausal status and HRT 
use (pre/peri-menopausal, postmenopausal and current HRT user, postmenopausal and former HRT user, 
postmenopausal and never HRT user). cAmong men only. 
 







Appendix C. Chapter 4 supplemental tables and figures
 
    
136 
 
Figure C.1 Distribution of basophil count in the analytic cohort (N=10,251) 
 
    
137 
 
Table C.1 Multivariable-adjusted hazard ratio for cancer incidence by 
tertile of eosinophil count, stratified by race, sex and cigarette smoking 
status, in ARIC participants, 1987-2006 
 Eosinophil Count 
(x109 cells/L) 
N Person-Years HR (95% CI)a 
Overall       
Tertile 1 (<0.07) 747 55223.5 1.00 (Reference) 
Tertile 2 (0.07-0.174) 663 54238.0 0.87 (0.78, 0.98) 
Tertile 3 (>0.175) 723 53338.1 0.92 (0.82, 1.03) 
P-Trend   0.20 
Whites       
Tertile 1 (<0.07) 560 39792.9 1.00 (Reference) 
Tertile 2 (0.07-0.174) 401 32339.3 1.01 (0.62, 1.62) 
Tertile 3 (>0.175) 473 34395.9 0.70 (0.43, 1.16) 
P-Trend   0.15 
Blacks       
Tertile 1 (<0.07) 187 15430.7 1.00 (Reference) 
Tertile 2 (0.07-0.174) 262 21898.7 0.82 (0.50, 1.37) 
Tertile 3 (>0.175) 250 18942.2 0.73 (0.42, 1.27) 
P-Trend   0.89 
Males       
Tertile 1 (<0.07) 390 24080.3 1.00 (Reference) 
Tertile 2 (0.07-0.174) 337 21508.4 0.71 (0.42, 1.20) 
Tertile 3 (>0.175) 424 25555.1 0.68 (0.40, 1.14) 
P-Trend   0.16 
Females       
Tertile 1 (<0.07) 357 31143.3 1.00 (Reference) 
Tertile 2 (0.07-0.174) 326 32729.6 1.07 (0.66, 1.71) 
Tertile 3 (>0.175) 299 27783.0 0.75 (0.43, 1.28) 
P-Trend   0.29 
Current Smokers     
Tertile 1 (<0.07) 192 10508.3 1.00 (Reference) 
Tertile 2 (0.07-0.174) 208 13539.1 0.86 (0.69, 1.06) 
Tertile 3 (>0.175) 275 16788.6 0.89 (0.72, 1.09) 
P-Trend   0.36 
Former Smokers     
Tertile 1 (<0.07) 272 20188.5 1.00 (Reference) 
Tertile 2 (0.07-0.174) 207 16490.5 0.85 (0.69, 1.03) 
Tertile 3 (>0.175) 232 16560.1 0.95 (0.78, 1.15) 
P-Trend   0.69 
Never Smokers       
Tertile 1 (<0.07) 282 24503.6 1.00 (Reference) 
Tertile 2 (0.07-0.174) 248 24208.4 0.90 (0.74, 1.08) 
Tertile 3 (>0.175) 216 19951.1 0.92 (0.76, 1.12) 
P-Trend   0.43 
Abbreviations: HR, hazard ratio; CI, confidence interval. aModels adjusted for study site (Jackson, Forsyth 
County, Minneapolis), race (white, black), sex, body mass index (<18.5, 18.5-24.9, 25.0-29.9, 30.0-34.9,  
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Table C.1 (continued) Multivariable-adjusted hazard ratio for cancer incidence by tertile of eosinophil 
count, stratified by race, sex and cigarette smoking status, in ARIC participants, 1987-2008 
 
>35.0 kg/m2), waist circumference (continuous), education level (<high school diploma, high school 
diploma, >high school or college graduate, graduate school) smoking status (never, former, current), pack-
years (continuous), environmental tobacco smoke (<1, >1 hour/week), alcohol intake (continuous), aspirin  
use in the two weeks prior to blood draw (yes/no), medical history (yes/no) of cardiovascular disease, 
hypertension, and diabetes. bAmong women only; Additionally adjusted for menopausal status and HRT 
use (pre/peri-menopausal, postmenopausal and current HRT user, postmenopausal and former HRT user, 
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Table C.2 Multivariable-adjusted hazard ratio for cancer mortality by 
tertile of eosinophil count, stratified by race, sex and cigarette smoking 
status, in ARIC participants, 1987-2008  
 Eosinophil Count 
(x109 cells/L) 
N Person-Years HR (95% CI)a 
Overall    
Tertile 1 (<0.07) 307 69018.1 1.00 (Reference) 
Tertile 2 (0.07-0.174) 314 66358.1 1.00 (0.84, 1.18) 
Tertile 3 (>0.175) 328 65238.3 0.97 (0.82, 1.15) 
P-Trend   0.71 
Whites    
Tertile 1 (<0.07) 220 50102.9 1.00 (Reference) 
Tertile 2 (0.07-0.174) 176 39915.3 0.99 (0.79, 1.24) 
Tertile 3 (>0.175) 205 42358.2 0.94 (0.75, 1.17) 
P-Trend   0.55 
Blacks    
Tertile 1 (<0.07) 87 18915.2 1.00 (Reference) 
Tertile 2 (0.07-0.174) 138 26442.8 1.02 (0.78, 1.34) 
Tertile 3 (>0.175) 123 22970.1 1.02 (0.77, 1.35) 
P-Trend   0.91 
Males    
Tertile 1 (<0.07) 176 30007.0 1.00 (Reference) 
Tertile 2 (0.07-0.174) 165 26333.5 0.95 (0.75, 1.20) 
Tertile 3 (>0.175) 196 31434.3 0.91 (0.72, 1.14) 
P-Trend   0.42 
Femalesb    
Tertile 1 (<0.07) 131 39011.1 1.00 (Reference) 
Tertile 2 (0.07-0.174) 149 40024.6 1.04 (0.81, 1.34) 
Tertile 3 (>0.175) 132 33894.0 1.03 (0.79, 1.34) 
P-Trend   0.86 
Current Smokers   
Tertile 1 (<0.07) 117 12996.8 1.00 (Reference) 
Tertile 2 (0.07-0.174) 128 16297.4 0.86 (0.66, 1.13) 
Tertile 3 (>0.175) 168 20108.9 0.90 (0.69, 1.17) 
P-Trend   0.50 
Former Smokers   
Tertile 1 (<0.07) 110 25040.5 1.00 (Reference) 
Tertile 2 (0.07-0.174) 102 20253.0 1.10 (0.82, 1.50) 
Tertile 3 (>0.175) 89 20488.7 0.96 (0.70,1.31) 
P-Trend   0.74 
Never Smokers    
Tertile 1 (<0.07) 79 30941.7 1.00 (Reference) 
Tertile 2 (0.07-0.174) 84 29807.6 1.12 (0.80, 1.57) 
Tertile 3 (>0.175) 71 24686.4 1.12 (0.79, 1.58) 
P-Trend   0.54 
Abbreviations: HR, hazard ratio; CI, confidence interval. aModels adjusted for study site (Jackson, Forsyth 
County, Minneapolis), race (white, black), sex, body mass index (<18.5, 18.5-24.9, 25.0-29.9, 30.0-34.9, 
>35.0 kg/m2), waist circumference (continuous), education level (<high school diploma, high school 
diploma, >high school or college graduate, graduate school) smoking status (never, former, current), pack-
years (continuous), environmental tobacco smoke (<1, >1 hour/week), alcohol intake (continuous), aspirin 
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Table C.2 (continued) Multivariable-adjusted hazard ratio for cancer mortality by eosinophil count tertile, 
stratified by race, sex and cigarette smoking status, in ARIC participants, 1987-2008 
 
use in the two weeks prior to blood draw (yes/no), medical history (yes/no) of cardiovascular disease, 
hypertension, and diabetes. bAmong women only; Additionally adjusted for menopausal status and HRT 
use (pre/peri-menopausal, postmenopausal and current HRT user, postmenopausal and former HRT user, 

























Abbreviations: HR, hazard ratio; CI, confidence interval. aModels adjusted for study site (Jackson, Forsyth County, Minneapolis), race (white, black), 
body mass index (<18.5, 18.5-24.9, 25.0-29.9, 30.0-34.9, >35.0 kg/m2), waist circumference (continuous), education level (<high school diploma, high 
school diploma, >high school or college graduate, graduate school) smoking status (never, former, current), pack-years (continuous), environmental 
tobacco smoke (<1, >1 hour/week), alcohol intake (continuous), aspirin use in the two weeks prior to blood draw (yes/no), medical history (yes/no) of 
cardiovascular disease, hypertension, and diabetes. 
Table C.3 Multivariable-adjusted hazard ratios for non-lung and lung cancer mortality by the absence/presence of basophils, stratified 
by cigarette smoking status, in the ARIC study, 1987-2008   
 Non-Lung Cancer Lung Cancer 
 N Person-Years HR (95% CI)a N Person-Years HR (95% CI)a 
Current Smokers             
Absence (<1%) 112 24048.9 1.00 (Reference) 104 24048.9 1.00 (Reference) 
Presence (>1%) 108 25192.6 0.96 (0.73, 1.27) 86 25192.6 0.74 (0.55, 1.00) 
Former Smokers       
Absence (<1%) 113 34711.0 1.00 (Reference) 43 34711.0 1.00 (Reference) 
Presence (>1%) 111 30844.7 1.07 (0.81, 1.42) 35 30844.7 0.82 (0.52, 1.33) 
Never Smokers       
Absence (<1%) 121 42638.5 1.00 (Reference) 12 42638.5 1.00 (Reference) 
Presence (>1%) 92 42377.7 0.74 (0.56, 0.99) 9 42377.7 0.92 (0.37, 2.28) 
 







Chapter 5. No association between pre-diagnostic monocyte count and 
cancer incidence and mortality  
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Abstract 
Monocytes are an important component of the host inflammatory response. Macrophages, 
which are derived from circulating monocytes, are one of the predominant immune cells 
in the tumor microenvironment and have been shown to promote tumor progression in 
this context. In this study, we examined the relationship between circulating, pre-
diagnostic monocyte count and subsequent cancer incidence and mortality in the 
Atherosclerosis Risk in Communities (ARIC) study. Study participants included men and 
women with total white blood cell (WBC) counts within the normal reference range and 
no history of cancer at baseline (N=10,255). Total WBC and subtype counts were 
measured at baseline (1987-1989) and cancer incidence and mortality data were 
ascertained through 2006 and 2008, respectively. Cox proportional hazards models were 
used to estimate the multivariable-adjusted hazard ratios (HR) and 95% confidence 
intervals (CI) by tertile of monocyte count. During follow-up, 2,142 incident primary 
cancers and 948 cancer deaths were ascertained. There was no association between 
monocyte count and cancer incidence. Compared to the lowest tertile, the highest tertile 
of monocyte count was associated with a slight, non-significant increased risk of total 
cancer mortality (HR: 1.13, 95% CI: 0.97, 1.33) and a significant increased risk of lung 
cancer-specific mortality (HR: 1.37, 95% CI: 1.03, 1.85). However, these associations did 
not persist among never smokers or after mutual adjustment for the other WBC subtypes. 
Among men and women with total WBC counts within then normal reference range, pre-
diagnostic circulating monocyte count does not seem to be an independent risk factor for 
cancer incidence or mortality. 
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Introduction 
Monocytes, a subtype of total white blood cell (WBC) count, are an important component 
of the host inflammatory response. From circulation, these cells migrate into the tissue 
and mature into the long-lived cells, macrophages and dendritic cells. Macrophages and 
dendritic cells, in turn, are a major source of localized growth factors and cytokines, and 
have the capacity for phagocytosis and antigen presentation (1, 2). Based on both 
laboratory and clinical studies, macrophages are also a major component of the tumor 
microenvironment, with well-established roles in the promotion of tumor growth and 
metastasis (3-5). In cancer patients, a higher count of macrophages in the tumor infiltrate 
has been associated with poorer prognosis of several cancer types, including bladder (6), 
breast (7, 8), and thyroid cancers (9). Elevated circulating levels of monocytes at cancer 
diagnosis have also been associated with poorer survival of cancers, including 
lymphoma, melanoma, and cervical, liver, and oral cancers (10-17). 
 
A role for macrophages in tumor initiation and promotion is also hypothesized. In this 
context macrophages may exert pro-tumoral effects, indirectly, as a component of the 
chronic inflammatory response, or directly, via the induction of genetic damage or 
instability, effects on matrix remodeling, and the production of growth factors (18-22). 
However, the relationship between pre-diagnostic monocyte or macrophage count and 
cancer incidence and mortality has not been well studied. In a small study of 669 Danish 
adults, elevated monocyte count was associated with an increased risk of overall cancer 
incidence in multivariable-adjusted models (23). Notably, however, this study did not 
examine the association with site-specific cancer incidence and the risk of cancer 
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mortality was not assessed. In another study of nearly 10,000 elderly Japanese men and 
women, higher pre-diagnostic levels of monocyte count were associated with increased 
risk of cancer mortality, based on an unadjusted comparison of survival curves (24).  
 
Given the limited prospective data, we investigated the association between pre-
diagnostic monocyte count and cancer incidence and mortality among healthy men and 
women in the Atherosclerosis Risk in Communities (ARIC) cohort, a large, prospective, 
community-based study. In this study, we used circulating monocyte count as a surrogate 
of macrophage levels in the tissue. Based on the pro-tumoral role of macrophages in the 
tumor microenvironment, we hypothesized that higher levels of pre-diagnostic monocyte 
count would be associated with an increased risk of cancer incidence and mortality.  
 
Materials and Methods 
Study population 
This study was conducted in the ARIC study, an ongoing, prospective cohort initiated 
between 1987 and 1989 to investigate the etiology of atherosclerosis and its sequelae. 
Men and women (N=15,792), ages 45 to 64 years, were enrolled from four U.S. 
communities, Forsyth County, NC; Jackson, MS; Washington County, MD; and suburban 
Minneapolis, MN. Participants were identified using probability sampling in Minneapolis 
and Washington County, while in Jackson, blacks were exclusively recruited and in 
Forsyth County blacks were oversampled (25). Participants from Washington County 
were not included in these analyses as baseline WBC subtype count was missing for more 
than 85% of participants (26). At enrollment, participants provided a blood sample and 
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reported information on sociodemographic factors, medical history, reproductive history, 
physical activity, alcohol and tobacco use and other lifestyle behaviors via standardized 
questionnaires.  
 
The analytic cohort included men and women that met the following eligibility criteria: 
(1) not residing in Washington County, MD (N=11,792); (2) no personal history of 
cancer, excluding cases of non-melanoma skin cancer (N=11,175); (3) white or black 
race (N=11,140); (4) total WBC count within two standard deviations of the mean in 
whites and blacks, separately, given the differences in absolute total WBC count by race 
(27) (N=10,351); (5) not missing baseline monocyte count (N=10,278); and (6) not 
missing information on cancer incidence (N=10,116) or mortality (N=10,255). 
 
Exposure ascertainment 
Total and differential WBC counts were measured at baseline and three years later at 
Visit 2. In the main analyses, we used baseline WBC subtype counts. Following 
venipuncture, samples were stored at 4°C and within 24 hours total WBC count was 
measured using automated particle counters in local, independent clinical laboratories. 
Subtypes were measured as a proportion of total WBCs and counts were calculated by 
multiplying the subtype proportion by the total WBC count. Based on repeat testing of 
individuals conducted one to two weeks apart, reliability coefficients for total WBC 
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The incidence of a first primary cancer, including date of diagnosis and site of cancer, 
was ascertained from study initiation through December 31, 2006 (29, 30). Cancer 
incidence was primarily identified by linkage to well-established state and/or county 
cancer registries that have a high completeness (≥90%) of cancer data (29). Hospital 
surveillance was used to identify cancer cases in Jackson prior to establishment of the 
Mississippi state cancer registry in 1996 (31), and all additional cancer cases for the other 
study sites (29, 32). At present, data on stage at diagnosis, cancer subtype and treatment 
are not consistently available for all cancers. 
 
Vital status was available through December 31, 2008. Deaths were identified through 
contact with relatives, physician or designated contact, or through a search of obituaries, 
funeral and hospital records, death certificates and the National Death Index (NDI). The 
date and cause of death were confirmed by death certificate for all reported deaths. Cause 
of death was coded using the Ninth International Statistical Classification of Diseases and 
Related Health Problems (ICD-9) for deaths through 1998 and ICD-10 for all subsequent 
deaths. Cause-specific mortality is available for 98% of decedents.  
 
Assessment of covariates 
Participants reported their highest education attainment, regular alcohol use, and intake of 
aspirin in the two weeks prior to baseline study visit. They also provided information on 
current cigarette smoking status and, if applicable, the average number of years of 
smoking and cigarettes smoked per day. These values were used to calculate pack-years 
([cigarettes per day*years smoking]/20 cigarettes per pack) among ever smokers. 
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Exposure to environmental tobacco smoke (ETS) was defined as being in close proximity 
to smokers for more than 1 hour per week (33, 34). Body mass index (BMI), calculated 
as weight (kg)/[height(m)]2, and waist circumference were collected by trained 
technicians at baseline study visit. A history of cardiovascular disease (CVD) was 
defined as having a prior diagnosis of angina pectoris, coronary heart disease, intermittent 
claudication or stroke. Participants were categorized as having hypertension if they 
reported use of any hypertensive medications or if they had systolic blood pressure ≥140 
mmHg or diastolic blood pressure ≥90 mmHg. Diabetes was defined as having a fasting 
glucose level ≥126 mg/dl, a non-fasting glucose level ≥200 mg/dl, a self-reported 
physician diagnosis of diabetes, or use of blood sugar lowering medications in the two 
weeks prior to enrollment. Women were categorized as being premenopausal if they had 
a menstrual cycle within two years of baseline or postmenopausal (35). Women missing 
information on menopausal status were categorized as being postmenopausal if they were 
55 years of age or older. Postmenopausal hormone use was categorized as current, former 
or never (35).  
 
Statistical analyses  
Baseline descriptive characteristics were compared by tertile of monocyte count using the 
chi-square test for categorical variables or ANOVA for continuous variables. Cox 
proportional hazards models were used to estimate the hazard ratio (HR) and 95% 
confidence interval (CI) for cancer incidence and mortality by tertile and continuous 
values of monocyte count. When modeling monocyte count continuously (per 
0.1x109 cells/L), the top and bottom 1% of values were excluded to account for the 
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potential effects of outliers. Continuous and categorical modeling of monocyte count 
was compared using the Akaike information criterion. Similar HRs were estimated 
using continuous values of monocyte count and are not presented in this chapter. Tests 
for linear trend across categories of monocyte count were calculated by introducing the 
median value of each tertile as continuous variable into models. In analyses of cancer 
incidence, follow-up time was accrued from age at baseline blood draw, with the origin 
defined as age 40 years and staggered late entries for persons over age 40 at baseline, to 
the first of the following events: (1) age at first primary cancer diagnosis, (2) age at death, 
or (3) age at end of follow-up (December 31, 2006). In analyses of cancer mortality, 
individuals were followed from age at baseline blood draw to (1) age at death or (2) age 
at end of follow-up (December 31, 2008). In models in which time accrued from year at 
baseline blood draw to (1) year at first primary cancer diagnosis or cancer death, (2) year 
at other death, or (3) year at end of follow-up, similar HRs were estimated and are not 
presented here. 
 
Multivariable models included the baseline covariates, race (white, black), study site 
(Jackson, MS, Forsyth County, Minneapolis, MN), BMI (<18.5, 18.5-24.9, 25.0-29.9, 
30.0-34.9, >35.0 kg/m2), waist circumference (continuous), education attainment (<high 
school diploma, high school diploma, >high school or college graduate, graduate school), 
cigarette smoking status (never, former, current), pack-years (continuous), ETS (<1 
hour/week, >1 hour/week), alcohol intake (g/wk), aspirin use in two weeks prior to blood 
draw (yes/no), and medical history of CVD (yes/no), hypertension (yes/no), and diabetes 
(yes/no). In women, the additional covariates, menopausal status and HRT use 
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(premenopausal, postmenopausal and current HRT user, postmenopausal and former 
HRT user, postmenopausal and never HRT user) were included in models. Additionally, 
mutual adjustment by counts of the other WBC subtypes, neutrophils, lymphocytes, 
eosinophils and basophils was also conducted. Missing pack-year and waist 
circumference information was replaced with the median value. Effect modification 
between monocyte count and select covariates known to modulate immune response, 
including race, sex, cigarette smoking status, BMI and recent aspirin use, was assessed by 
introducing a cross-product term in models and using the Wald test to test for statistical 
significance. For all models, the proportional hazards assumption was assessed by 
introducing an interaction term between monocyte count and follow-up time. In all cases, 
the interaction term was not statistically significant, confirming this assumption. Rates of 
cancer incidence and cancer mortality were standardized to the age, race, and sex 
distribution of the analytic cohort. 
  
Cancer site-specific analyses were conducted in models of cancer incidence and cancer 
mortality for the four most common cancers (i.e., female breast cancer, colorectal cancer, 
lung cancer, and prostate cancer). Additionally, the following sensitivity analyses were 
performed: (1) excluding incident cancer cases and deaths within one and five years from 
baseline blood draw in order to address any bias due to reverse causation; (2) excluding 
individuals with monocyte counts outside the clinical reference range, 0.2 to 0.95 x 109 
cells/L, to more rigorously restrict analyses to individuals with no underlying acute or 
chronic inflammatory conditions; (3) among never smokers and persons who did not 
report recent aspirin use to account for the possibility of residual confounding by these 
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variables; and (4) using monocyte count measured at Visit 2 as the exposure of interest 
among a subset of the participants with available data (N=6,547); In these analyses, time 
at risk was initiated at age at Visit 2. All analyses were conducted using STATA version 
11.2 (Stata Corporation, College Station, TX, 2012). 
 
Results  
In the analytic cohort, the median monocyte count was 0.33 x 109 cells/L (interquartile 
range: 0.21, 0.44). Table 5.1 shows the distribution of baseline characteristics by tertile of 
monocyte count. Monocyte count varied by study site. Individuals with high monocyte 
count were more likely to be male, white, current cigarette smokers, and to report 
increased pack-years, exposure to ETS, and aspirin use. Participants with high monocyte 
count were also more likely to have a larger waist circumference, although there was no 
difference in BMI, and to have a medical history of CVD and diabetes, compared to 
participants with low monocyte count.  
 
Cancer incidence 
Between 1987 and 2006, 2,142 incident primary cancers were ascertained during a total 
of 163,160 person-years. Table 5.2 presents the multivariable-adjusted HR of cancer 
incidence by tertile of monocyte count. There was no association between monocyte 
count tertile and cancer risk, overall, or in analyses stratified by race, sex or cigarette use 
(all p-interaction terms >0.2). There was also no evidence of effect modification by BMI 
and recent aspirin use. Similar estimates were found after mutual adjustment for the other 
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WBC subtypes, among persons with monocyte count within the normal reference range, 
and after using monocyte count measured at Visit 2. 
 
Cancer mortality 
Between 1987 and 2008, 948 cancer deaths and 201,209.3 person-years accrued. In the 
overall study population, individuals in the highest tertile of monocyte count had a slight 
but not statistically significant increased risk of cancer mortality (HR: 1.13, 95% CI: 
0.97, 1.33), compared to the lowest tertile (Table 5.3). However, risks did not increase 
linearly by tertile of monocyte count (p-trend=0.07). Similar estimates were found after 
restricting the analysis to persons with monocyte counts within the normal reference 
range (0.2 to 0.95 x109 cells/L) and in models using monocyte count measured at Visit 2. 
However, the positive association between monocyte count and cancer mortality did not 
persist after excluding cancer deaths within the first several years of follow-up. In 
stratified analyses, this association was stronger in whites (HR: 1.21, 95% CI: 0.98, 1.48, 
p-trend=0.03) than blacks (HR: 1.01, 95% CI: 0.77, 1.31, p-trend=0.92) and in women 
(HR: 1.29, 95% CI: 1.02, 1.64, p-trend=0.03) compared to men (HR: 1.00, 95% CI: 0.81, 
1.24, p-trend=0.80), but there was no significant effect modification by race or sex (all p-
interaction terms >0.1). There was no association between monocyte count tertile and 
cancer mortality in strata of cigarette smoking status (Table 5.3) and aspirin use. There 
was also no evidence of a statistical interaction between monocyte count tertile and 
cigarette smoking status, BMI or recent aspirin use (all p-interaction terms >0.2).  
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In fully adjusted models, including mutual adjustment of the other WBC subtypes, there 
was no association between the highest tertile of monocyte count and cancer mortality, 
overall, or by sex, race or cigarette smoking status (Table 5.3). Rather, in this fully 
adjusted model, there was a non-significant reduced risk of total cancer mortality in the 
middle tertile of monocyte count compared to the lowest tertile (HR: 0.87, 95% CI: 0.71, 
1.05).  
 
Table 5.4 presents the results for cancer incidence and mortality site-specific analyses. 
There was no association between monocyte count tertile and lung, colorectal, prostate, 
or female breast cancer incidence. The highest tertile of monocyte count was associated 
with a 1.37-fold (HR: 1.37, 95% CI: 1.03, 1.85, p-trend=0.01) increased risk of lung 
cancer mortality, overall (Table 5.4) and among current smokers only. An increased risk 
of lung cancer mortality was found after mutual adjustment for the other WBC subtypes, 
however this estimate was no longer statistically significant. No associations were found 
for colorectal, prostate or female breast cancer mortality.  
 
Discussion 
In this large prospective study, among men and women without clinically evident 
inflammation (i.e., total WBC counts within the normal reference range), there was no 
association between monocyte count and cancer incidence. High levels of pre-diagnostic 
monocyte count were associated with a non-significant increased risk of total cancer 
mortality and a significant increased risk of lung cancer mortality, however these 
associations did not persist after mutual adjustment for the other WBC subtypes. Given 
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these results, circulating levels of pre-diagnostic monocyte count do not seem to be an 
independent risk marker for cancer incidence or mortality. 
 
Only one previous study has examined the association between pre-diagnostic monocyte 
count and cancer incidence. Contrary to our finding of a null association, in a study of 
669 Danish adults, conducted by Sajadieh et al (23), high monocyte count (>0.60 x109 
cells/L) was associated with a two-fold (HR: 2.00, 95% CI: 1.10, 3.70) increased risk of 
overall cancer incidence in multivariable-adjusted models. There are several possible 
explanations for this discrepancy. First, the prior study did not adjust for total WBC or 
WBC subtype counts, which we found, in analyses of cancer mortality, to attenuate the 
association with monocyte count. Second, the significant positive association reported by 
Sajadieh et al may be due to the inclusion of individuals with monocyte counts above the 
normal reference range. Specifically, in that study, the upper limit of monocyte count was 
3.9 x109 cells/L as compared to the upper limit in the present study, 1.8 x109 cells/L, and 
the upper limit of the normal reference range, 0.95 x109 cells/L. Third, a limitation of the 
Sajadieh et al study is the lack of detailed information on pack-years and ETS. Based on 
our study, cigarette smoking is a potentially strong confounder of the association between 
monocyte count and cancer incidence and mortality. Thus, we cannot exclude the 
possibility that the increased risk of cancer incidence reported by Sajadieh et al may be 
explained, in part, by residual confounding by cigarette smoke exposure. Moreover, this 
bias may be particularly significant given the high prevalence of current smokers at 
baseline in this cohort (46%).  
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In the present study, we observed a positive, but not statistically significant, association 
between monocyte count and total cancer mortality. However, this association was no 
longer present after mutual adjustment for the other WBC subtypes, suggesting that 
monocytes may be in the causal pathway between other WBC subtypes and tumor 
development and progression. This possible explanation is consistent with the current 
understanding of macrophage activation, in which lymphocytes, neutrophils and 
basophils are involved in the polarization of macrophages into primarily pro-tumoral or 
anti-tumoral cells (36).  
 
Based on in vitro and in vivo studies, tumor cells recruit macrophages, which are derived 
from circulating monocytes, to the tumor and co-opt their functions to promote tumor cell 
motility and proliferation, tissue remodeling, and angiogenesis (22, 37). Macrophages are 
also hypothesized to be factors in tumor initiation and promotion, directly, via the 
production of reactive oxygen species, reactive nitrogen intermediates and growth 
factors, or indirectly, as a component of the inflammatory response (19-21, 38). Our null 
findings, however, suggest that pre-diagnostic monocytes may not be a relevant marker 
of inflammation in the context of tumor development and progression, nor of localized 
macrophage carcinogenic activity, among adults with no underlying acute immune 
condition.   
 
Alternatively, the lack of an association in this study may be due to the characterization 
of circulating monocytes as a single entity. This may not be a biologically meaningful 
measure given that monocytes consist of three main subtypes and both monocytes and 
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macrophages have been shown to display impressive plasticity depending, in part, on the 
inflammatory microenvironment (36, 39). In particular, both monocytes and activated 
macrophages may be reversibly polarized to the primarily anti-tumoral M1 phenotype or 
the pro-tumoral M2 phenotype (39). Thus, future studies measuring monocyte subsets as 
well as other downstream inflammatory products of the monocyte-mediated 
inflammatory response may be warranted.  
 
Intra-individual variation of monocyte count over time in healthy adults may also account 
for our null findings. To our knowledge, the intra-individual variation of monocyte count 
over the short- and long-terms has not been previously investigated. However, in the 
present study, among a subset of the analytic cohort with a one-time repeat measure of 
monocyte count from Visit 2, monocyte counts were only weakly correlated when 
compared continuously (Spearman rho=0.33) and by tertiles (Kappa=0.17). Such large 
intra-individual variations may have attenuated any true associations. 
 
In addition to potential residual confounding by cigarette smoking and the significant 
variation of circulating monocyte count over time, another limitation of this study is the 
absence of information on tumor stage, grade and treatment. Without this information, we 
were unable to evaluate whether monocyte count has any specific effects on tumor 
aggressiveness or treatment effectiveness.  
 
Our study also has several strengths. The ARIC study is a prospective, population-based 
cohort with detailed information collected on a wide-array of socio-demographic 
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characteristics, lifestyle risk factors and medical history as well as over 20 years of 
follow-up for cancer incidence and mortality. Additionally, this is one of a few, large 
cohort studies to have measured baseline WBC subtype counts and reliably ascertained 
cancer outcomes over time.  
 
In conclusion, among healthy men and women with total WBC counts within the normal 
reference range, pre-diagnostic levels of monocytes were not an independent risk factor 
for cancer incidence or mortality. Our findings do not preclude the possibility that more 
pronounced difference in monocyte count, such as abnormally elevated levels, may be 
informative for cancer risk. Additionally, levels of macrophages in benign tissue may be 
a risk marker for subsequent cancer incidence and mortality. Indeed, macrophages are 
longer lived cells than monocytes and are a major source of localized cytokines and 
growth factors (2). Future studies evaluating the association between pre-diagnostic 
macrophage level and cancer incidence and mortality may clarify the etiological role of 
these cells in the early stages of carcinogenesis. 
 
Acknowledgments 




    
158 
References 
1. Longo D, Fauci A, Kasper D, Hauser S, Jameson J, Loscalzo J. Harrison's 
Principles of Internal Medicine. 18 ed: McGraw-Hill; 2011. 
2. Coussens LM, Werb Z. Inflammation and cancer. Nature. 2002;420:860-7. 
3. Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. 
Nature. 2008;454:436-44. 
4. Mantovani A, Sozzani S, Locati M, Allavena P, Sica A. Macrophage polarization: 
tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. 
Trends Immunol. 2002;23:549-55. 
5. Mantovani A, Sozzani S, Locati M, Schioppa T, Saccani A, Allavena P, et al. 
Infiltration of tumours by macrophages and dendritic cells: tumour-associated 
macrophages as a paradigm for polarized M2 mononuclear phagocytes. Novartis Found 
Symp. 2004;256:137-45; discussion 46-8, 259-69. 
6. Hanada T, Nakagawa M, Emoto A, Nomura T, Nasu N, Nomura Y. Prognostic 
value of tumor-associated macrophage count in human bladder cancer. Int J Urol. 
2000;7:263-9. 
7. Tsutsui S, Yasuda K, Suzuki K, Tahara K, Higashi H, Era S. Macrophage 
infiltration and its prognostic implications in breast cancer: the relationship with VEGF 
expression and microvessel density. Oncol Rep. 2005;14:425-31. 
8. Leek RD, Lewis CE, Whitehouse R, Greenall M, Clarke J, Harris AL. Association 
of macrophage infiltration with angiogenesis and prognosis in invasive breast carcinoma. 
Cancer Res. 1996;56:4625-9. 
9. Ryder M, Ghossein RA, Ricarte-Filho JC, Knauf JA, Fagin JA. Increased density 
of tumor-associated macrophages is associated with decreased survival in advanced 
thyroid cancer. Endocr Relat Cancer. 2008;15:1069-74. 
10. Lee YY, Choi CH, Sung CO, Do IG, Huh S, Song T, et al. Prognostic value of 
pre-treatment circulating monocyte count in patients with cervical cancer: comparison 
with SCC-Ag level. Gynecol Oncol. 2012;124:92-7. 
11. Lee SD, Kim SH, Kim YK, Lee SA, Park SJ. Prognostic Significance of 
Preoperative Peripheral Blood Monocyte Ratio in Patients with Hepatocellular 
Carcinoma. World J Surg. 2014. 
12. Sasaki A, Kai S, Endo Y, Iwaki K, Uchida H, Tominaga M, et al. Prognostic 
value of preoperative peripheral blood monocyte count in patients with colorectal liver 
metastasis after liver resection. J Gastrointest Surg. 2007;11:596-602. 
13. Sasaki A, Iwashita Y, Shibata K, Matsumoto T, Ohta M, Kitano S. Prognostic 
value of preoperative peripheral blood monocyte count in patients with hepatocellular 
carcinoma. Surgery. 2006;139:755-64. 
14. Tsai YD, Wang CP, Chen CY, Lin LW, Hwang TZ, Lu LF, et al. Pretreatment 
circulating monocyte count associated with poor prognosis in patients with oral cavity 
cancer. Head Neck. 2013. 
15. Wilcox RA, Ristow K, Habermann TM, Inwards DJ, Micallef IN, Johnston PB, et 
al. The absolute monocyte count is associated with overall survival in patients newly 
diagnosed with follicular lymphoma. Leuk Lymphoma. 2012;53:575-80. 
 
    
159 
16. Bari A, Tadmor T, Sacchi S, Marcheselli L, Liardo EV, Pozzi S, et al. 
Monocytosis has adverse prognostic significance and impacts survival in patients with T-
cell lymphomas. Leuk Res. 2013;37:619-23. 
17. Rochet NM, Kottschade LA, Grotz TE, Porrata LF, Markovic SN. The Prognostic 
Role of the Preoperative Absolute Lymphocyte Count and Absolute Monocyte Count in 
Patients With Resected Advanced Melanoma. Am J Clin Oncol. 2013. 
18. Balkwill F, Charles KA, Mantovani A. Smoldering and polarized inflammation in 
the initiation and promotion of malignant disease. Cancer Cell. 2005;7:211-7. 
19. Qian BZ, Pollard JW. Macrophage diversity enhances tumor progression and 
metastasis. Cell. 2010;141:39-51. 
20. Meira LB, Bugni JM, Green SL, Lee CW, Pang B, Borenshtein D, et al. DNA 
damage induced by chronic inflammation contributes to colon carcinogenesis in mice. J 
Clin Invest. 2008;118:2516-25. 
21. Pang B, Zhou X, Yu H, Dong M, Taghizadeh K, Wishnok JS, et al. Lipid 
peroxidation dominates the chemistry of DNA adduct formation in a mouse model of 
inflammation. Carcinogenesis. 2007;28:1807-13. 
22. Pollard JW. Tumour-educated macrophages promote tumour progression and 
metastasis. Nat Rev Cancer. 2004;4:71-8. 
23. Sajadieh A, Mouridsen MR, Selmer C, Intzilakis T, Nielsen OW, Haugaard SB. 
Monocyte number associated with incident cancer and mortality in middle-aged and 
elderly community-dwelling Danes. Eur J Cancer. 2011;47:2015-22. 
24. Kim KI, Lee J, Heo NJ, Kim S, Chin HJ, Na KY, et al. Differential white blood 
cell count and all-cause mortality in the Korean elderly. Exp Gerontol. 2013;48:103-8. 
25. The Atherosclerosis Risk in Communities (ARIC) Study: design and objectives. 
The ARIC investigators. Am J Epidemiol. 1989;129:687-702. 
26. Prizment AE, Anderson KE, Visvanathan K, Folsom AR. Inverse association of 
eosinophil count with colorectal cancer incidence: atherosclerosis risk in communities 
study. Cancer Epidemiol Biomarkers Prev. 2011;20:1861-4. 
27. Lim EM, Cembrowski G, Cembrowski M, Clarke G. Race-specific WBC and 
neutrophil count reference intervals. Int J Lab Hematol. 2010;32:590-7. 
28. Nieto FJ, Szklo M, Folsom AR, Rock R, Mercuri M. Leukocyte count correlates 
in middle-aged adults: the Atherosclerosis Risk in Communities (ARIC) Study. Am J 
Epidemiol. 1992;136:525-37. 
29. Ahmed RL, Schmitz KH, Anderson KE, Rosamond WD, Folsom AR. The 
metabolic syndrome and risk of incident colorectal cancer. Cancer. 2006;107:28-36. 
30. Prizment AE, Anderson KE, Visvanathan K, Folsom AR. Association of 
inflammatory markers with colorectal cancer incidence in the atherosclerosis risk in 
communities study. Cancer Epidemiol Biomarkers Prev. 2011;20:297-307. 
31. Mississippi Cancer Registry Reporting Manual Revised 2011. Manual2011. 
32. Prizment AE, Folsom AR, Dreyfus J, Anderson KE, Visvanathan K, Joshu CE, et 
al. Plasma C-reactive protein, genetic risk score, and risk of common cancers in the 
Atherosclerosis Risk in Communities study. Cancer Causes Control. 2013;24:2077-87. 
33. Howard G, Wagenknecht LE, Burke GL, Diez-Roux A, Evans GW, McGovern P, 
et al. Cigarette smoking and progression of atherosclerosis: The Atherosclerosis Risk in 
Communities (ARIC) Study. JAMA. 1998;279:119-24. 
 
    
160 
34. Kan H, Heiss G, Rose KM, Whitsel EA, Lurmann F, London SJ. Prospective 
analysis of traffic exposure as a risk factor for incident coronary heart disease: the 
Atherosclerosis Risk in Communities (ARIC) study. Environ Health Perspect. 
2008;116:1463-8. 
35. Nabulsi AA, Folsom AR, Szklo M, White A, Higgins M, Heiss G. No association 
of menopause and hormone replacement therapy with carotid artery intima-media 
thickness. Atherosclerosis Risk in Communities (ARIC) Study Investigators. Circulation. 
1996;94:1857-63. 
36. Biswas SK, Mantovani A. Macrophage plasticity and interaction with lymphocyte 
subsets: cancer as a paradigm. Nat Immunol. 2010;11:889-96. 
37. Condeelis J, Pollard JW. Macrophages: obligate partners for tumor cell migration, 
invasion, and metastasis. Cell. 2006;124:263-6. 
38. Grivennikov SI, Greten FR, Karin M. Immunity, inflammation, and cancer. Cell. 
2010;140:883-99. 





    
161 
 
Table 5.1 Baseline characteristics by tertile of monocyte count in ARIC participants, 1987-
1989 




Tertile 2         
(0.273, 0.399) 
Tertile 3       
(0.400, 1.820) 
Total, N 3,458 3,397 3,423 
Study Sitea, %    
    Jackson, MS 37.5 29.4 27.4 
    Forsyth County, NC 31.3 38.8 31.8 
    Minneapolis, MN 31.2 31.7 40.8 
Male, % 36.7 44.7 54.1 
Blacks, % 43.0 34.1 30.6 
Age (years), Mean (SD)  53.6 (5.7) 53.9 (5.7) 54.2 (5.9) 
Education, %    
    <High school 23.0 21.7 21.1 
    High school or college       
    graduate 39.2 38.9 39.0 
    Graduate school 37.8 39.5 39.9 
    Missing, N 4 7 6 
BMI (kg/m2), %    
    <18.5 0.7 0.7 0.9 
    18.5-24.99 32.4 33.1 29.9 
    25.0 29.99 39.0 39.1 41.1 
    30.0-34.99 18.4 18.1 19.3 
    >35.00 9.4 9.0 8.9 
    Missing, N 2 4 3 
Waist Circumference (cm), 
Mean (SD) 
95.8 (14.0) 96.7 (13.8) 97.4 (13.9) 
    Missing, N 2 0 1 
Cigarette Smoking Status, %    
    Never 48.9 42.2 31.5 
    Former 30.8 32.8 33.9 
    Current 20.4 25.0 34.6 
    Missing, N 1 5 2 
Pack-Yearsb, Mean (SD) 23.8 (21.8) 24.1 (21.6) 25.5 (22.1) 
    Missing, N 59 75 56 
ETSc (hours/week), %    
    <1 31.6 30.3 27.1 
    >1 68.4 69.7 72.9 
    Missing, N 23 17 20 
Alcohol Intaked, Mean (SD) 
(g/wk) 100.4 (110.1) 111.0 (135.6) 118.1 (140.8) 
    Missing, N 23 21 24 
CVDe, % 8.0 9.4 11.9 
Hypertensionf, % 36.0 34.6 37.3 
    Missing, N 1 0 2 
Diabetesg, % 11.7 10.9 12.8 
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Table 5.1 (continued) Baseline characteristics by tertile of monocyte count in ARIC 
participants, 1987-1989 




Tertile 2         
(0.273, 0.399) 
Tertile 3       
(0.400, 1.820) 
    Missing, N 5 6 3 
Aspirin usedh 44.2 43.8 47.1 
    Missing, N 28 25 28 
Abbreviations: BMI, body mass index; SD, standard deviation; ETS, environmental tobacco 
smoke; CVD, cardiovascular disease; HRT, hormone replacement therapy. aParticipants from 
Washington County, MD were excluded from analyses due to substantial missing WBC subtype 
count data at this site. bPack-years among ever smokers only. Pack-years was calculated as the 
average number of cigarettes smoked per day multiplied by the number of years of smoking and 
divided by 20. cETS defined as the average number of hours per week of close contact with 
people when they are smoking. dAlcohol intake among participants who reported usually having 
at least one drink per week. eCVD defined as having a history of angina pectoris, coronary heart 
disease, intermittent claudication, or stroke. fHypertension defined as use of any hypertensive 
medications, systolic blood pressure >140 mmHg, or diastolic blood pressure >90 mmHg. 
gDiabetes defined as having a fasting glucose level >126 mg/dl, non-fasting glucose level >200 
mg/dl, a physician diagnosis of diabetes, or using sugar-lowering medications in two weeks prior 
to enrollment. hAspirin use in two weeks prior to study enrollment. 
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Table 5.2 Multivariable-adjusted hazard ratios for cancer incidence by tertile of monocyte count, 










HR (95% CI)b HR (95% CI)c, d 
Overall          
1 670 55396.4 207.1 1.00 (Reference) 1.00 (Reference) 
2 696 54027.7 212.2 1.01 (0.91, 1.13) 0.98 (0.87, 1.10) 
3 758 52618.0 216.6 1.01 (0.91, 1.12) 0.98 (0.86, 1.11) 
P-Trend    0.88 0.74 
Whites      
1 414 32371.1 218.9 1.00 (Reference) 1.00 (Reference) 
2 462 36496.5 215.7 0.97 (0.85, 1.11) 0.92 (0.79, 1.08) 
3 550 37153.9 229.8 0.99 (0.87, 1.13) 0.97 (0.82, 1.14) 
P-Trend    0.90 0.77 
Blacks      
1 256 23025.4 186.1 1.00 (Reference) 1.00 (Reference) 
2 234 17531.2 206.1 1.10 (0.92, 1.31) 1.06 (0.87, 1.28) 
3 208 15464.1 193.1 1.02 (0.84, 1.23) 0.95 (0.76, 1.17) 
P-Trend    0.79 0.58 
Males      
1 300 19798.4 245.5 1.00 (Reference) 1.00 (Reference) 
2 387 23511.1 268.4 1.08 (0.93, 1.26) 1.08 (0.91, 1.28) 
3 459 27409.1 245.1 0.98 (0.84, 1.14) 0.93 (0.78, 1.12) 
P-Trend    0.69 0.33 
Femalese      
1 370 35598.0 175.4 1.00 (Reference) 1.00 (Reference) 
2 309 30516.5 165.9 0.93 (0.80, 1.08) 0.86 (0.72, 1.02) 
3 299 25208.9 193.1 1.04 (0.89, 1.22) 1.01 (0.84, 1.22) 
P-Trend    0.68 0.93 
Current Smokers    
1 160 10698.2 250.1 1.00 (Reference) 1.00 (Reference) 
2 196 12839.0 250.0 1.02 (0.82, 1.26) 0.95 (0.76, 1.20) 
3 315 17210.7 261.8 1.09 (0.90, 1.33) 0.99 (0.76, 1.20) 
P-Trend    0.36 0.97 
Former Smokers    
1 216 17084.7 216.1 1.00 (Reference) 1.00 (Reference) 
2 235 17781.1 219.0 1.02 (0.84, 1.22) 1.05 (0.85, 1.30) 
3 258 18133.5 210.2 1.03 (0.86, 1.24) 1.04 (0.83, 1.30) 
P-Trend    0.73 0.75 
Never Smokers    
1 294 27613.5 183.0 1.00 (Reference) 1.00 (Reference) 
2 264 23366.3 187.3 1.02 (0.86, 1.21) 0.96 (0.79, 1.16) 
3 185 17253.7 177.8 0.91 (0.75, 1.09) 0.90 (0.72, 1.13) 
P-Trend    0.35 0.35 
Abbreviations: HR, hazard ratio; CI, confidence interval. aIncidence rate per 1,000 individuals from 1987 to 
2006 standardized to the age, race and sex distribution of the analytic cohort. bModels adjusted for study 
site (Jackson, Forsyth County, Minneapolis), race (white, black), body mass index (<18.5, 18.5-24.9, 25.0-
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Table 5.2 (continued) Multivariable-adjusted hazard ratios for cancer incidence by monocyte count, 
stratified by race, sex and cigarette smoking status, in the ARIC study, 1987-2006   
 
29.9, 30.0-34.9, >35.0 kg/m2), waist circumference (continuous), education level (<high school diploma, 
high school diploma, >high school or college graduate, graduate school) smoking status (never, former, 
current), pack-years (continuous), environmental tobacco smoke (<1, >1 hour/week), alcohol intake 
(continuous), aspirin use in the two weeks prior to blood draw (yes/no), medical history (yes/no) of 
cardiovascular disease, hypertension, and diabetes. cAdditionally adjusted for neutrophil count (tertiles), 
lymphocyte count (tertiles), eosinophil count (tertiles) and basophil count (binary). dConducted among 
subset with available measures of all WBC subtpes (N=10,054). eAdditionally adjusted for menopausal 
status and HRT use (pre/peri-menopausal, postmenopausal and current HRT user, postmenopausal and 
former HRT user, postmenopausal and never HRT user).
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Abbreviations: HR, hazard ratio; CI, confidence interval. aMortality rate per 1,000 individuals from 1987 to 
2008 standardized to the age, race and sex distribution of the analytic cohort. bModels adjusted for study 
site (Jackson, Forsyth County, Minneapolis), race (white, black), body mass index (<18.5, 18.5-24.9, 25.0- 
Table 5.3 Multivariable-adjusted hazard ratios for cancer mortality by tertile of monocyte count, stratified 







HR (95% CI)b HR (95% CI)c, d 
Overall      
1 278 68689.1 83.9 1.00 (Reference) 1.00 (Reference) 
2 278 66480.1 84.9 0.95 (0.80, 1.12) 0.87 (0.71, 1.05) 
3 387 64638.7 109.1 1.13 (0.97, 1.33) 0.98 (0.82, 1.18) 
P-Trend    0.07 0.99 
Whites      
1 150 40557.1 80.0 1.00 (Reference) 1.00 (Reference) 
2 170 45208.7 79.2 0.95 (0.76, 1.19) 0.88 (0.68, 1.13) 
3 276 46014.0 111.5 1.21 (0.98, 1.48) 1.04 (0.82, 1.34) 
P-Trend    0.03 0.56 
Blacks      
1 128 28131.9 90.9 1.00 (Reference) 1.00 (Reference) 
2 108 21271.4 95.0 0.93 (0.72, 1.21) 0.85 (0.64, 1.12) 
3 111 18624.7 104.9 1.01 (0.77, 1.31) 0.88 (0.66, 1.19) 
P-Trend    0.92 0.45 
Males      
1 138 24608.3 110.4 1.00 (Reference) 1.00 (Reference) 
2 155 29045.9 107.2 0.90 (0.72, 1.14) 0.87 (0.68, 1.13) 
3 242 33621.1 126.6 1.00 (0.81, 1.24) 0.93 (0.72, 1.20) 
P-Trend    0.80 0.70 
Femalesd      
1 140 44080.7 62.1 1.00 (Reference) 1.00 (Reference) 
2 123 37434.2 66.5 0.96 (0.75, 1.23) 0.82 (0.62, 1.07) 
3 145 31017.6 94.8 1.29 (1.02, 1.64) 1.03 (0.78, 1.36) 
P-Trend    0.03 0.79 
Current Smokers     
1 102 12914.1 150.0 1.00 (Reference) 1.00 (Reference) 
2 102 15638.0 132.0 0.80 (0.61, 1.06) 0.74 (0.55, 1.00) 
3 207 20736.1 172.8 1.14 (0.90, 1.46) 1.04 (0.79, 1.37) 
P-Trend    0.09 0.41 
Former Smokers     
1 81 21242.1 78.9 1.00 (Reference) 1.00 (Reference) 
2 97 21912.2 90.3 1.12 (0.83, 1.51) 1.09 (0.78, 1.51) 
3 123 22342.0 100.5 1.29 (0.96, 1.72) 1.03 (0.73, 1.45) 
P-Trend    0.08 0.90 
Never Smokers     
1 95 34532.9 56.2 1.00 (Reference) 1.00 (Reference) 
2 78 28869.7 56.6 0.99 (0.73, 1.34) 0.85 (0.60, 1.19) 
3 57 21537.5 51.1 0.84 (0.60, 1.18) 0.73 (0.49, 1.09) 
P-Trend    0.33 0.12 
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Table 5.3 (continued) Multivariable-adjusted hazard ratios for cancer mortality by tertile of monocyte 
count, stratified by race, sex and cigarette smoking status, in the ARIC study, 1987-2008 
 
29.9, 30.0-34.9, >35.0 kg/m2), waist circumference (continuous), education level (<high school diploma, 
high school diploma, >high school or college graduate, graduate school) smoking status (never, former, 
current), pack-years (continuous), environmental tobacco smoke (<1, >1 hour/week), alcohol intake 
(continuous), aspirin use in the two weeks prior to blood draw (yes/no), medical history (yes/no) of 
cardiovascular disease, hypertension, and diabetes. cAdditionally adjusted for neutrophil count (tertiles), 
lymphocyte count (tertiles), eosinophil count (tertiles) and basophil count (binary). d Conducted among 
subset with available measures of all WBC subtpes (N=10,191). eAdditionally adjusted for menopausal 
status and HRT use (pre/peri-menopausal, postmenopausal and current HRT user, postmenopausal and 
former HRT user, postmenopausal and never HRT user).
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Table 5.4 Multivariable-adjusted hazard ratios for site-specific cancer incidence and mortality by monocyte count in the 




Cancer Incidence Cancer Mortality 
N Person-Years HR (95% CI)a N Person-Years HR (95% CI)a 
Lung             
1 64 55396.4 1.00 (Reference) 69 68689.1 1.00 (Reference) 
2 65 54027.7 1.03 (0.92, 1.15) 72 66480.1 0.90 (0.64, 1.25) 
3 144 52618.0 0.95 (0.85, 1.07) 145 64638.7 1.38 (1.03, 1.85) 
P-Trend   0.41   0.01 
Colorectal       
1 73 55396.4 1.00 (Reference) 16 68689.1 1.00 (Reference) 
2 66 54027.7 0.92 (0.66, 1.29) 8 66480.1 0.51 (0.22, 1.20) 
3 70 52618.0 0.91 (0.65, 1.28) 17 64638.7 0.99 (0.49, 2.02) 
P-Trend   0.61   0.99 
Female Breastb       
1 145 35598.0 1.00 (Reference) 22 44080.7 1.00 (Reference) 
2 119 30516.5 0.92 (0.72, 1.18) 22 37434.2 1.23 (0.68, 2.24) 
3 109 25208.9 1.02 (0.79, 1.32) 17 31017.6 1.17 (0.61, 2.22) 
P-Trend   0.92   0.61 
Prostate       
1 128 19750.6 1.00 (Reference) 13 24559.4 1.00 (Reference) 
2 173 23455.4 1.18 (0.94, 1.48) 13 28989.1 0.85 (0.39, 1.86) 
3 172 27354.7 1.00 (0.79, 1.26) 15 33566.1 0.88 (0.40, 1.91) 
P-Trend   0.90   0.75 
Abbreviations: HR, hazard ratio; CI, confidence interval. aModels adjusted for study site (Jackson, Forsyth County, Minneapolis), race (white, black), body mass 
index (<18.5, 18.5-24.9, 25.0-29.9, 30.0-34.9, >35.0 kg/m2), waist circumference (continuous), education level (<high school diploma, high school diploma, 
>high school or college graduate, graduate school) smoking status (never, former, current), pack-years (continuous), environmental tobacco smoke (<1, >1 
hour/week), alcohol intake (continuous), aspirin use in the two weeks prior to blood draw (yes/no), medical history (yes/no) of cardiovascular disease, 
hypertension, and diabetes. bAdditionally adjusted for menopausal status and HRT use (pre/peri-menopausal, postmenopausal and current HRT user, 
postmenopausal and former HRT user, postmenopausal and never HRT user).  
 








Chapter 6. Cytomegalovirus IgG antibodies and risk of cancer mortality 
in the third National Health and Nutrition Examination Survey 
(NHANES III)  
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Abstract 
A role for cytomegalovirus (CMV), an endemic beta herpes virus, in tumor development 
and progression is postulated based on laboratory studies. In this study, we examined the 
prospective association between CMV IgG level, a proposed marker of subclinical CMV 
reactivation, and subsequent cancer mortality among CMV seropositive adults, ages 40 to 
70 years, in the third National Health and Nutrition Examination Survey (NHANES III) 
(N=5,063). Levels of CMV IgG were measured at baseline, between 1988 and 1994, and 
information on cause-specific mortality was available through December 31, 2011 
through linkage with the National Death Index. Multivariable-adjusted hazard ratios (HR) 
and 95% confidence intervals (CI) for cancer mortality were estimated by binary category 
of CMV IgG level. During follow-up, 505 cancer deaths occurred. In the overall cohort, 
there was no association between CMV IgG level and cancer mortality (HR: 0.89, 95% 
CI: 0.67, 1.18). However, in analyses stratified by race, black participants with high 
CMV IgG had a 38% (HR: 1.38, 95% CI: 1.02, 1.89) increased risk of cancer mortality, 
while there was no association in whites (HR: 0.74, 95% CI: 0.53, 1.04) or Mexican 
Americans (HR: 1.00, 95% CI: 0.60, 1.67) (p-interaction term=0.02). Among blacks, a 
significant association between CMV IgG level and cancer mortality persisted after 
excluding cancer cases within five years of baseline blood draw. Our findings support a 
link between the host immune response mounted against CMV and cancer mortality in 
immunocompetent black adults. Future studies are warranted to explore the mechanism 
underlying this association and the differences by race further. 
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Introduction 
Cytomegalovirus (CMV) is an endemic beta herpes virus with seroprevalence estimates 
in the U.S. ranging from 36.6% in 6 to 11 years olds to 90.8% in adults 80 years and 
older (1). Immunocompetent individuals infected with CMV mount an extensive and life-
long immune response to ensure viral latency (2). Post infection, a low-level CMV IgG 
antibody titer is established which persists throughout the lifetime and may vary 
depending on the frequency and intensity of subclinical viral reactivation (3-5). While 
CMV infection is not associated with clinically overt symptoms in immunocompetent 
individuals, there is mounting evidence from prospective epidemiological studies 
supporting an association between CMV infection and/or IgG level and several chronic 
health conditions, including cardiovascular disease (CVD) (6-10), cancer (11, 12), frailty 
(13, 14), and cognitive decline (15), and all cause (6, 13, 16-19) and CVD mortality (9, 
16, 17).  
 
Cytomegalovirus (CMV) viral products may directly promote tumor development and 
progression by altering the expression of factors regulating cell survival, replication, 
motility and adhesion (20-25). Another mechanism by which CMV may exert 
carcinogenic effects is by altering host immunity. In in vitro studies CMV has been 
shown to induce immune suppression (26, 27), which may compromise tumor 
immunosurveillance, the process by which the host immune system detects and 
eliminates premalignant and malignant cells (28). Subclinical CMV reactivation may also 
deregulate the host inflammatory response resulting in systemic and localized 
inflammation (23), an etiological factor for several types of cancer (29-31).  
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Previous prospective studies have evaluated the relationship between CMV serostatus 
(seropositive versus seronegative) and breast and prostate cancer incidence; in these 
studies, no associations were found (11, 32, 33). Other studies have quantified the risk of 
cancer incidence and mortalty by CMV IgG levels. In a small study of young women, 
high CMV IgG was associated with an increased risk of invasive breast cancer, compared 
to lower CMV IgG levels (11). Interestingly, in this study, CMV seropositivity, compared 
to seronegativity, was not associated with breast cancer risk (11). In a subsequent study, a 
significant increase in CMV IgG level in the years preceding breast cancer was found in 
this same cohort (12). Only one study has reported the association between CMV IgG 
levels and cancer mortality. In this large prospective cohort, high CMV IgG levels were 
associated with a non-significant increased risk of cancer mortality compared to 
seronegative persons. Among CMV seropositive persons, however, there was no 
difference in the risk of cancer mortality by level of CMV IgG (6).  
 
In this study, we prospectively evaluated the association between CMV IgG levels and 
cancer mortality among CMV seropositive persons in a U.S. population-based study, the 
third National Health and Nutrition Examination Survey (NHANES III). We 
hypothesized that more active CMV infection, as indicated by higher levels of CMV IgG, 
would be associated with an increased risk of cancer mortality.  
 
Materials and Methods 
Study population 
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The third National Health and Nutrition Examination Survey (NHANES III) is a 
nationally representative study population of non-institutionalized, civilian, United States 
citizens aged two months and older, recruited between 1988 and 1994. Study participants 
were identified through a complex, multi-stage, clustered, stratified sampling approach, 
with oversampling of African Americans, Mexican Americans, children (< 5 years) and 
the elderly (> 60 years). Sample weights based on the U.S. Census Bureau population 
estimates at the time were generated for each person to provide nationally representative 
estimates of health conditions. A priori, the analytic cohort was limited to adults, ages 40 
to 70 years in order to minimize the confounding effects of age, given that age is a major 
determinant of CMV IgG level, particularly among older age groups (1, 34). Participants 
included in the analytic cohort attended the mobile examination center (MEC) and met 
the following eligibility criteria: (1) no missing data for CMV serostatus, CMV IgG OD 
level, or cause-specific mortality (N=6,362); (2) no personal history of cancer except skin 
carcinoma (N=6,102); (3) not pregnant at the time of blood draw, given that pregnancy 
alters immune response (N=6,087); and (4) cause of death not due to HIV in order to 
restrict the study population to immunocompetent healthy adults (N=6,078). The main 
analyses were additionally limited to CMV seropositive individuals as there were a 




Cytomegalovirus IgG optical density (OD) (arbitrary units (AU)/ml) was measured in 
stored, frozen (-20C) sera samples collected at baseline using an Enzyme Linked 
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Immunoassay (ELISA) (Quest International, Inc., Miami, FL) in 2006. Cytomegalovirus 
IgG OD values greater than 1.05 AU/ml were determined to be seropositive. Because this 
assay was conducted by NHANES III to determine serostatus and not to quantify CMV 
IgG levels, approximately one-third of CMV IgG levels were arbitrarily right-censored 
per batch. Among CMV seropositive persons in this analytic cohort, a total of 50% of 
IgG values were right-censored. Access to the continuous IgG OD values requires special 
permission from the National Center for Health Statistics (NCHS).  
 
Mortality follow-up 
Vital status and date of cause-specific mortality were available as of December 31, 2011 
through linkage with the National Death Index (NDI). Access to this data requires special 
permission from the NCHS. Cause of death was determined using the underlying cause of 
death on death certificates and classified according to the International Classification of 
Diseases, 10th Revision (ICD-10). Deaths occurring before 1999 were recoded according 
to the ICD-10 system by NCHS (35). The ICD-10 codes, C00-C97, indicated cases of 
cancer-specific mortality. In analyses, follow-up time accrued from the date of baseline 
blood draw, between 1988 and 1994, until the first of the following events occurred: (1) 
date of cancer death or (2) administrative censoring on December 31, 2011. 
 
Covariates assessment 
At baseline, study participants completed a series of detailed questionnaires, underwent a 
clinical examination and provided a blood sample. Self-reported information on age, race, 
education attainment, marital status, annual family income, and health insurance 
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coverage (yes/no), including Medicare, Medicaid and private insurance, was based on 
self-report. Medicare was collected. Participants were categorized as residing near a 
population of one million people or not, based on the U.S. Department of Agriculture 
urban/rural code. The household crowdedness index was calculated as the number of 
persons dwelling in a residence divided by the number of rooms and categorized as <0.5, 
>0.5 to 1, >1 (36). Having regular health care access was defined as having at least one 
usual source of medical care in case of sickness or for routine care. Cigarette smoking 
status was categorized as never (<100 cigarettes), former (>100 cigarettes and not 
currently smoking), and current. Among ever smokers, the average number of cigarettes 
smoked (currently or at the time of quitting) and the total years of smoking were used to 
calculate pack-years ([cigarettes per day*years smoking]/20 cigarettes per pack). Trained 
technicians at mobile examination centers obtained anthropometric measurements, 
including weight, height, and waist circumference. Weight and height measurements 
were used to calculate body mass index (BMI) (weight (kg)/[height (m)]2). A medical 
history of CVD was defined as having had a heart attack, stroke, or congestive heart 
failure. Hypertension was defined as either a physician diagnosis, systolic blood pressure 
>140 mm/Hg, diastolic blood pressure >90 mm/Hg, or use of anti-hypertensive 
medications. Participants were classified as being diabetic if they reported a physician 
diagnosis or used any sugar-lowering medications in 30 days prior to enrollment. Women 
were categorized as being postmenopausal if they did not have their menstrual period in 
the past 12 months. Women missing information for this variable was categorized as 
being postmenopausal if they were 51 years of age or older. Postmenopausal hormone 
use was defined as use of oral estrogen or female hormone pill other than oral 
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contraceptives. Non-prescription and prescription non-steroidal anti-inflammatory drug 
(NSAID) use in the 30 days prior to blood draw were based on self-report and medical 
container review by NHANES III staff. Baseline levels of C-reactive protein (CRP) 
(<0.3, >0.3 mg/dl) were measured using latex-enhanced nephelometry.  
 
Statistical Analyses  
All statistical analyses incorporated the appropriate sample weights to account for the 
sampling approach. Cytomegalovirus (CMV) seropositive participants were categorized 
as having low CMV IgG levels, defined as being within the arbitrary limit of detection, or 
high CMV IgG levels. Means and proportions of baseline covariates were compared 
across categories of CMV IgG level using linear regression for continuous values and the 
chi-squared test for categorical values.  
  
Cox proportional hazards models were used to estimate the hazard ratio (HR) and 95% 
confidence interval (CI) of cancer specific mortality by category of CMV IgG level. 
Multivariable-adjusted models included the baseline covariates, age, sex, race (non-
Hispanic white, non-Hispanic black, Mexican American, other), education attainment 
(<high school diploma, high school diploma, > high school), marital status 
(married/cohabitating, widowed/separated/divorced, never married), census region 
(Northeast, Midwest, South, West), country of origin (U.S., foreign), annual family 
income (<$20,000, >$20,000), cigarette smoking status (never, former, current), pack-
years (continuous), BMI (<18.5, 18.5-24.9, 25.0-29.9, 30.0-34.9, >35.0 kg/m2), health 
insurance coverage (yes/no), medical history (yes/no) of CVD and diabetes, NSAID use 
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in past month (yes/no), and CRP level (<0.3, >0.3 mg/dl). Missing values for pack-years 
were replaced with the median value and missing categorical data were replaced with an 
indicator variable. Urban/rural index, house crowdedness index, usual health care, waist 
circumference, hypertension, and menopausal status were not associated with CMV IgG 
level and, therefore, were not included in final multivariable-adjusted models. Effect 
modification between CMV IgG category and select factors which may modulate CMV 
pathogenesis, including sex, race, cigarette smoking status, BMI, and NSAID use, were 
assessed by introducing a cross-product term in models and using the Wald test to assess 
statistical significance. The proportional hazards assumption was assessed by introducing 
a cross-product term between CMV IgG level and follow-up time into models. In all 
cases, the interaction term was not statistically significant.  
 
Exploratory, cancer mortality site-specific analyses were conducted for the four most 
common cancers (i.e., female breast, colorectal, lung, and prostate cancers). Additionally, 
the following sensitivity analyses were performed: (1) excluding cancer deaths within 
one and five years of baseline blood draw to address any bias due to reverse causality; (2) 
excluding cancer deaths due to leukemia or lymphoma, which directly affect immune 
cells, as there may be a differential association between CMV and blood cancers 
compared to the more common epithelial cancers; (3) excluding individuals with a 
medical history of autoimmune or inflammatory diseases, including lupus and 
rheumatoid arthritis, and recent users of NSAIDs, as these conditions/drugs may alter 
CMV pathogenesis; and (4) excluding individuals with a history of skin carcinoma at 
baseline as the type of skin cancer (basal cell versus melanoma) was not specified. We 
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also compared CMV IgG levels to the reference group, CMV seronegative persons; 
however, these analyses are considered exploratory due to the small number of CMV 
seronegative persons. All analyses were conducted using STATA version 11.2 (Stata 
Corporation, College Station, TX, 2012). 
 
Results 
Of the total 5,063 seropositive men and women, 50% had detectable levels of CMV IgG 
antibody (mean: 2.13 OD units, 95% CI: 2.08, 2.17), and 50% had antibody levels above 
the arbitrary threshold designated per batch, and were therefore right-censored. Table 6.1 
presents the distribution of baseline characteristics by CMV IgG antibody level. 
Compared to persons with low CMV IgG antibody levels, seropositive persons with high 
titers, were slightly older; more likely to be female; more likely to be black; more likely 
to be less educated; more likely to have an annual family income <$20,000; more likely 
to be uninsured; more likely to be a current cigarette smoker; more likely to report a 
diagnosis of CVD and diabetes; and more likely to have CRP levels >0.3. There were no 
differences in BMI, waist circumference, pack-years, menopausal status, or NSAID use 
by level of CMV IgG. Additionally, geographic characteristics, such as census region and 
urban residence, did not vary by CMV IgG category. The distribution of baseline 
characteristics by level of CMV IgG in whites, blacks and Mexican Americans are shown 
in Appendix D, Tables D.1-D.3. In Mexican Americans, current smokers were more 
likely to have high levels of CMV IgG while there was a suggestive trend in whites and 
no difference in blacks. Unlike in whites, blacks and Mexican Americans with high CMV 
IgG were more likely to also have high levels of CRP and, among Mexican Americans, a 
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greater proportion of uninsured persons had high levels of CMV IgG, while there was no 
difference in whites or blacks.  
 
Between 1988 and 2011, 505 cancer deaths occurred during a total of 86,213 person-
years. The leading causes of cancer deaths were lung (N= 175), colorectal (N=36), 
female breast (N=37) and prostate (N=34) cancer. Table 6.2 presents the multivariable-
adjusted HRs of cancer mortality by level of CMV IgG among CMV seropositive 
individuals. Overall, higher CMV IgG was not associated with an increased risk of cancer 
mortality, compared to low CMV IgG levels (HR: 0.89, 95% CI: 0.67, 1.18). However, 
among blacks, high CMV IgG was associated with a 38% (HR: 1.38, 95% CI: 1.02, 1.89) 
increased risk of cancer mortality, while there was a marginal inverse association in 
whites (HR: 0.74, 95% CI: 0.53, 1.04) and no association in Mexican Americans (HR: 
1.00, 95% CI: 0.60, 1.67) (all p-interaction terms< 0.02). There was no evidence of a 
statistical interaction between category of CMV IgG and select factors, which may 
modulate CMV pathogenesis, including sex, cigarette smoking status, BMI, or recent 
NSAID use (all p-interaction terms >0.3).  
 
In sensitivity analyses, a significant positive association among blacks remained after 
excluding cancer deaths within five years of baseline blood draw, persons who reported 
using NSAIDs in the month prior to baseline, and persons with a medical history of lupus 
and skin cancer at baseline (Appendix D, Table D.4). A positive association was present, 
but no longer statistically significant, after removing persons with a history of rheumatoid 
arthritis (Appendix D, Table D.4). We also examined the leading causes of cancer death 
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by race to determine if the differential association by race may be due to differences in 
the types of cancer affecting these groups; No significant differences were found in the 
types of cancer deaths in whites, blacks or Mexican Americans (p-value=0.58; Appendix 
D, Figure D.1). Additionally, there was no association between high CMV IgG and non-
cancer mortality in blacks. 
 
In cancer mortality site-specific analyses, high CMV IgG was not associated with female 
breast, colorectal, lung or prostate cancer (Table D.3). We had limited power to conduct 
cancer mortality site-specific analyses by race. Nevertheless, among blacks, there was a 
suggestive positive association between high CMV IgG and lung cancer mortality (HR: 
1.54, 95% CI: 0.96, 2.46) compared to low CMV IgG. Excluding cancer deaths due to 
leukemia or lymphoma did not alter risk estimates.  
 
Figure D.1 shows the risk of cancer mortality in CMV seropositive persons, overall, and 
by level of CMV IgG, relative to CMV seronegative persons. In multivariable-adjusted 
models, there was no association between CMV serostatus and cancer mortality (HR: 
1.25, 95% CI: 0.83, 1.88) nor was there any association in persons with low (HR: 1.32, 
95% CI: 0.84, 2.09) or high CMV IgG (HR: 1.16, 95% CI: 0.78, 1.74). Given the low 
number of cancer deaths among CMV seronegatives, and particularly in blacks (N=11) 
and Mexican Americans (N=4), further stratification by race may result in unstable risk 
estimates. Nevertheless, in exploratory analyses, blacks with higher CMV IgG levels had 
an 89% (HR: 1.89, 95% CI: 1.09, 3.30) increased risk of cancer mortality compared to 
CMV seronegatives, while there was no association between low CMV IgG and cancer 
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mortality (HR: 1.35, 95% CI: 0.71, 2.57, p-trend=0.003). Additionally, no associations 
were found for either high or low CMV IgG in whites and Mexican Americans 
(Appendix D, Table D.5).  
 
Discussion 
In this U.S. population-based prospective study, there was no association between CMV 
IgG level and cancer mortality overall, however black participants with high CMV IgG 
levels had a significantly increased risk of total cancer mortality, compared to black 
CMV seropositive participants with low CMV IgG. In exploratory analyses, blacks with 
high CMV IgG antibody titer also had an increased risk of cancer mortality compared to 
black CMV seronegative persons. No associations were found in whites or Mexican 
Americans. The significant positive association between CMV IgG level and cancer 
mortality among black seropositive participants persisted after excluding cancer deaths 
within five years of baseline blood draw to account for the presence of subclinical 
disease. Additionally, we did not find any significant difference in the leading causes of 
cancer mortality in whites, blacks and Mexican Americans. Thus, the differential 
association between CMV IgG level and cancer mortality by race does not seem to be 
driven by a specific cancer type. Overall, our findings support an association between the 
host immune response mounted against CMV and cancer mortality in immunocompetent 
black adults.  
 
Only one prospective study, conducted in the EPIC-Norfolk study, has previously 
evaluated the association between CMV IgG level and cancer mortality. Consistent with 
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our findings, in this cohort study of over 13,000 men and women, the highest tertile of 
CMV IgG was not associated with cancer mortality among CMV seropositive persons 
(6). However in this previous study, set in the United Kingdom, differential associations 
by race could not be evaluated. Additionally, a limitation of this previous study was the 
inclusion of persons with a history of cancer at baseline. Thus, the levels of CMV IgG 
may reflect the effects of cancer and/or treatment rather than an individual’s baseline 
CMV activity, positively biasing risk estimates. However, in this case, this does not seem 
to be a major source of bias given that a null association was reported between CMV IgG 
level and cancer mortality.   
 
The mechanism underlying our finding of a differential relationship between CMV IgG 
and cancer mortality in blacks compared to whites and Mexican Americans is not known. 
Nevertheless, our finding of a positive association between CMV IgG level and cancer 
mortality among blacks may provide indirect support for a causal role for CMV in 
carcinogenesis. This is plausible based on several lines of evidence implicating CMV in 
oncomodulation, via the infection tumor cells (22, 23). In clinical studies, CMV has been 
detected in tumor cells, but not in the surrounding tissue, in cases of prostate (37), colon 
(38), cervical (39), and breast (40) cancers. Additionally, findings from in vitro and in 
vivo studies suggest a direct role for CMV in carcinogenesis. In these studies, CMV viral 
products have been shown to affect cell survival, proliferation and differentiation, and 
gene expression (41-44). Cytomegalovirus (CMV) may also promote cancer development 
and progression indirectly by deregulating the inflammatory and cell-mediated immune 
responses (23).  
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It is also possible that increased CMV activity is a surrogate marker of suppressed 
immunity and inflammation, rather than a causal factor. Specifically, CMV reactivation 
has been shown to be dependent on host immunity (45, 46). Indeed, even subclinical 
changes in immune function may affect CMV reactivation. This is supported by several 
studies, which have reported higher CMV IgG levels in the elderly (4), astronauts in 
space (47), and persons experiencing stress (48). Thus, CMV IgG levels may be a marker 
of general immune dysfunction, unrelated to the downstream effects of CMV 
pathogenesis.  
 
Additionally, we cannot discount the potential effects of unmeasured or residual 
confounding by other factors in our analyses. In particular, given the strong association 
between CMV IgG level and socioeconomic status (3), it is plausible that participants 
with high CMV IgG levels also have poorer health behaviors and access to care, resulting 
in less frequent cancer screening, higher stage and grade at diagnosis, and less aggressive 
treatment options. Importantly, however, although confounding by these unmeasured 
factors may result in a spurious positive association between CMV IgG and cancer 
mortality, it is unlikely that such confounding would be differential by race. Furthermore, 
if the association between CMV IgG and cancer mortality were explained by 
confounding due to socioeconomic factors, one would expect a similar positive 
association with non-cancer mortality, however this was not observed. 
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Previous studies examining the relationship between CMV and all-cause, CVD, and 
cancer mortality have not evaluated differences by race (6, 9, 13, 16-19). One possible 
explanation for the differential association reported in this study may be that genetic 
variant(s) in persons of African American descent directly or indirectly affect CMV 
pathogenesis. Indeed, several studies have identified genetic polymorphisms associated 
with differences in host immunity in blacks compared to whites (49-53). Importantly 
though, this explanation does not clarify the differential effect of CMV by race in the 
context of cancer mortality specifically. Alternatively, race may be a marker of 
unmeasured social/cultural factors, which modify the association between CMV IgG and 
cancer mortality. To explore this explanation further, future studies, with adequate 
sample size to stratify by both race and factors such as smoking, BMI and NSAIDs use, 
may be informative.  
 
In the present study, the main analyses were conducted among CMV seropositive 
participants, with the reference group being CMV seropositive individuals with low 
CMV IgG levels. As such, our analyses evaluate the association between the host 
immune response to CMV IgG and cancer mortality. Due to the small number of CMV 
seronegative participants in the predefined age range (40 to 70 years), we had limited 
power to compare CMV IgG levels to persons who were CMV seronegative, particularly 
after racial stratification. This limitation is not specific to this study, but rather is an issue 
for all U.S. based cohort studies, given that the majority of adults over the age of 40 years 
are CMV seropositive and CMV seroprevalence reaches nearly 100% in the very elderly 
(1). In addition to issues of power, CMV seronegative persons may also have major 
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differences with respect to age, sociodemographic factors, health behaviors, and medical 
history, compared to CMV seropositive persons. Thus, inclusion of this comparator group 
may introduce bias due to residual confounding.  
 
Our findings should be interpreted in light of several limitations. First, we utilized a one-
time measure of CMV IgG, precluding the assessment of time-varying changes. In 
NHANES III, among a subset of women, ages 12 to 49 years, the prevalence of recent 
CMV infection, re-infection or re-activation, based on levels of IgM and IgG avidity, was 
3% or lower (54). Thus, it is unlikely that we have included IgG levels transiently 
elevated due to recent, acute infection. Nevertheless, the stability of CMV IgG as a 
marker of established infection has not been well evaluated. Second, although CMV IgG 
is a widely proposed marker of CMV activity (3-5, 17), there is no direct evidence to 
support this. Third, in the total NHANES III study population, approximately one third of 
CMV IgG levels were right-censored per batch. Although, there was not a single 
maximum detectable threshold, we would not expect significant differences in the 
distribution of CMV IgG per batch, and, thus, the maximum detectable limits are unlikely 
to vary significantly by batch as well. Furthermore, any misclassification that may have 
resulted from this censoring approach would be non-differential, biasing our findings 
towards the null. Another consequence of the right censoring of IgG levels is that we 
were unable to explore finer categorizations of CMV IgG level. Fourth, we had limited 
power to detect associations with site-specific cancers and to explore effect modification 
among blacks. Finally, because information on cancer incidence was not available, we 
were unable to explore the role of CMV in tumor initiation and promotion or the impact 
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of CMV infection on stage and grade of disease. Strengths of this study include the use of 
a large, U.S. population-based cohort, with a significant proportion of black participants, 
detailed information on demographic and lifestyle risk factors, including socioeconomic 
status, and highly complete data on cause-specific mortality collected over 23 years of 
follow-up.  
  
In conclusion, we report an association between high CMV IgG level and an increased 
risk of cancer mortality in CMV seropositive blacks, but not whites or Mexican 
Americans. These findings suggest that more active CMV infection, as measured by 
CMV IgG antibody titer, may be associated with cancer progression. Further, the 
differential association between CMV and cancer mortality by race may have important 
implications for the disparate burden of cancer deaths in blacks, particularly given the 
high prevalence of CMV infection in U.S. adults. Additional studies are needed to 
validate our results and to explore the mechanisms underlying our findings. 
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Table 6.1 Baseline characteristics by levels of CMV IgG in CMV seropositive 
adults, ages 40 to 70 years, in the NHANES III study, 1988-1994 
  Low CMV IgG High CMV IgG 
Total, N 2,526 2,537 
Mean Age (years) (SE) 53.3 (0.36) 54.1 (0.38) 
Male, % 53.3 37.0 
Race, %    
      Non-Hispanic white 74.4 71.2 
      Non-Hispanic black 10.9 14.4 
     Mexican American 10.2 9.2 
      Other 4.5 5.2 
Census Region, %    
      Northeast 19.3 18.3 
      Midwest 22.2 23.4 
      South 38.4 38.8 
      West 20.4 19.6 
Urban Residencea, % 48.8 45.8 
Country of Origin, %    
      United States 83.3 83.0 
      Other 16.3 16.7 
      Missing 0.4 0.3 
Household Crowding Indexb, %   
      <0.5 54.0 53.6 
      0.5-0.99  36.0 37.4  
       >1        10.0 8.9 
      Missing     0.1 0.0 
Education, %    
      Less than high school 33.7 36.2 
      High school diploma 29.1 32.5 
      More than high school 36.5 30.8 
      Missing 0.6 0.6 
Marital Status, %    
      Married, cohabitating 74.1 70.5 
      Widowed, divorced, separated 20.4 24.2 
      Never married 5.2 5.2 
      Missing 0.3 0 
Annual Family Income >$20,000, % 70.6 62.0 
      Missing 1.4 2.2 
Uninsuredc, % 10.8 13.8 
      Missing 1.5 15 
>1 Usual Source of Medical Cared, % 83.6 84.7 
Body Mass Index (kg/m2)e, %    
     <18.5 1.1 2.1 
      18.5-24.9 34.0 32.1 
      25.0-29.9 37.5 35.7 
      30.0-34.9 18.5 18.4 
       >35.0 8.9 11.7 
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Table 6.1 (continued) Baseline characteristics by levels of CMV IgG in CMV 
seropositive adults, ages 40 to 70 years in the NHANES III study, 1988-1994 
  Low CMV IgG High CMV IgG 
      Missing 0.2 0.0 
Waist Circumferences (cm), Mean 
(SE) 96.5 (0.58) 95.8 (0.38) 
      Missing, %  3.2 3.2 
Postmenopausalf, % 65.9 64.3 
Cigarette Smoking Status, %    
      Never 40.4 40.6 
      Former 35.0 29.5 
      Current 24.6 29.9 
Pack-Yearsg, Mean (SE) 32.9 (1.2) 34.4 (1.1) 
      Missing, % 2.3 3.0 
Cardiovascular Diseaseh, % 6.8 9.0 
Hypertensioni, % 45.8 44.7 
Diabetesj, % 6.9 8.8 
      Missing 0 0.2 
C-Reactive Protein >0.3 mg/dL, %  34.1 38.3 
      Missing 0.4 1.1 
NSAID Use in Past Monthk, % 57.5 56.5 
Abbreviations: SE, standard error. aUrban residence defined as residing near a population of one million 
people based on the U.S. Department of Agriculture urban/rural code. bHousehold crowding index was 
calculated as the number of persons dwelling in a residence divided by the number of rooms. cPersons were 
uninsured if they did not have Medicare, Medicaid or private insurance. dUsual source of medical care was 
defined as having at least one medical facility or physician to contact in case of sickness or for routine care. 
eBody mass index calculated as weight (kg) divided by height (m) squared. fPostmenopausal was defined as 
not having a menstrual period in the past 12 months. gPack-year calculated among ever smokers as the 
number of cigarettes per day multiplied by years smoking and then divided by 20. hCardiovascular disease 
was defined as having had a heart attack, stroke, or congestive heart failure. iHypertension was defined as 
either a physician diagnosis, systolic blood pressure >140 mm/Hg, diastolic blood pressure >90 mm/Hg, or 
use of anti-hypertensive medications in the 30 days prior to enrollment. jDiabetes defined based on a 
physician diagnosis or use of any sugar-lowering medications in 30 days prior to enrollment. kNon-
prescription and prescription non-steroidal anti-inflammatory drug (NSAID) use in the 30 days prior to 






















































Abbreviations: HR, hazard ratio; CI, confidence interval. aModels adjusted for age, sex, race (non-Hispanic 
white, non-Hispanic black, Mexican American, other), education attainment (<high school diploma, high 
school diploma, > high school), marital status (married/cohabitating, widowed/separated/divorced, never 
married), census region (Northeast, Midwest, South, West), country of origin (U.S., foreign), annual family 
income (<$20,000, >$20,000), cigarette smoking status (never, former, current), pack-years (continuous), 
BMI (<18.5, 18.5-24.9, 25.0-29.9, 30.0-34.9, >35.0 kg/m2), health insurance coverage (yes/no), medical 
history (yes/no) of CVD and diabetes, NSAID use in past month (yes/no), and CRP level (<0.3, >0.3  
Table 6.2 Multivariable-adjusted hazard ratios for cancer mortality 
by CMV IgG level, stratified by race, sex and cigarette smoking 
status, in CMV seropositive participants, ages 40 to 70 years, in the 
NHANES III study, 1988-2011 
  Low CMV IgG High CMV IgG 
Total     
    N 231 274 
    Person-Years 43734.1 42478.8 
    HR (95% CI)a 1.00 (Reference) 0.89 (0.67, 1.18) 
Whites     
    N 102 93 
    Person-Years 16192.9 14852.9 
    HR (95% CI)a 1.00 (Reference) 0.74 (0.53, 1.04) 
Blacks     
    N 63 115 
    Person-Years 11331 13811.2 
    HR (95% CI)a 1.00 (Reference) 1.38 (1.02, 1.89)* 
Mexican Americans   
    N 61 58 
    Person-Years 14475.8 12506.4 
    HR (95% CI)a 1.00 (Reference) 1.00 (0.60, 1.67) 
Males     
    N 133 139 
    Person-Years 23410.0 15907.5 
    HR (95% CI)a 1.00 (Reference) 1.00 (0.66, 1.50) 
Females     
    N 98 135 
    Person-Years 20324.2 25671.3 
    HR (95% CI)a 1.00 (Reference) 0.75 (0.52, 1.10) 
Never Smokers   
    N 72 67 
    Person-Years 18932.3 19046.2 
    HR (95% CI)a 1.00 (Reference) 0.80 (0.46, 1.42) 
Former Smokers   
    N 70 72 
    Person-Years 13542.9 11489.9 
    HR (95% CI)a 1.00 (Reference) 0.64 (0.33, 1.24) 
Current Smokers   
    N 89 135 
    Person-Years 11258.9 11942.7 
    HR (95% CI)a 1.00 (Reference) 1.12 (0.79, 1.58) 
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Table 6.2 (continued) Multivariable-adjusted hazard ratios for cancer mortality by CMV IgG level, 
stratified by race, sex and cigarette smoking status, in CMV seropositive participants, ages 40 to 70 years, 
in the NHANES III study, 1989-2011 
 
mg/dl). Asterisk indicates a significant interaction (p-interaction term=0.02) between black race, high CMV 
IgG level and white race low CMV IgG level. 
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Table 6.3 Multivariable-adjusted hazard ratios for cancer site-specific mortality 
by CMV IgG level in CMV seropositive participants, ages 40 to 70 years, in the 
NHANES III study, 1988-2011 
  Low CMV IgG  High CMV IgG     
Lung     
    N 74 101 
    Person-Years 43734.1 42478.8 
    HR (95% CI)a 1.00 (Reference) 1.11 (0.70, 1.75) 
Colorectal     
    N 18 18 
    Person-Years 43734.1 42478.8 
    HR (95% CI)a 1.00 (Reference) 0.49 (0.15, 1.65) 
Female Breast     
    N 18 19 
    Person-Years 20324.2 26571.3 
    HR (95% CI)b 1.00 (Reference) 0.49 (0.17, 1.42) 
Prostate     
    N 15 19 
    Person-Years 15907.5 23410.0 
    HR (95% CI)a 1.00 (Reference) 1.44 (0.56, 3.73) 
Abbreviations: HR, hazard ratio; CI, confidence interval. aModels adjusted for age, sex, race (non-Hispanic 
white, non-Hispanic black, Mexican American, other), education attainment (<high school diploma, high 
school diploma, > high school), marital status (married/cohabitating, widowed/separated/divorced, never 
married), census region (Northeast, Midwest, South, West), country of origin (U.S., foreign), annual family 
income (<$20,000, >$20,000), cigarette smoking status (never, former, current), pack-years (continuous), 
BMI (<18.5, 18.5-24.9, 25.0-29.9, 30.0-34.9, >35.0 kg/m2), health insurance coverage (yes/no), medical 
history (yes/no) of CVD and diabetes, NSAID use in past month (yes/no), and CRP level (<0.3, >0.3  
mg/dl). bAdditionally adjusted for menopausal status and hormone replacement therapy use 
(premenopausal, postmenopausal plus hormone use, postmenopausal and no hormone use).  
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Figure 6.1 Multivariable-adjusted hazard ratios for cancer mortality by CMV serostatus and CMV IgG 
level in adults, ages 40 to 70 years, in the NHANES III study, 1988-2011. Models adjusted for age, sex, 
race (non-Hispanic white, non-Hispanic black, Mexican American, other), education attainment (<high 
school diploma, high school diploma, > high school), marital status (married/cohabitating, 
widowed/separated/divorced, never married), census region (Northeast, Midwest, South, West), country of 
origin (U.S., foreign), annual family income (<$20,000, >$20,000), cigarette smoking status (never, former, 
current), pack-years (continuous), BMI (<18.5, 18.5-24.9, 25.0-29.9, 30.0-34.9, >35.0 kg/m2), health 
insurance coverage (yes/no), medical history (yes/no) of CVD and diabetes, NSAID use in past month 
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Table D.1 Baseline characteristics by levels of CMV IgG in white CMV seropositive 
adults, ages 40 to 70 years, in the NHANES III study, 1988-1994 
  Low CMV IgG High CMV IgG 
Mean Age (years) (SE) 53.8 (0.42) 55.0 (0.50) 
Male, % 53.7 37.1 
Census Region, %    
      Northeast 19.6 18.7 
      Midwest 25.2 25.5 
      South 38.1 39.0 
      West 17.0 16.8 
Urban Residencea, % 43.6 38.3 
Country of Origin, %    
      United States 93.3 92.1 
      Other 6.5 7.7 
      Missing 0.2 0.3 
Household Crowding Indexb, %    
      <0.5 61.0 62.7 
      0.5-0.99 33.9 33.9 
      >1 5.1 3.4 
Education, %    
      Less than high school 35.5 40.4 
      High school diploma 23.9 26.4 
      More than high school 40.1 32.7 
      Missing 0.6 0.5 
Marital Status, %    
      Married, cohabitating 77.2 73.6 
      Widowed, divorced, separated 18.4 22.5 
      Never married 4.3 3.9 
      Missing 0.2 0.0 
Annual Family Income >$20,000, % 76.2 67.6 
      Missing 0.7 1.7 
Uninsuredc, % 7.8 9.4 
      Missing 1.3 1.3 
>1 Usual Source of Medical Cared, % 85.2 86.7 
Body Mass Index (kg/m2)e, %    
     <18.5 1.1 2.1 
      18.5-24.9 34.0 32.1 
      25.0-29.9 37.5 35.7 
      30.0-34.9 18.5 18.4 
       >35.0 8.9 11.7 
      Missing 0.2 0.0 
Waist Circumference (cm), Mean (SE) 96.8 (0.72) 95.6 (0.5) 
      Missing, % 3.1 2.5 
Postmenopausalf, % 67.8 68.2 
Cigarette Smoking Status, %    
      Never 37.9 37.0 
      Former 37.7 33.9 
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Table D.1 (continued) Baseline characteristics by levels of CMV IgG in white CMV 
seropositive adults, ages 40 to 70 years, in the NHANES III study, 1988-1994 
  Low CMV IgG High CMV IgG 
      Current 24.5 29.0 
Pack-Yearsg, Mean (SE) 36.1 (1.5)  38.6 (1.4) 
      Missing, %  1.7 3.0 
Cardiovascular Diseaseh, % 6.9 9.0 
Hypertensioni, % 44.9 43.8 
Diabetesj, % 5.9 7.7 
      Missing 0 0.3 
C-Reactive Protein >0.3 mg/dL, %  33.2 35.5 
      Missing 0.2 1.0 
NSAID Use in Past Monthk, % 63.0 62.3 
Abbreviations: SE, standard error. aUrban residence defined as residing near a population of one million 
people based on the U.S. Department of Agriculture urban/rural code. bHousehold crowding index was 
calculated as the number of persons dwelling in a residence divided by the number of rooms. cPersons were 
uninsured if they did not have Medicare, Medicaid or private insurance. dUsual source of medical care was 
defined as having at least one medical facility or physician to contact in case of sickness or for routine care. 
eBody mass index calculated as weight (kg) divided by height (m) squared. fPostmenopausal was defined as 
not having a menstrual period in the past 12 months. gPack-year calculated among ever smokers as the 
number of cigarettes per day multiplied by years smoking and then divided by 20. hCardiovascular disease 
was defined as having had a heart attack, stroke, or congestive heart failure. iHypertension was defined as 
either a physician diagnosis, systolic blood pressure >140 mm/Hg, diastolic blood pressure >90 mm/Hg, or 
use of anti-hypertensive medications in the 30 days prior to enrollment. jDiabetes defined based on a 
physician diagnosis or use of any sugar-lowering medications in 30 days prior to enrollment. kNon-
prescription and prescription non-steroidal anti-inflammatory drug (NSAID) use in the 30 days prior to 
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Table D.2 Baseline characteristics by levels of CMV IgG in black CMV seropositive 
adults, ages 40 to 70 years, in the NHANES III study, 1988-1994 
  Low CMV IgG High CMV IgG 
Mean Age (years) (SE) 51.4 (0.48) 52.3 (0.39) 
Male, % 51.0 36.0 
Census Region, %    
      Northeast 19.6 18.7 
      Midwest 25.2 25.5 
      South 38.1 39.0 
      West 17.0 16.8 
Urban Residencea, % 55.9 57.0 
Country of Origin, %    
      United States 91.5 92.8 
      Other 7.1 6.4 
      Missing 1.4 0.8 
Household Crowding Indexb, %    
      <0.5 45.6 41.1 
      0.5-0.99 38.5 40.8 
      >1 15.9 18.1 
Education, %    
      Less than high school 33.5 34.9 
      High school diploma 36.8 43.4 
      More than high school 29.3 20.7 
      Missing 0.4 1.0 
Marital Status, %    
      Married, cohabitating 51.6 53.2 
      Widowed, divorced, separated 37.2 36.9 
      Never married 10.7 9.6 
      Missing 0.5 0.4 
Annual Family Income >$20,000, % 52.0 44.6 
      Missing 1.7 3.5 
Uninsuredc, % 14.3 14.9 
      Missing 1.1 1.0 
>1 Usual Source of Medical Cared, % 82.6 82.4 
Body Mass Indexe (kg/m2), %    
     <18.5 2.6 1.9 
      18.5-24.9 28.3 24.3 
      25.0-29.9 35.7 35.7 
      30.0-34.9 18.8 21.9 
       >35.0 14.4 16.2 
      Missing 0.2 0.0 
Waist Circumference (cm), Mean (SE) 96.7 (0.8) 97.8 (0.5) 
      Missing, % 4.2 5.9 
Postmenopausalf, % 54.4 60.2 
Cigarette Smoking Status, %    
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Table D.2 (continued) Baseline characteristics by levels of CMV IgG in black CMV 
seropositive adults, ages 40 to 70 years, in the NHANES III study, 1988-1994 
  Low CMV IgG High CMV IgG 
      Never 41.1 40.9 
      Former 22.3 20.3 
      Current 36.6 38.8 
Pack-Yearsg, Mean (SE) 22.1 (0.9)   22.8 (0.8) 
      Missing, %  4.9  3.1 
Cardiovascular Diseaseh, % 8.1 10.2 
Hypertensioni, % 56.9 59.8 
Diabetesj, % 10.2 13.1 
      Missing 0.0 0.1 
C-Reactive Protein >0.3 mg/dL, %  41.4 49.4 
      Missing 1.0 1.9 
NSAID Use in Past Monthk, % 38.2 44.3 
Abbreviations: SE, standard error. aUrban residence defined as residing near a population of one million 
people based on the U.S. Department of Agriculture urban/rural code. bHousehold crowding index was 
calculated as the number of persons dwelling in a residence divided by the number of rooms. cPersons were 
uninsured if they did not have Medicare, Medicaid or private insurance. dUsual source of medical care was 
defined as having at least one medical facility or physician to contact in case of sickness or for routine care. 
eBody mass index calculated as weight (kg) divided by height (m) squared. fPostmenopausal was defined as 
not having a menstrual period in the past 12 months. gPack-year calculated among ever smokers as the 
number of cigarettes per day multiplied by years smoking and then divided by 20. hCardiovascular disease 
was defined as having had a heart attack, stroke, or congestive heart failure. iHypertension was defined as 
either a physician diagnosis, systolic blood pressure >140 mm/Hg, diastolic blood pressure >90 mm/Hg, or 
use of anti-hypertensive medications in the 30 days prior to enrollment. jDiabetes defined based on a 
physician diagnosis or use of any sugar-lowering medications in 30 days prior to enrollment. kNon-
prescription and prescription non-steroidal anti-inflammatory drug (NSAID) use in the 30 days prior to 
blood draw.  
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Table D.3 Baseline characteristics by levels of CMV IgG in Mexican American 
CMV seropositive adults, ages 40 to 70 years, in the NHANES III study, 1988-1994 
  Low CMV IgG High CMV IgG 
Mean Age (years) (SE) 52.7 (0.96) 50.7 (0.72) 
Male, % 53.0 38.6 
Census Region, %    
      Northeast 14.9 21.3 
      Midwest 8.1 10.7 
      South 39.1 31.6 
      West 38.0 36.4 
Urban Residencea, % 62.3 71.6 
Country of Origin, %    
      United States 34.7 33.8 
      Other 64.6 66.1 
      Missing 0.7 0.0 
Household Crowding Indexb, %    
      <0.5 22.1 24.2 
      0.5-0.99 47.4 49.1 
     >1 30.2 26.6 
Education, % 0.3 0.0 
      Less than high school 27.0 16.6 
      High school diploma 57.2 60.8 
      More than high school 14.2 22.3 
      Missing 1.6 2.8 
Marital Status, %    
      Married, cohabitating 77.3 69.4 
      Widowed, divorced, separated 16.8 23.5 
      Never married 5.2 7.0 
      Missing 0.6 0.0 
Annual Family Income >$20,000, % 51.8 44.8 
      Missing 4.5 0.8 
Uninsuredc, % 23.1 38.6 
      Missing 3.9 3.2 
>1 Usual Source of Medical Cared, % 79.0 79.0 
Body Mass Indexe (kg/m2), %    
     <18.5 0.1 0.2 
      18.5-24.9 25.3 24.8 
      25.0-29.9 42.4 34.6 
      30.0-34.9 25.8 28 
       >35.0 6.1 12.4 
      Missing 0.3 0.0 
Waist Circumference (cm), Mean (SE) 96.7 (1.2) 97.1 (0.9) 
      Missing, % 2.5 4.2 
Postmenopausalf, % 59.3 50.5 
Cigarette Smoking Status, %    
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Table D.3 (continued) Baseline characteristics by levels of CMV IgG in Mexican 
American CMV seropositive adults, ages 40 to 70 years, in the NHANES III study, 
1988-1994 
  Low CMV IgG High CMV IgG 
      Never 47.0 54.6 
      Former 31.5 21.0 
      Current 21.5 24.4 
Pack-Yearsg, Mean (SE)  22.7 (3.3) 16.9 (1.5)  
      Missing, % 1.3  2.1 
Cardiovascular Diseaseh, % 5.2 7.4 
Hypertensioni, % 40.7 46.4 
Diabetesj, % 10.3 11.2 
      Missing 0.0 0.1 
C-Reactive Protein >0.3 mg/dL, %  37.3 39.5 
      Missing 1.0 1.9 
NSAID Use in Past Monthk, % 50.6 47.7 
Abbreviations: SE, standard error. aUrban residence defined as residing near a population of one million 
people based on the U.S. Department of Agriculture urban/rural code. bHousehold crowding index was 
calculated as the number of persons dwelling in a residence divided by the number of rooms. cPersons were 
uninsured if they did not have Medicare, Medicaid or private insurance. dUsual source of medical care was 
defined as having at least one medical facility or physician to contact in case of sickness or for routine care. 
eBody mass index calculated as weight (kg) divided by height (m) squared. fPostmenopausal was defined as 
not having a menstrual period in the past 12 months. gPack-year calculated among ever smokers as the 
number of cigarettes per day multiplied by years smoking and then divided by 20. hCardiovascular disease 
was defined as having had a heart attack, stroke, or congestive heart failure. iHypertension was defined as 
either a physician diagnosis, systolic blood pressure >140 mm/Hg, diastolic blood pressure >90 mm/Hg, or 
use of anti-hypertensive medications in the 30 days prior to enrollment. jDiabetes defined based on a 
physician diagnosis or use of any sugar-lowering medications in 30 days prior to enrollment. kNon-
prescription and prescription non-steroidal anti-inflammatory drug (NSAID) use in the 30 days prior to 
blood draw.  
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Table D.4 Multivariable-adjusted hazard ratios for cancer mortality by CMV IgG 
level in black CMV seropositive participants, ages 40 to 70 years, in the NHANES 
III study, 1988-2011 
  
Low CMV IgG              
HR (95% CI) 
High CMV IgG                 
HR (95% CI)a 
Excluding cancer deaths within 5 
years of baseline 
1.00 (Reference) 1.39 (1.02, 1.90) 
Excluding users of prescription 
steroid drugs 
1.00 (Reference) 1.41 (1.04, 1.93) 
Excluding persons with a history 
of lupus at baseline 
1.00 (Reference) 1.39 (1.02, 1.89) 
Excluding persons with a history 
of rheumatoid arthritis at baseline 
1.00 (Reference) 1.29 (0.89, 1.87) 
Excluding baseline cases of skin 
cancer 
1.00 (Reference) 1.39 (1.01, 1.89) 
Abbreviations: HR, hazard ratio; CI, confidence interval. aModels adjusted for age, sex, race (non-Hispanic 
white, non-Hispanic black, Mexican American, other), education attainment (<high school diploma, high 
school diploma, > high school), marital status (married/cohabitating, widowed/separated/divorced, never 
married), census region (Northeast, Midwest, South, West), country of origin (U.S., foreign), annual family 
income (<$20,000, >$20,000), cigarette smoking status (never, former, current), pack-years (continuous), 
BMI (<18.5, 18.5-24.9, 25.0-29.9, 30.0-34.9, >35.0 kg/m2), health insurance coverage (yes/no), medical 
history (yes/no) of CVD and diabetes, NSAID use in past month (yes/no), and CRP level (<0.3, >0.3  
mg/dl). 
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Figure D.1 Distribution of types of cancer mortality in NHANES III, 1988-2011
 





Table D.5 Multivariable-adjusted hazard ratios for cancer mortality by CMV serostatus and CMV IgG level, stratified 
by race, sex and cigarette smoking status, in participants, ages 40 to 70 years, in the NHANES III study, 1988-2011 




Overall Low CMV IgG High CMV IgG     
Total         
    N 74 505 231 274 
    Person-Years 18572.3 86212.9 43734.1 42478.8 
    HR (95% CI)a 1.00 (Reference) 1.25 (0.83, 1.88) 1.32 (0.84, 2.09) 1.16 (0.78, 1.73) 
    P-Trend      0.63 
Whites         
    N 58 195 102 93 
    Person-Years 14180.8 31045.8 16192.9 14852.9 
    HR (95% CI)a 1.00 (Reference) 1.24 (0.79, 1.94) 1.41 (0.85, 2.35) 1.05 (0.68, 1.61) 
    P-Trend      0.96 
Blacks         
    N 11 178 63 115 
    Person-Years 2242.6 25142.2 11331.0 13811.2 
    HR (95% CI)a 1.00 (Reference) 1.64 (0.92, 2.90) 1.35 (0.71, 2.57) 1.89 (1.09, 3.30) 
    P-Trend      0.003 
Mexican Americans         
    N 4 119 61 58 
    Person-Years 1936.8 26982.2 14475.8 12506.4 
    HR (95% CI)a 1.00 (Reference) 3.20 (0.60, 17.0) 3.19 (0.58, 17.6) 3.23 (0.62, 16.89) 
    P-Trend      0.24 
Males         
    N 49 272 133 139 
    Person-Years 10416.6 39317.5 23410.0 15907.5 
    HR (95% CI)a 1.00 (Reference) 1.29 (0.80, 2.08) 1.31 (0.74, 2.30) 1.27 (0.82, 1.95) 
    P-Trend      0.3 
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Table D.5 (continued) Multivariable-adjusted hazard ratios for cancer mortality by CMV serostatus and CMV IgG 
level, stratified by race, sex and cigarette smoking status, in participants, ages 40 to 70 years, in the NHANES III study, 
1988-2011  




Overall Low CMV IgG High CMV IgG     
Females     
    N 25 233 98 135 
    Person-Years 8155.7 46895.5 20324.2 26571.3 
    HR (95% CI)a 1.00 (Reference) 1.19 (0.65, 2.17) 1.37 (0.73, 2.59) 1.04 (0.55, 1.97) 
    P-Trend      0.77 
Never Smokers         
    N 17 139 72 67 
    Person-Years 7836.0 37978.5 18932.3 19046.2 
    HR (95% CI)a 1.00 (Reference) 1.23 (0.50, 3.04) 1.37 (0.58, 3.28) 1.06 (0.38, 3.00) 
    P-Trend      0.92 
Former Smokers         
    N 30 142 70 72 
    Person-Years 6450.2 25032.8 13542.9 11489.9 
    HR (95% CI)a 1.00 (Reference) 1.25 (0.66, 2.39) 1.50 (0.70, 3.21) 0.95 (0.51, 1.77) 
    P-Trend      0.73 
Current Smokers         
    N 27 224 89 135 
    Person-Years 4286.2 23201.6 11258.9 11942.7 
    HR (95% CI)a 1.00 (Reference) 1.39 (0.78, 2.50) 1.34 (0.79, 2.26) 1.45 (0.74, 2.85) 
    P-Trend       0.29 
Abbreviations: HR, hazard ratio; CI, confidence interval. aModels adjusted for age, sex, race (non-Hispanic white, non-Hispanic black, Mexican American, 
other), education attainment (<high school diploma, high school diploma, > high school), marital status (married/cohabitating, widowed/separated/divorced, 
never married), census region (Northeast, Midwest, South, West), country of origin (U.S., foreign), annual family income (<$20,000, >$20,000), cigarette 
smoking status (never, former, current), pack-years (continuous), BMI (<18.5, 18.5-24.9, 25.0-29.9, 30.0-34.9, >35.0 kg/m2), health insurance coverage (yes/no), 
medical history (yes/no) of CVD and diabetes, NSAID use in past month (yes/no), and CRP level (<0.3, >0.3 mg/dl)
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The primary objective of this dissertation was to investigate the effects of the immune 
states, low-grade chronic inflammation and subclinical immunosuppression, on the risk 
of cancer incidence and mortality. This dissertation work complements rapidly 
accumulating data from laboratory studies elucidating the role of immune components in 
carcinogenesis by quantifying the risk of cancer incidence and mortality by levels of 
immune markers in immunocompetent adults. Additionally, we explored socio-
demographic, behavioral, and genetic factors that may modify the effects of these factors 
on carcinogenesis.  
 
In order to study the complex roles of host immunity in carcinogenesis, we utilized the 
immune markers, white blood cell (WBC) subtype (i.e., neutrophil, lymphocyte, 
monocyte, basophil) count and cytomegalovirus (CMV) IgG antibody titer. Based on 
studies conducted in the laboratory and clinical setting, each of the WBC subtypes have 
differential roles in host immunity and may also exert unique effects in carcinogenesis (1, 
2). Additionally, CMV is postulated to be a surrogate marker and/or causal factor of 
suppressed immunity and deregulated inflammation; this may be an important 
mechanism linking CMV infection with cancer (3). Furthermore, in the interest of 
evaluating the effects of low-grade inflammation and subclinical immune capacity, 
specifically, we examined inter-individual variations of these markers among 
immunocompetent adults, restricting the analytic cohorts to persons with total WBC 
count within the normal reference range, in analyses of WBC subtype counts, and 
persons with asymptomatic CMV infection.  
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In chapters two through five of this dissertation, we present our findings from a 
prospective study conducted in the Atherosclerosis Risk in Communities (ARIC) study 
on the relationship between pre-diagnostic WBC counts and cancer incidence and 
mortality. These findings are summarized in Table 7.1. Among men and women with 
total WBC counts within the normal reference range, higher neutrophil count was 
associated with an 11% increased risk of total cancer incidence and a 44% increased risk 
of total cancer mortality. These positive associations were independent of the effects of 
the other WBC subtypes and in cancer site-specific analyses higher neutrophil count was 
associated with significant increased risks of lung cancer incidence and mortality and 
breast cancer mortality.  
 
We also found that men with higher lymphocyte counts had a 25% reduced risk of cancer 
incidence, after excluding cases of prostate cancer, and an increased risk of prostate 
cancer incidence. Similar significant findings were present after mutual adjustment for 
the other WBC subtypes. In contrast, in women, high lymphocyte count was associated 
with a 40% increased risk of cancer mortality. However, in stratified analyses, this 
association was only present among current smokers; thus, the independent contribution 
of lymphocytes to cancer mortality in women is questionable. 
 
Although basophils constitute a very small proportion of the total WBC count (0-3%), we 
found that the presence of these cells in the peripheral blood was associated with a 
reduced risk of cancer incidence and mortality. Notably, this association was independent 
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of the other WBC subtypes, including eosinophil count, another WBC subtype also 
involved in the host allergic response. 
 
High monocyte count was associated with a slight, but not significant, increased risk of 
total cancer mortality and a significant increased risk of lung cancer mortality. However, 
after further adjustment for the other WBC subtypes, these associations were no longer 
found. Furthermore, in comparisons of monocyte count measured three years apart, there 
was considerable intra-individual variation, suggesting that this marker may not be 
informative in either the research or clinical settings.  
 
Lastly, chapter six examines the prospective association between CMV IgG level and 
cancer mortality among CMV seropositive men and women, ages 40-70, in the third 
National Health and Nutrition Examination Survey (NHANES III). In this study, higher 
CMV IgG antibody titer was associated with a 38% increased risk of cancer mortality in 
blacks who are CMV seropositive, while no association was present in whites or Mexican 
Americans.  
 
To our knowledge, this dissertation is among the first efforts to thoroughly evaluate the 
association between pre-diagnostic WBC subtype counts and CMV IgG antibody titer 
and subsequent cancer incidence and mortality. Generally, our findings suggest that low-
grade inflammation and subclinical immunosuppression, as measured by these circulating 
immune markers, may be associated with an increased risk of cancer incidence and 
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mortality. Furthermore, these findings may have important implications for both cancer 
etiology and cancer prevention, as described below.  
 
While previous epidemiological studies have examined total WBC count as a marker of 
systemic inflammation in the context of tumor development and progression (4-8), we 
provide evidence that each of the WBC subtypes may be involved in different, potentially 
opposing, etiological pathways in carcinogenesis. In particular, high neutrophil count, 
within the normal reference range, may be a relevant marker of the pro-tumoral effects of 
chronic inflammation. Our findings expand upon laboratory studies, which have shown 
that neutrophils in the tumor microenvironment may directly promote tumor progression 
(9, 10), by suggesting that pre-diagnostic neutrophil count, measured years prior to the 
onset of cancer, may also be relevant to subsequent cancer incidence and mortality. This 
is a particularly important contribution to the cancer etiology literature as in vitro models 
of inflammation in the early stages of carcinogenesis are missing (1). Notably, although 
macrohages are also a critical component of the tumor micro-environment (11), pre-
diagnostic monocytes, a precursor of macrophages, does not seem to be a marker of 
cancer risk. This finding, however, does not preclude the possibility that the pre-
diagnostic macrophage-mediated inflammatory response in the tissue may be relevant in 
carcinogenesis.  
  
In addition to the pro-tumoral effects of chronic inflammation, the host immune response 
may also exert anti-tumoral effects. The tumor immunosurveillance hypothesis, which 
posits a role for the host immune system in identifying and clearing premalignant and 
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malignant cells, was introduced over 50 years ago (12). However, this hypothesis has 
garnered more wide-spread interest only recently based on accumulating experimental 
evidence from mice models and prognostic studies (13). Our findings of an inverse 
association between lymphocyte count and cancer incidence in men and an inverse 
association between basophils and cancer incidence and mortality, overall, provide some 
of the first epidemiological support for this concept. Moreover, our findings suggest that 
even normal variations in immune capacity, as measured by counts of these markers, may 
affect the tumor immunosurveillance response.  
 
Our findings may also support the direct involvement of lymphocytes and basophils in 
the tumor immunosurveillance response. Additionally, we observed a differential 
association between lymphocyte count and cancer by sex, such that an inverse association 
with cancer incidence was present in men only and a positive association with cancer 
mortality was found in women. Moreover, among men, the inverse association with 
cancer incidence was limited to non-prostate cases of cancer. These findings suggest, for 
the first time, that the role of lymphocytes in carcinogenesis may be dependent on the 
hormonal milieu. More specifically, it is plausible that hormonal levels affect the absolute 
and relative levels of circulating and localized lymphocyte subsets (14), accounting for 
our study findings. 
 
Historically, basophils have not been a well-studied component of the immune system in 
part because of the low levels of basophils in healthy individuals. Our findings of an 
inverse association between basophil count and cancer incidence and mortality may 
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suggest a novel role for this cell as part of the tumor immunosurveillance response. 
Indeed, there are several potential pathways by which basophils may exert anti-tumoral 
effects, including through the production of histamine and interleukin-4, both of which 
have anti-tumoral properties (15-17).  
 
Cytomegalovirus activity may be another informative marker of host immunity in the 
context of cancer development and progression. Specifically our findings suggest that the 
host immune response to CMV infection, as measured by CMV IgG antibody titer, may 
be a marker of cancer mortality risk among black men and women. While our findings 
may suggest a potential direct role for CMV in carcinogenesis, possibly through the 
suppression of the immune response and the deregulation of inflammation, we cannot 
discount alternate possible explanations. For example, CMV activity may be a surrogate 
marker of host immune capacity or another, unmeasured factor. Furthermore, our finding 
of a differential association by race may also have important implications towards 
explaining and reducing the disparate burden of cancer deaths in blacks. 
 
The results presented in this dissertation may also have important future implications for 
the clinical setting. Circulating levels of neutrophils, lymphocytes, and basophils may 
have utility for cancer risk stratification in the general immunocompetent population. In 
particular, combining these markers into a panel may be most appropriate as we have 
shown that each of these factors have independent effects on the risk of cancer incidence 
and mortality. More refined risk stratification, in turn, may guide clinical decision-
making in terms of screening recommendations, the promotion of behavior modifications, 
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and the use of preventative agents, which may reduce inflammation and increase immune 
capacity. Importantly, we have shown that many modifiable lifestyle factors are 
associated with differences in levels of these immune markers within the normal 
reference range. Pending validation of the predictability of these markers, integrating 
these measures into clinical practice would likely be feasible as the measurement of 
WBC subtype counts is non-invasive, inexpensive, and frequently recommended for 
other indications.  
 
Additionally, if future studies support a causal role for the WBC subtypes and CMV in 
carcinogenesis, the development of interventions targeting specific immune pathways 
may also be a beneficial preventative strategy. While substantial efforts have been 
dedicated to the development of immunotherapeutic approaches for cancer treatment 
(18), similar approaches may be applicable in the preventative setting.  
 
The significance of this area of research, more generally, is underscored by its 
widespread applicability. First, the immune states, low-grade inflammation and 
immunosupression, are hypothesized to be shared etiological factors for many commonly 
occurring cancers (1, 19). Furthermore, in addition to being independent etiological 
factors in carcinogenesis, these immune pathways are also hypothesized to mediate the 
effects of many common exposures, such as obesity, cigarette smoke, and age (1). 
Finally, in this study, we demonstrate that elevated levels even within the normal 
reference range may be meaningful in terms of cancer incidence and mortality risk. Thus, 
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a substantial proportion of the burden of cancer incidence and mortality in U.S. adults 
may be explained by immune factors.  
 
Perhaps the greatest challenge in the interpretation our study findings is the use of a one-
time measure of WBC subtype count and CMV IgG level. In these analyses, we assume 
that a one-time measure of these biomarkers reflects the usual baseline immune response 
in healthy adults. In order to strengthen the basis of this assumption, in analyses of WBC 
subtype count we restricted the analytic cohort to persons with total WBC counts within 
the clinically normal range so as not to include episodes of acute immune response. 
Additionally, in sensitivity analyses we further excluded persons with specific WBC 
subtype counts outside the normal reference range.  
 
While these approaches may minimize the likelihood of including acute responses, they 
do not account for intra-individual variation within the normal reference range. To our 
knowledge, the short- and long-term variation of WBC subtypes has not been previously 
investigated. However, in a study with over 40 years of follow-up, accounting for time-
varying measures of total WBC count measured every two years compared to using a 
single baseline measure did not markedly alter the association between total WBC count 
and all cause mortality (20). Additionally, in comparisons of WBC subtype count 
measured at baseline and three years later, in ARIC, we found that there was fair 
agreement for each of the WBC subtypes, with the exception of monocyte count. 
Notably, however, the consequences of intra-individual variation in the range observed 
on the attenuation of risk estimates has been shown to be substantial for moderate 
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associations (21). Thus, our findings are likely underestimates of the true associations. 
With respect to CMV IgG levels, there is no longitudinal data evaluating changes over 
time. However, by categorizing CMV IgG levels broadly, we minimize the effects of 
intra-individual changes over time. Future studies will be necessary to determine if our 
findings persist after accounting for time-varying changes of both WBC subtype counts 
and CMV IgG and to explore different relevant periods of exposure over the lifetime. 
 
Pre-diagnostic levels of WBC subtype count and CMV IgG may influence carcinogenesis 
at various stages, from tumor initiation to tumor progression and metastasis. In the 
absence of information on tumor stage and grade at diagnosis and the treatments 
administered, however, we were unable to determine at what stage of carcinogenesis 
these markers may be most relevant. Nevertheless, in analyses of WBC subtype count, 
we noted differences in the risk of cancer incidence versus mortality suggesting that the 
pathways mediated by neutrophils and basophils may be more relevant for tumor 
progression while lymphocytes may be primarily involved in the earliest stages of 
carcinogenesis, leading to tumor initiation. In contrast, in analyses of CMV IgG, 
information on cancer incidence was missing, thus we were only able to evaluate the 
association of this marker with a unique subset of cancers that progress to metastasis and 
death.  
 
Despite these limitations, this dissertation also has several strengths. We utilized data 
collected in two large and well-established studies, ARIC and NHANES III. In these 
studies, information on cancer incidence (ARIC only) and cancer mortality was highly 
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complete, based primarily on cancer registry data and the National Death Index (NDI), 
and was prospectively collected over 17 to 23 years of follow-up. Few other studies with 
prospectively collected data on cancer outcomes have also measured baseline immune 
markers. Additionally, at baseline, information on relevant, potential confounders, 
including education attainment, cigarette smoking status, pack-years, alcohol intake, 
body mass index (BMI), non-steroidal anti-inflammatory drug (NSAID) use and medical 
history of cardiovascular disease (CVD), diabetes and hypertension, were collected using 
standardized approaches. Another strength of these studies is the large sample size, which 
included over 10,000 participants in ARIC and 5,000 participants in NHANES III. Given 
the large sample sizes, we were able to explore effect modification by several important 
factors, including sex, BMI category, and cigarette smoking status and to examine cancer 
site-specific analyses. Further, in both study populations, racial minorities were well 
represented enabling us to explore differences by race.  
 
Given that the studies included in this dissertation are among the first to examine the 
associations between pre-diagnostic WBC subtype and CMV IgG level and cancer 
incidence and/or mortality, we undertook a broad approach to examining these 
relationships. As such, our findings should be considered exploratory and hypothesis 
generating. Future studies are warranted to validate our results and to expand upon our 
findings.  
 
Our findings point to several potential directions for future research. Firstly, larger 
studies are necessary to explore the association between these immune markers and 
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cancer site-specific incidence and mortality. Such studies will provide more accurate 
estimates of the risk associated with these immune markers and identify potential 
differential associations by cancer site. Because WBC subtype count can only be 
measured within 24 hours of blood draw, however, it will be challenging to identify large 
cohort studies with prospectively collected information on cancer outcomes, which have 
already measured subtype counts. Identifying large studies with available measures of 
CMV IgG may be more feasible as this titer can be measured in stored blood samples in 
established cohorts.  
 
Secondly, in order to explore the potential etiological pathways mediated by WBC 
subtypes and CMV IgG, measurements of subpopulations of WBC subtypes and 
additional immune markers may be informative. In particular, information on the relative 
and absolute counts of lymphocyte subsets may clarify our finding of a differential role 
for lymphocytes in carcinogenesis in men and women, and including downstream 
products of neutrophils, lymphocytes and basophils into models may also provide insight 
into these etiological pathways. Additionally, one proposed mechanism linking CMV 
infection to tumor development and progression is through the deregulation of 
inflammatory pathways and the induction of immune suppression. In order to evaluate 
the relevance of this pathway in immunocompetent adults, it will be necessary to quantify 
to what extent markers of inflammation and immune capacity mediate the effects of this 
virus on cancer incidence and mortality.  
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Thirdly, large networks of genes affect immune function and functional polymorphisms 
of these genes have been associated with several types of cancers (22-27). Indeed, several 
genetic variants associated with WBC subtype phenotype and CMV pathogenesis have 
been identified (28-31). Exploring the association between these variants and cancer may 
elucidate the etiological role of these immune factors. Furthermore, such analyses may be 
preferable to evaluating circulating levels of markers, as genetic variants are not subject 
to confounding or the effects of subclinical disease (32). Genetic variants may also 
modify the association between circulating levels of immune markers and cancer risk. As 
part of this dissertation, we considered the effects of a single nucleotide polymorphism 
(SNP) in the gene for the Duffy antigen receptor for chemokines (DARC) in analyses of 
neutrophils count. While the presence of this polymorphism did not significantly modify 
the association between neutrophil count and subsequent cancer incidence and mortality, 
there was a suggestive interaction suggesting that among carriers of this polymorphism 
neutrophil count may be more strongly associated with cancer mortality. Genetic analyses 
may be particularly informative in future analyses examining CMV IgG levels as genetic 
differences may explain our finding of a differential association by race.  
 
Lastly, studies evaluating the predictive accuracy of these immune biomarkers in addition 
to traditional risk factors for subsequent cancer risk and progression will be necessary to 
determine the clinical significance of our findings. While, estimating the c statistic using 
receiver operating characteristic (ROC) curves may help to address the future clinical 
utility of these markers, comparisons of global model fit based on the log likelihood 
function may also provide important information (33).  
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Table 7.1 Summary of the independent associations between pre-diagnostic WBC subtype counts and 
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